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Background: Cardiovascular disease is a leading cause of death worldwide. Retinal vessel 
calibre is a non-invasive in vivo marker of cardiovascular disease and is linked to 
cardiovascular risk factors. However, the longitudinal impact of cardiovascular risk factors 
on retinal vessel calibre is unknown. 
Hypothesis: Retinal vessel calibre at early middle age is influenced by longitudinally 
measured cardiovascular risk factors from early childhood.  
Method: Simple and multiple linear regression analysis of longitudinal data from the 
Dunedin Study (n=1037 at birth) was performed with age and sex stratification and 
adjustment for cardiovascular risk factors and socioeconomic status. The dependent variable 
was retinal vessel calibre (arterioles and venules) at age 38 and the independent variables 
were blood pressure (ages 7, 9, 11, 13, 15, 18, 26, 32 and 38), body mass index (all phases), 
glycated haemoglobin, lipids, inflammatory markers, smoking, endothelial function and 
cardiorespiratory fitness variably assessed between ages 3, 5, 7, 9, 11, 13, 15, 18, 21, 26, 32 
and 38. A group based trajectory model for systolic blood pressure was also used as an 
independent variable.  
Results: Elevated blood pressure from ages 7 through to 38 was consistently and 
significantly associated with narrower arterioles and wider venules at age 38. At age 7 every 
10 mmHg rise in systolic blood pressure was associated with age 38 arteriolar narrowing of 
1.42 µm in females and 1.38 µm in males; and age 38 venular widening of 1.81 µm in 
females and 1.66 µm in males, p < 0.05, after adjusting for covariates. Trajectory modelling 
showed the highest blood pressures at ages 7 and 11 continued to age 32 and 38 as 
hypertensives with significant arteriolar narrowing at age 38 (15.20 µm narrower in females 
and 6.64 µm narrower in males (p<0.05) compared with normotensives) in a clinically 
meaningful manner with evidence of a dose response in multiple linear regression analysis. 
Novel findings in this study includes statistically significant associations between greater 
cardiorespiratory fitness and wider arterioles (females: β = 0.337, p < 0.001, males: β = 
0.321, p <0.001) and narrower venules (females: β = - 0.311, p = 0.004, males: β = - 0.351, p 
< 0.001) with adjustment for fellow retinal vessel calibre. This significance was lost when 
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adjusted for other covariates. Better level of endothelial function was significantly associated 
with wider venules in multiple linear regression analysis for males (β = 4.403, p = 0.006).  
Many of the other variables either had no statistically significant association or non-
consistent statistically significant association with retinal vessel calibre in multiple linear 
regression analysis. 
Conclusion: The major finding of this study is that childhood through early mid-life blood 
pressure and the trajectories of blood pressure from childhood to early mid-life predict retinal 
vessel calibre in early midlife which is a predictor of cardiovascular events and mortality. 
These data suggest the effects of elevated blood pressure manifest early in life and are 
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Cardiovascular and circulatory diseases are recognised as the leading cause of death 
worldwide.1, 2 In 2013, there were more than 54 million deaths globally with 32% of 
these deaths (17 million) being attributed to cardiovascular disease (CVD).1 The main 
contributors of CVD are ischaemic heart disease (IHD) and cerebrovascular disease.1 
New Zealand is no different with CVD being the leading cause of mortality, 
contributing to 35% of all deaths and 5% of adults living with CVD.3 While the 
majority of  coronary heart disease (CHD) is attributed to epicardial coronary arteries, 
coronary microvascular dysfunction also plays a significant role in CHD as exemplified 
by patients who present with acute coronary syndrome with minimal atherosclerotic 
plaques at coronary angiography.2 Hence, the reasoning is that microvasculature 
elsewhere in the body may be an indirect marker of CHD. CVD and more specifically 
CHD is an entity with significant prevalence and morbidity to warrant a non-invasive 
tool to aid in risk stratification and prevention. 
There is an old saying that the ‘eyes are a window to your soul’;4 and this is not too far 
from the truth. The retinal vasculature can be viewed in vivo directly and non-
invasively providing an early individualised biomarker for CVD,2, 5 with evidence for 
association with cardiovascular risk factors even in children;6-8 however, the 
relationship between longitudinal cardiovascular risk factors and retinal vessel calibre 
(RVC) is unknown.8 Wider retinal venular calibres and narrower arteriolar calibres 
have been associated with an increased risk of cardiovascular disease.5, 9, 10  
The Dunedin Multidisciplinary Health and Development (‘Dunedin’) Study provides 
longitudinal data to address the relationship between cardiovascular risk factors and 
retinal vessel calibre. The Dunedin study is made of a complete birth cohort of 
consecutive births, representative of the South Island population in New Zealand in the 
early 1970s, followed from birth to age 38.11, 12 The strengths of this cohort lie in the 
long follow up time and the high retention rates, with retention rates 90% or greater 
than in all but one phase of the study.11 Hence, the effect of longitudinally measured 
cardiovascular risk factors from age 3 to age 38 on RVC at age 38 were investigated 
with stratification by age and sex and adjustment for covariates and socioeconomic 
status (SES) during statistical analysis. These cardiovascular risk factors included: body 
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mass index (BMI) from age 3, blood pressure (BP) from age 7, waist-hip ratio, 
cardiorespiratory fitness (VO2 max), glycated haemoglobin (HbA1c), total cholesterol, 
high density lipoprotein (HDL), non-HDL cholesterol, white blood cell (WBC) count, 
high sensitivity C-reactive protein (hsCRP), fibrinogen, interleukin 6 (IL-6), smoking 
history and Framingham-reactive hyperaemia index (FRHI) from various phases across 
age 15 to 38 .  
This chapter outlines the link between CVD and RVC, current algorithms used for 
predicting CVD, the variables investigated in this study and their association with 
CVD, the methodology behind RVC measurement and the pathophysiology behind 
RVC change.  
 
1.2 Scientific Background 
1.2.1 Retinal microvascular change and cardiovascular disease 
Microvascular changes in the retina linked to cardiovascular disease include focal 
narrowing of arterioles, arteriovenous nicking and signs of retinopathy (such as 






Figure 1-1: Retinal vascular signs of microvascular disease.  
Black arrow = focal arteriolar narrowing. White arrow = arterio-venous nicking. 
Yellow arrow = haemorrhage. Blue arrow = microaneurysm. Red arrow = cotton wool 
spot.13  
 
However, none of these clinical signs have been studied as extensively as RVC. 
Various CVD risk factors have also been linked to RVC. More specifically arteriolar 
narrowing has been linked to hypertension and venular dilation linked to metabolic 
disorders.2 
Several prominent studies have looked at the relationship between RVC and CVD risk 
over time. The Atherosclerosis Risk in Communities (ARIC) study was one of the first 
prospective study (n = 9648, age = 51 to 72, follow up time = 3.5 years) to demonstrate 
a link between lower arterio-venous ratio (AVR) and increased risk of CHD events in 
women but not in men after adjusting for traditional cardiovascular risk factors; 
however it was difficult to ascertain whether the effect was from the arterioles or 
venules, although it was presumed it was from the arterioles.2, 14 Similarly another 
notable prospective study, The Blue Mountain Eye Study (BMES) (n = 3654, age > 49)  
which followed participants for 10 years showed that wider venular calibre predicted 
CHD events in males and women aged 49 to 75 and narrower arteriolar calibre and 
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narrower AVR predicted CHD events in women aged 49 to 75; after adjusting for 
traditional cardiovascular risk factors.15 Data from the Beaver Dam Eye Study (BDES) 
(n = 4926, age 43 to 84, follow up time = 10 years) was contradictory suggesting that 
there was no association between arteriole diameter, venule diameter, AVR and CHD 
events.16 However, pooled data from the BMES and BDES, demonstrated that narrower 
retinal arterioles and wider venules predicted increased risk of CHD mortality in middle 
aged participants.2 
Further evidence of a relationship between RVC and CHD events was demonstrated by 
a recent meta-analysis (n= 22159, mean age = 62 years, follow up time = 5-14 years) by 
McGeechan et al.9 This group demonstrated that narrower retinal arterioles and wider 
retinal venules were associated with increased risk of CHD in women, but not men, 
independent of traditional CHD risk factors (age, cholesterol, HDL, smoking status, 
diabetes, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), BP 
medications, WBC)9 These results are consistent with the concept that microcirculation 
dysfunction plays a greater role in CHD in women, with women more likely to present 
with cardiac syndrome X (acute coronary syndrome with  insignificant atherosclerotic 
plaques found on coronary angiography), as well as outcomes of revascularisation or 
coronary artery bypass grafting being worse in women.2  
McGeechan, et al, also conducted research on whether RVC could independently 
predict CHD events over and above traditional CHD risk factors and if so whether it 
should be incorporated into clinical practice such as in the Framingham risk score. The 
data analysed was from the ARIC study (n= 9155, age 45 to 64 years, follow up time = 
8.8 years) where it was found that women with narrower retinal arterioles and wider 
retinal venules had a higher incidence of CHD events after adjusting for Framingham 
risk variables. However, the results were disappointing in that area under the ROC 
curve only increased from 0.695 to 0.706 (1.7%) and this was only applicable to 
women.10  
The relatively small sample size and young age of the cohort, makes the Dunedin study 
at its current point in time less than ideal for finding relationships between RVC and 
CVD events. Landmark studies such as ARIC, BMES and BDES had a larger sample 
size and an older population, hence generating a large enough number of CVD events 
for sufficient power in the analysis.14-16 However, the large number of longitudinally, 
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reliably and accurately measured cardiovascular risk factors make the Dunedin study 
ideal to evaluate the relationship between cardiovascular risk factors from early 
childhood to early middle age and RVC measured at early middle age. 
 
1.2.2 Current algorithms to predict cardiovascular disease events 
The Framingham risk score is an algorithm used to predict 10-year risk of CHD 
(myocardial infarction and coronary death) in a free living population aged 20 to 79 
years who are free of CHD and diabetes, based on risk factors: age, sex, smoking, total 
cholesterol, HDL cholesterol, SBP and BP treatment, quantifying the risk into < 10% or 
low risk, 10-20% or medium risk and > 20% or high risk.17, 18  
New Zealand has its own modification of the Framingham risk score called PREDICT 
developed by Professor Rod Jackson and his team. PREDICT is an online tool that is 
available for use by general practitioners which looks at the 5-year CVD risk of an 
individual based on both traditional Framingham risk factors and NZ adjusted 
Framingham predictors. The traditional Framingham risk predictors include age, sex, 
smoking, diabetic status, total cholesterol / HDL ratio and BP. The NZ specific risk 
factors are: (i) ethnicity (Maori, Pacific Island, Indo-Asian), (ii) family history of 
premature CVD, (iii) total cholesterol > 8 mmol/L or total cholesterol/HDL > 8, (iv) BP 
> 170/100 mmHg and (v) type 2 Diabetes Mellitus > 10 years duration or with HbA1c 
> 64 mmol/mol or with microalbuminuria. A maximum of one NZ specific risk factor 
can be used and this adds 5% to the 5-year risk. The PREDICT model stratifies 
individuals into low risk (<2.5%, 2.5-5%, 5-10% ) moderate risk (10-15%), high risk 
(15-20%) and very high risk (20-25%, 25-30% and >30%) of CVD over the next 5 
years.3, 19 CVD is defined in the PREDICT model as vascular or atherosclerotic CVD 
hospitalisations and deaths: (i) ischaemic CHD events including coronary artery bypass 
graft surgery and percutaneous coronary intervention, (ii) ischaemic and haemorrhagic 
cerebrovascular events, including transient ischaemic attacks but not trauma, (iii) 
Peripheral vascular disease including arterial aneurysms and procedures unless 
specified as non-atherosclerotic causes and (iv) congestive heart failure and 
cardiomyopathies unless specified as non-ischaemic causes.19 Figure 1.2 demonstrates 






Figure 1-2: PREDICT 5-year cardiovascular risk scoring table.3 
 
1.2.3 Variables assessed in the study 
BP, diabetes, cholesterol (total, HDL, low density lipoprotein (LDL)), smoking, age 
and sex are traditional cardiovascular risk factors which have been considered in 
previous algorithms such as the Framingham risk calculator.17, 18 Hence more 
specifically the impact of the following variables on RVC at age 38 was explored: SBP, 
DBP, mean arterial blood pressure (MABP), HbA1c, total cholesterol, HDL, non-HDL 
cholesterol, pack years smoked; with stratification to age (3 to 38) and sex. The 
literature review (described in chapter 2 of thesis) and the results from the Dunedin 
study (chapter 4) provided consistent evidence of an association between SBP and 
RVC, hence the relationship between SBP trajectories (work by Dr Theodore)20 and 
RVC at age 38 was also analysed.  
From the Framingham cohort there was also strong evidence for obesity being an 
independent and longitudinal predictor of CVD events.21 A meta-regression analysis of 
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prospective studies up to the year 2006 found a significant association between elevated 
waist-hip ratio and increased risk of CVD risk after adjusting for covariates.22 Hence 
the relationship between anthropometric measurements, BMI and waist-hip ratio and 
RVC was explored, stratified by age and sex.  
Previous studies have shown associations between inflammatory markers and CVD 
events.23-27Therefore, the relationship between fibrinogen, IL-6, hsCRP and WBC and 
RVC was also assessed with age and sex stratification.  
Measures of endothelial dysfunction, brachial flow-mediated dilation (a measure of 
macrovascular endothelial function) correlate with coronary artery endothelial function, 
and endothelial dysfunction assessed by peripheral arterial tonometry (PAT) is related 
to increased CVD risk and events.28 Endothelial function measured at age 38 in the 
form of PAT was hence assessed for any association with RVC, stratified by sex. 
Cardiorespiratory fitness is a strong predictor of CVD, with higher cardiorespiratory 
fitness (measured as maximal oxygen consumption or VO2 Max) associated with 
decreased CVD risk.29, 30 Hence the effect of VO2 Max on RVC was assessed in the 
Dunedin study. 
There is some evidence for lower SES, parental SES and childhood and early life 
factors being associated with greater risks and incidence of CVD.31 Lower SES in  
high-income countries is associated with modifiable and behavioural risk factors for 
CVD. Hence the effect of SES (early childhood SES from birth to age 15; and age 38 
SES) was considered as a covariate in multiple linear regression analysis. 
 
1.2.4 Retinal vessel calibre measurement 
In 1974, Parr and Spears developed a technique for assessing generalised arteriolar 
narrowing., where they measured all the retinal arteriolar calibres between half and one 
disc diameter from the disc margin. The reason this area was selected was because 
these vessels were unequivocally arterioles instead of arteries here. A single sum was 
found called the central retinal artery equivalent (CRAE). Hubbard later extended 
Parr’s method to include venules finding a single sum called the central retinal vein 
equivalent (CRVE). Combining their techniques, they generated a reliable, semi-
automated system for measuring CRAE, CRVE and AVR. Knudston made further 
refinements to this formula, based on the six largest arterioles and venules to compute 
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these retinal vascular measures.32 The ‘Knudston-Parr-Hubbard’ formula was used to 
assess RVC in the Dunedin study.33 
There are however, some limitations to the ‘Knudston-Parr-Hubbard’ formula that 
preclude it from clinical applications, whilst the use in research has been widespread. 
The limitations are as follow:34  
i) The ‘Parr-Hubbard’ formulas were dependent on the number of vessels 
measured, and the constants used were dependent on the units used for 
measurement; Knudston developed a revised set of formula which 
summarised the RVC measurement better with greater accuracy and 
reproducibility. However, the new ‘Knudston-Parr-Hubbard’ formula is far 
from perfect and it is thought that further refinement is necessary.  
ii) There are no age, sex and BP level specific reference levels. Normative 
levels are necessary for clinical implementations of this data; however, this 
may be difficult due to the heterogeneity of RVC measurements from 
numerous systemic and environmental influences including various systemic 
(hypertension, diabetes) and ocular (diabetic retinopathy, glaucoma) 
confounders. 
iii) There remains an unresolved issue related to magnification from cameras 
and ocular refractive medias/ refractive errors. Methods have been utilised 
to adjust for this, including the use of biometric data (axial length of the 
eye). In fact, prominent studies (BDES, BMES, Singapore Cohort Study of 
the Risk Factors for Myopia (SCORM)) found no relationship between 
refraction/ axial length and RVC after adjustment for ocular magnification, 
suggesting no biological link between ocular biometry and RVC. Some 
studies have resorted to use of AVR to account for ocular magnification, 
however, the limitation here is that arteriolar and venular components can 
no longer be assessed independently. A low AVR may either be due to 
narrower arterioles or wider venules; and this is important to decipher as 
there is evidence that different disease processes affect different vasculature 
(narrower arterioles are associated with hypertension, whereas wider 




iv) There is also the issue between confounding effects by the fellow RVC. (i.e. 
the effect exerted on arteriolar calibre by venules and vice-versa.) One 
approach to remedy this is by adjusting for the fellow RVC in the analysis. 
This also corrects for any ocular magnification effects as they would affect 
both vessels by the same magnitude and would be adjusted for by fellow 
RVC adjustment. 
v) There are dynamic and physiological changes of RVC with each cardiac 
cycle which a static digital retinal photo cannot capture, however, because 
the variation is small and random it is thought that it is likely to only 
produce non-differential misclassification. 
vi) Emerging research has shown that retinal background colour may be a 
potential source of measurement error. In the Sydney Myopia study,35 RVC 
was significantly wider in children with East Asian ethnicity than white 
background, consistent with other population based studies. However, 
retinal arteriolar calibre was no longer significantly different between East 
Asian children and white children when confined to children with dark 
brown iris, a surrogate marker of retinal pigment colour. Hence questions 
have been raised to whether retinal pigment colour is another source of 
measurement error or whether it reflects genetic difference and inheritability 
of RVC with iris colour (a complex human trait with very high heritability).  
 
1.2.5 Pathophysiology of retinal vessel calibre change 
While a complete understanding of the mechanism underlying RVC change is lacking, 
some theories have been postulated for vessel change. Ageing, long term hypertension, 
arteriosclerosis, inflammation and endothelial dysfunction are thought to affect RVC.34  
Hypertensive retinopathy is well documented. High BP initiates vasospasm and 
increases vasomotor tone (local autoregulation), viewed as generalised arteriolar 
narrowing.34 Persistent elevation of BP causes arteriosclerotic changes (thickening of 
the tunica intima, tunica media hyperplasia and hyaline degeneration) manifesting as 
focal/ diffuse narrowing and opacification of arteriolar walls (clinically seen as silver 
and copper wiring).34 Later stages of hypertensive retinopathy include arteriovenous 
nipping, break-down of blood retinal barrier with failure of autoregulation, increased 
10 
 
permeability, necrosis of smooth muscle and endothelial cells; and retinal haemorrhage 
and exudates.34 There is some evidence for nitric oxide (NO) dependent endothelial 
dysfunction (i.e. decreased levels of NO contributing to impaired endothelial 
vasodilation) as a key element of arteriolar narrowing in hypertension.34 
The reason for retinal venular dilation is less clear, however it is thought that 
inflammation and endothelial dysfunction also play a part.34 Obese individuals have 
increased markers of endothelial activation and chronic vascular inflammation, greater 
blood volume and higher leptin levels.34 These factors may cause NO release resulting 
in venular dilation.34 In Diabetes, retinal hypoxaemia from hyperglycaemia induced 
microvascular damage is thought to cause arteriolar and venular dilation to increase 
perfusion of retinal tissue.34 Smoking impairs endothelial dependent relaxation of 
arterioles resulting in retinal hypoxaemia and subsequent venular dilation.34, 36, 37 
 
1.3 Objectives 
The aim of this Masters research study is to test the hypothesis that RVC is 
influenced at early middle age by longitudinally measured cardiovascular risk 
factors from early childhood to early middle age. More specifically does change 
in cardiovascular risk factors (hypertension, diabetes, anthropometry, lipids, 
inflammation, smoking, endothelial function and cardiorespiratory fitness from 
age 3 to age 38 impact on RVC measurement at age 38?  
 
1.4 Nomenclature 
In this thesis, the Dunedin Multidisciplinary Health and Development Study is 
referred to as the Dunedin study. Participants were assessed at various ages in the 
Dunedin study and each age of assessment may be alluded to as a phase (e.g. age 
3 of assessment is referred to as phase 3). While CVD encompasses CHD, 
cerebrovascular disease and other circulatory diseases, the focus of this thesis is 
on risk factors primarily associated with CHD, with the use of CVD 






The second chapter will provide a systematic review of the literature on the 
impact of cardiovascular risk factors on RVC. The third chapter will explain the 
methodology of the study. The fourth chapter will be results and the fifth chapter 
the discussion. The references are listed in chapter six. The appendices will 
include chapter seven (detailed literature review) and chapters eight to 12 






2 Literature Review 
2.1 Outline 
A systematic review of the available literature on associations between cardiovascular 
risk factors and RVC was performed. Two databases were use, OVID MEDLINE from 
1946 to present and EMBASE from 1947 to present (September 2017) using keyword 
searches (detailed search criteria in chapter 7 – appendix A, section 7.1, p. 1). The 
abstracts were searched through to find articles that were relevant to the hypothesis. 
Articles which were relevant were read in detail. Review articles were then further 
siphoned through to find citations that were relevant to the hypothesis and these articles 
were read in detail as well. A set of inclusion and exclusion criteria were followed to 
choose the most appropriate articles. 
Inclusion criteria: 
- RVC as endpoint or dependent variable 
- CVD risk factors as exposure or independent variable 
- Adjustment for fellow RVC in statistical analysis 
Exclusion criteria: 
- Population sample restricted to specific groups, e.g. participants with 
rheumatoid arthritis, type 1 diabetes mellitus and diabetic retinopathy. 
- RVC as exposure or independent variable 
- Different measures of retinal vessel composition, e.g. length to diameter ratio as 
opposed to RVC 
- No adjustment for fellow RVC as covariate in statistical analysis 
Table 2.1 shows the number of articles that were discovered from the above search 
criteria, subdivided into relevant study number (regardless of whether adjustment for 
fellow RVC was made) and included study number that were summarised in detail 
(adjustment for fellow RVC made in statistical analysis). Table 2.2 depicts the overall 
search strategy via a ‘Preferred Reporting Items for Systematic Reviews and Meta-
Analyses’ (PRISMA) flow diagram.38 A detailed summary of the included studies in 





Table 2-1: Study numbers included in literature review. 
Variable Relevant study number  Included study number 




Diabetes 21 10 
Lipids 15 6 
Inflammation 14 4 
Smoking 8 4 
Endothelial function 2 1 
Total 155 57 
 
Table 2-2: PRISMA flow diagram of literature review. 
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Additional records identified 
through other sources 
n = 5 
Records after duplicates removed 
n = 2436 
Records screened 
n = 2436 
Records excluded 
n = 2281 
Full-text articles 
assessed for eligibility 
n = 155 
Full-text articles 
excluded, with reasons 
n = 98 
No adjustment for 
fellow RVC 
 
Studies included in 
synthesis 





There was one prospective cohort studies39 and 14 cross-sectional studies,40-53 with 
adjustment for covariates. The single cohort study involved participants between the 
ages 45 to 64. Five out 14 cross-sectional studies had children as study participants, 
with children as young as age 3.43, 44, 46-48 
Higher BP was consistently and significantly associated with narrower CRAE in all 15 
studies and with wider CRVE in the cohort study39 and six out of the 14 cross-sectional 
studies.42, 45-49 Higher SBP, which was measured in six cross-sectional studies, was 
consistently and significantly associated with narrower CRAE.40, 43, 46-48, 53 Higher 
MABP, which was measured in the cohort study39 and ten cross-sectional studies,42-49, 
51, 52 was significantly associated with narrower CRAE in the cohort study and in eight 
cross-sectional studies.39, 42, 44, 45, 47, 49, 51, 52 Five cross-sectional studies measured 
DBP,40, 43, 46-48 and in two of these studies higher DBP was significantly associated with 
narrower CRAE.40, 47 Hypertension status, measured in six cross-sectional studies was 
consistently and significantly associated with narrower CRAE.40, 41, 44, 47, 49, 50 Elevated 
SBP in three cross-sectional studies,46-48 elevated MABP in the cohort study39 and six 
cross-sectional studies39, 42, 45-47, 49 and hypertension status in one cross-sectional study49 
were significantly associated with wider CRVE. DBP was not significantly associated 
with change in CRVE. The magnitude of association of BP/ hypertension status and 
CRAE was greater than the magnitude of association of BP/ hypertension status and 
CRVE. In the cohort study by Liew et al (2008), each interquartile increase of current 
MABP was associated with -4.8 µm change in CRAE and +1.8 µm change in CRVE, p 
< 0.001.39 In the Sydney Paediatric Eye Disease Study, with participants aged 3 to 6 
years, a rise in 10mmHg of SBP was significantly associated with -1.70 µm change in 
CRAE, p = 0.02, with no significant association for CRVE.43 In the Singapore 
Prospective Study Program and Singapore Cardiovascular Cohort Study 2, grade III 
hypertension was significantly associated with -10.8 µm change in CRAE, p < 0.0001 
and +4.8 µm change in CRVE, p = 0.0004.49 At no point was elevated BP or 
hypertension status significantly associated with wider CRAE or narrower CRVE. 
The literature review is consistent with prior understanding of the effect of blood 
pressure on retinal vessel calibre. Hypertension causes vasospasm, increased vasomotor 
tone, NO dependent endothelial dysfunction and arteriosclerotic changes cumulating in 
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generalised arteriolar narrowing.34 Similarly, inflammation and endothelial dysfunction 
from hypertension is thought to cause venular dilation.34 However, there was no study 
in the literature which followed study participants from birth to adulthood to study the 
effects of long term hypertension on RVC in adulthood. Hence, there is a gap in the 
literature which the Dunedin study could potentially address. 
 
2.2.2 Anthropometry and Metabolic syndrome 
The relevant anthropometry reviewed were BMI and waist circumference, with review 
also of metabolic syndrome. Metabolic syndrome was defined either as per the ‘Third 
Report of the National Cholesterol Education Program Adult Treatment Panel (ATP 
III),54 or as per the International Diabetes Federation consensus worldwide definition.55. 
The definition of metabolic syndrome was based on the presence of three of the 
following five variables, central obesity measure as waist circumference, low HDL, 
high triglycerides, high fasting plasma glucose and high BP, with the definition from 
the International Diabetes Federation including central obesity as a compulsory 
variable.56 Waist-hip ratio was not assessed in the included studies. There were five 
prospective cohort studies39, 53, 57-59 and 12 cross-sectional studies42-44, 50, 51, 54, 55, 60-64 
with adjustment for covariates. Nine out of 17 studies (two cohort57, 59 and seven cross-
sectional43, 44, 60-64)  had children as study participants, as young as age 3. Fourteen 
studies measured BMI ( five cohort39, 53, 57-59 and nine cross-sectional42-44, 51, 60-64) and 
elevated BMI was significantly associated with narrower CRAE in four cohort39, 53, 58, 59 
and six cross-sectional studies42-44, 60, 62, 64 and wider CRVE in four cohort39, 53, 58, 59 and 
eight cross-sectional studies.42-44, 51, 60, 62-64 In the large prospective cohort study, ARIC, 
an interquartile increase in BMI was significantly associated with -0.7 µm change in 
CRAE, p = 0.001 and +0.6 µm change in CRVE, p < 0.001.39 The association between 
BMI and RVC in adults39, 42, 53, 58 was mirrored in children.43, 44, 59, 60, 62, 64 Three cross-
sectional studies looked at metabolic syndrome50, 54, 55 with metabolic syndrome 
significantly associated with narrower CRAE54 and wider CRVE50 in the respective 
studies. One cohort study57 and two cross-sectional studies50, 64 assessed the association 
of waist circumference with RVC. Wider waist circumference was significantly 
associated with narrower CRAE in children64 and wider CRVE in children64 and 
adults50 in the respective cross-sectional studies.  
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However, no study followed the study participants from childhood to adulthood. The 
Dunedin study is unique in that it followed a cohort from early childhood to early 
middle age. Obese individuals are thought to have increased markers of endothelial 
activation and vascular inflammation, greater blood volume and higher leptin levels, 
which may increase venular diameter by NO release; hence explaining the strong 
association between higher BMI and wider venular calibre.34 Longitudinal data from 
BMES also showed that wider venular calibres at baseline was predictive of incident 
obesity at 5-year follow up, hence demonstrating the possible role of microvasculature 
change in venules in weight gain.34  
 
2.2.3 Blood glucose 
There were two prospective cohort studies39, 65 and eight cross-sectional studies42, 50, 51, 
66-70 that fulfilled the inclusion criteria. The Lingtou eye cohort study showed that 
elevated  fasting plasma glucose (FPG) measured annually over 5 years (2008 to 2012) 
was significantly associated with narrower CRAE and wider CRVE in 2012 after 
adjustment for covariates.65 The ARIC prospective study found no significant 
association between current and past FPG and CRAE.39 Current elevated FPG was 
significantly associated with wider CRVE when adjusted for covariates, but past FPG 
defined as an average of past visits three and six years ago was not significantly 
associated with CRVE.39  Other studies that were included were all cross-sectional in 
nature and provided mixed results of widening or non-significance association between 
blood glucose and CRAE; and narrowing, widening or non-significance association 
between rise in glucose/HbA1c and positive diabetic status and CRVE. No study 
looked at the association of blood glucose in children and RVC. 
Furthermore, evidence from other large notable studies, BMES, BDES and Rotterdam 
is strongest for the association between diabetes and larger RVC.34 It is thought that 
reduced vascular reactivity due to endothelial dysfunction from inflammation 
secondary to diabetes may play a role in venular dilation.34 The Dunedin study 
measured blood glucose via HbA1c at phases 32 and 38, and hence is not able to 





Six studies looked at the effect of triglycerides, total cholesterol, LDL and HDL on 
RVC with adjustment for covariates. No study looked at all four lipid variables, some 
only looking at one or two variables. There were two prospective cohort studies39, 53 
and four cross-sectional studies.42, 50, 51, 71 Four studies (two cohort39, 53 and two cross-
sectional studies50, 71) measured triglycerides, with elevated triglycerides in the two 
cohort studies50, 71 associated with narrower CRAE. There was no significant 
association between triglycerides and CRVE. All six studies measured HDL, with 
elevated HDL associated with narrower CRAE in the two cohort studies39, 53and one 
cross-sectional study42. HDL was also significantly associated with narrower CRVE in 
two cross-sectional studies.42, 51 Elevated LDL was significantly associated with wider 
CRVE in the two studies (one cohort39 and one cross-sectional study42) that explored 
this and had no significant effect on CRAE. One cohort53 and one cross-sectional 
study71 measured total cholesterol with no significant effect on either CRAE or CRVE.  
One study looked at the effect of HDL, triglycerides and total cholesterol on children 
with no significant effect on CRAE or CRVE.71 The Dunedin study measured lipids at 
age 26, 32 and 38 and is not able to address the relationship between dyslipidaemia in 
childhood and RVC at age 38. It is thought that dyslipidaemia (elevated LDL, elevated 
triglycerides and lower HDL levels) is associated with inflammation and endothelial 
dysfunction resulting in wider venular calibres.34 Various large studies such as ARIC, 
Multi-ethnic study of atherosclerosis (MESA), BMES and Rotterdam in part provide 
evidence for this association.34 
 
2.2.5 Inflammation 
Two studies were prospective cohort39, 53 and two studies were cross-sectional.72, 73 
Explored inflammatory markers were C-reactive protein (CRP), fibrinogen and WBC. 
No studies were found fulfilling the inclusion criteria and exploring the association of 
IL-6 on RVC. Elevated CRP, WBC and fibrinogen were consistently and significantly 
associated with wider CRVE. The association with CRAE was not significant. No study 




No study had children as study participants. The Dunedin study started measuring 
markers of inflammation from age 26 and hence is unable to look at association 
between markers of inflammation in children and RVC. Inflammation and endothelial 
dysfunction as demonstrated by large notable studies, ARIC, Rotterdam, BMES and 
MESA is now considered the major underlying mechanism of RVC change, venular 
dilation.34, 39, 53, 73  
 
2.2.6 Smoking 
There were two prospective cohort studies39, 53 and two cross-sectional studies42, 51 
which evaluated the effect of smoking on RVC. Smoking was consistently associated 
with wider CRVE and associated with wider CRAE in one cohort53 and one cross-
sectional study51 after adjusting for covariates. 
Understandably no study looked at smoking in children and RVC change. The Dunedin 
study measured pack years of tobacco smoked from the age of 18. Smoking is thought 
to cause higher carbon monoxide levels and endothelium dependent vessel relaxation 
with secondary hypoxaemia to retinal tissue and subsequent venular dilation.34 
 
2.2.7 Endothelial function 
There was one cross-sectional study which looked at brachial flow mediated dilation 
(FMD) (a marker of macrovascular endothelial function), where elevated brachial FMD 
(better endothelial function) was significantly associated with narrower CRVE.74 
Reduced brachial FMD is a marker of endothelial dysfunction74 and the corollary is that 
reduced brachial FMD is significantly associated with wider CRVE. This is further 
evidence of a possible mechanism for other cardiovascular risk factors (elevated BMI, 
blood sugar, dyslipidaemia, markers of inflammation and smoking) being related to 
endothelial dysfunction and being associated with wider venular calibre. Nguyen et al, 
had study participants between the ages 45 to 84.74 The Dunedin study measured PAT ( 




2.2.8 Cardiorespiratory fitness 
No studies were found on cardiorespiratory fitness as measured by VO2 max and RVC. 
The Dunedin study is novel in that VO2 max was measured at phases 15, 26, 32 and 38. 
This allows the possibility of testing for an association between cardiorespiratory 
fitness from teenager to early middle age and RVC at early middle age. 
 
2.3 Age, sex and socioeconomic status 
The relationship between age, sex and SES was not formally reviewed as these 
variables were rarely independently evaluated, but age and sex were commonly used as 
covariates when assessing CVD risk factors with RVC. Socioeconomic status was not a 
commonly tested variable. One cross-sectional Swedish study, which looked at the 
association between RVC and markers of SES (parental education, household income 
and migrant background) of children (mean age 7.3, n = 358) found no significant 
association when adjusted for age, sex, BMI and the other markers of SES.75 There was 
no adjustment for fellow RVC in this study. 
In one study there was a significant increase in in RVC from birth (CRAE of 85.5 µm, 
CRVE of 130.0 µm) to age six, almost doubling (CRAE of 165.6 µm, CRVE of 232.0 
µm).32 Data from adult population suggests that from age six to middle age, CRVE 
remains approximately the same, while CRAE continues to increase to 202.3 µm in 
those over the age of 43.32 From middle age to elderly, population data consistently 
show a decrease in RVC (both CRAE and CRVE) with increasing age, however the 
absolute difference is small, with persons over age 80 having 10-15 µm smaller RVC 
compared with those aged 55-60;32 or a decrease of 1.8-4.8 µm for each increase in 
decade from middle age as demonstrated by BDES and BMES after adjusting for sex, 
hypertension and other risk factors.34 In summary the data suggests that after an initial 
increase in RVC with increasing age, from middle age onwards the RVC decrease in 
size.32 
Few studies have specifically investigated the associations between sex and RVC, and 
the findings are inconsistent. In BMES both CRAE and AVR were consistently larger 
in women compared to males, consistent with other large studies, the Cardiovascular 
Health Study (CHS) and MESA. There is currently no adequate explanation for the 




2.4  Summary 
The systematic literature review has demonstrated elevated BP (especially SBP) to be 
most consistently and significantly associated with narrower CRAE, with significant 
association also demonstrated between higher BP and wider CRVE. Metabolic (higher 
BMI, higher blood glucose and dyslipidaemia) and inflammatory factors (elevated 








To answer the hypothesis that RVC at early middle age is influenced by longitudinally 
measured cardiovascular risk factors from early childhood to early middle age, data 
from a prospective cohort study, the Dunedin study, was analysed. Dunedin is a major 
city located in the Southern coastal region of the South Island in New Zealand. The 
study participants (n = 1037, 51.6% males) were recruited from a complete birth cohort 
born between 1st April 1972 and 30th March 1973 in the metropolitan area 
(geographical area of 3315km2).11  
The original cohort of 1037 participants is representative of the South Island, New 
Zealand population in the early 1970s. To be eligible for the study the participants had 
to be living in the greater Dunedin Metropolitan area 3 years after their birth at Queen 
Mary Maternity Hospital, Dunedin; the only maternity hospital in Dunedin at that time. 
The participants who agreed to take part (91%) were no different from the 9% who 
declined or were unable to take part with regards to birthweight, family socioeconomic 
status and maternal prenatal and neonatal complications. Participants were 
predominantly white, with 7.5% self-identifying as Maori which matches the ethnic 
distribution of South Island, New Zealand.11The study had high retention rates, with 
greater than 90% retention rates in all but one of its phases. (Table 3.1)11 The Otago 
Ethics committee approved each phase of the study and informed consent was obtained 




Table 3-1: Retention rates in the Dunedin study.11 
Age Number Percent of living study 
members (%) 
3 1037 100 
5 991 96 
7 954 92 
9 955 92 
11 925 90 
13 850 82 
15 976 95 
18 993 97 
21 992 97 
26 980 96 
32 972 96 
38 961 95 
 
 Measurement of variables at various ages 
Participants were called for assessment at age 3, 5, 7, 9, 11, 13, 15, 18, 21, 26, 32, 38 
and currently are being assessed at age 45 in the ongoing Dunedin study. Various 
variables were measured at each phase of assessment (Table 3.2),11 including and not 
limited to blood pressure, HbA1c, BMI, waist-hip ratio, total cholesterol, HDL, CRP, 
fibrinogen, IL-6, smoking, Framingham-reactive hyperaemia index (F-RHI), VO2 max, 
age, sex and SES. The methodology used by the Dunedin study staff to measure these 




Table 3-2: Relevant variables measured at each phase in the Dunedin study. 11 
Phase Variable  
Birth Sex, SES 
3 BMI, SES 
5 BMI, SES 
7 BMI, SBP, DBP K-5, DBP K-4, SES 
9 BMI, SBP, DBP K-5, DBP K-4, SES 
11 BMI, SBP, DBP K-5, DBP K-4, SES 
13 BMI, SBP, DBP K-5, DBP K-4, SES 
15 BMI, SBP, DBP K-5, VO2 max, SES  
18 BMI, SBP, DBP K-5, smoking 
21 BMI, smoking 
26 BMI, SBP, DBP K-5, waist-hip ratio, 
total cholesterol, HDL, WBC, VO2 max, 
CRP, smoking 
32 BMI, SBP, DBP K-5, waist-hip ratio, 
total cholesterol, HDL, WBC, VO2 max, 
CRP, fibrinogen, HbA1c, smoking,  
38 BMI, SBP, DBP K-5, waist-hip ratio, 
total cholesterol, HDL, WBC, VO2 max, 
CRP, fibrinogen, HbA1c, smoking, IL-6, 
FRHI, SES   
SES 0-15 is an average of SES from age 1-15. K-5 = Korotkoff phase 5. K-4 = 




3.2.1 Blood pressure  
Blood pressure (SBP and DBP) was measured at phase 7, 9, 11, 13, 15, 18, 26, 32 and 
38.11 Blood pressure was measured using the ‘London School of Hygiene and Tropical 
Medicine blind mercury sphygmomanometer (Cinetronics Ltd, Mildenhall, United 
Kingdom)’ up to the age of 18 and a ‘Hawksley random-zero sphygmomanometer 
(Hawksley and Sons Ltd, Sussex, United Kingdom)’ with a constant deflation valve 
between ages 26 to 38.20 Measurements were done in a quiet room with participants 
supine at ages 7 to 18 and sitting at ages 26 to 38.20, 76 Blood pressures were measured 
from the right arm to the nearest 2 mmHg.76 Three readings 5 minutes apart were taken 
for ages 7 to 13 and ages 26 to 32; one blood pressure reading was taken for age 15 and 
two readings for age 18.20, 76 Pregnant individuals were excluded for age 26 (n=30), age 
32 (n=26) and at age 38 (n=8).20 
SBP was assessed at the first Korotkoff sound and DBP assessed at the fourth and fifth 
Korotkoff sounds for ages 7 to 13 years and at the fifth Korotkoff sound for ages 15 to 
38 years; and were based on the mean of readings for each phase where there were 
multiple readings.20, 76 MABP was calculated as the sum of one-third of SBP and two-
thirds of DBP.77 
In children up to the age of 17, pre-hypertension is defined as an average SBP and/or 
average DBP between the 90th and 95th centiles. Hypertension (HTN) is defined as 
average SBP and/ or DBP > 95th centile for age, sex and height obtained on at least 3 
occasions. (Stage 1 HTN is average SBP +/- DBP 95 to 99% + 5 mmHg. Stage 2 HTN 
is average SBP +/- DBP > 99% + 5 mmHg.)78 
In adults, there are two major guidelines for hypertension classification and this is 
based on the mean of two or more readings at each of two or more visits post initial 
screening.  
The 2003 seventh report by Joint National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure (JNC 7) guidelines are as follows:79 
- Normal is SBP lower than 120 mmHg and DBP lower than 80 mmHg. 
- Pre-HTN is SBP 120-139 mmHg and/ or DBP 80-89 mmHg. 
- Stage 1 HTN is SBP 140-159 mmHg and/ or DBP 90-99 mmHg. 
- Stage 2 HTN is SBP 160 mmHg or greater and/ or DBP 100mmHg or greater. 
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The 2013 European Society of Hypertension (ESH)/ European Society of Cardiology 
(ESC) guidelines are as follow:80 
- Optimal BP is SBP lower than 120 mmHg and lower than 80 mmHg. 
- Normal BP is SBP of 120-129 mmHg and/ or DBP of 80-84 mmHg. 
- High-normal BP is SBP of 130-139 mmHg and/ or DBP of 85-89 mmHg. 
- Grade 1 HTN is SBP of 140-159 mmHg and/ or DBP of 90-99 mmHg. 
- Grade 2 HTN is SBP of 160-179 mmHg and/ or DBP 100-109 mmHg. 
- Grade 3 HTN is SBP 180 mmHg or greater and/ or DBP of 110 mmHg or 
greater 
- Isolated systolic HTN is 140 mmHg or greater and DBP lower than 90 mmHg. 
 
3.2.2 Body mass index 
BMI at each phase was calculated by diving weight by height2, units of kg/m2. Weight 
was assessed with participants in light clothing and was measured to the nearest 0.1kg 
using calibrated scales. Height was measured to the nearest millimetre using a portable 
stadiometer (Harpenden; Holtain, Ltd., Crosswell, UK). 28 
For children up to the age of 17, BMI less than the 5th percentile for their age and sex is 
considered to be underweight, 5th to 84th percentile is healthy weight, 85th to 94th 
percentile is overweight and 95th and greater percentile is obesity.81 In adults BMI 
under 18.5 is underweight, 18.5 to 24.9 is normal weight, 25.0 to 29.9 is overweight, 
30.0-39.9 is obesity and 40.0 or greater is extreme obesity.82 
 
3.2.3 Waist-hip ratio 
Waist girth was an average of two measurements of the perimeter at the level of the 
noticeable waist (locate between the inferior costal border and the iliac crest) using a 
calibrated steel tape to the nearest millimetre gradation.28, 83 
Hip girth was a mean of two measurements (to the nearest millimetre gradation) of the 
perimeter measured at the level of the greatest protuberance and at the level of the 
symphysis pubis anteriorly.12, 83 
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Waist and hip measurements were used to calculate the waist/hip ratio (waist girth 
divided by hip girth), an index of central adiposity.12, 83  
A waist-hip ratio of > 0.90 in men and > 0.85 in women is associated with a 
substantially increased risk of metabolic complications.82 
 
3.2.4 Smoking  
Smoking was assessed as cumulative pack-years of cigarettes smoked (number of packs 
of cigarettes smoked per day multiplied by the number of years smoked at that rate) at 
phases 18, 21, 26, 32 and 38. This was computed from tobacco use data up to age 18, 
ages 18 to 21, ages 21 to 26, ages 26 to 32 and ages 32 to 38.84 
 
3.2.5 Biochemistry 
Biomarkers that are relevant to the thesis include total cholesterol, HDL, non-HDL 
cholesterol, HbA1c, WBC, fibrinogen, IL-6 and hsCRP. Participants were 
phlebotomised non fasting at the same time each day (1615 to 1645 hours).28 
 Lipids   
Non-fasting total cholesterol (mmol/L) and HDL cholesterol (mmol/L) was measured 
using colorimetric assay. Total cholesterol was determined enzymatically using 
cholesterol oxidase and cholesterol esterase with inter-day coefficient of variation 
ranging from 2.3 % to 3.5 %. Whereas HDL cholesterol was determined enzymatically 
by cholesterol oxidase and cholesterol esterase coupled with polyethylene glycol to 
amino groups.28. Non-HDL cholesterol (mmol/L) was calculated by subtracting HDL 
from total cholesterol measurements. Non-HDL cholesterol is a combination of LDL 
and triglycerides.85 
A lower total cholesterol, lower non-HDL cholesterol and a higher HDL value lowers 
cardiovascular risk. Participants with total cholesterol > 7.5 mmol/L are at high risk of 
deleterious cardiovascular outcomes. Due to limitations of calculating LDL with the 
Friedewald formula, use of non-HDL cholesterol is an acceptable alternative for CVD 
risk prediction. Non-HDL cholesterol targets in treatment are < 2.6 mmol/L, < 3.4 
mmol/L and < 3.8 mmol/L dependent on very high CVD risk, high risk and moderate 
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risk subjects respectively.  HDL < 1.0 mmol/L in men and < 1.2 mmol/L in women are 
associated with increased CVD risk.86 
 Glycated haemoglobin 
HbA1c was measured in the serum and expressed as a percentage of total haemoglobin. 
This was measured as a percentage of total haemoglobin using ion exchange high 
performance liquid chromatography (Variant II: Bio-Rad, Hercules, CA, USA) with 
inter-day coefficient of variation between 1.6% to 2.1%; and a method certified by the 
National Glycohemoglobin Standardisation Program (http://www.ngsp.org/).28 
HbA1c of 6.5% or greater is the cut off value for diagnosis of Diabetes Mellitus.87, 88 
 Inflammatory markers 
3.2.5.3.1 White blood cell count 
WBC count was measured by flow cytometry with a Coulter STKS (Coulter 
Corporation, Miami, FL) at age 26, Sysmex XE2100 (Sysmex Corporation, Japan) at 
age 32 and Sysmex XE5000 (Sysmex Corporation, Japan) at age 38.83  
The normal value of WBC in adults is between 4.5 - 11.0 x109/L.89 
3.2.5.3.2 High sensitivity C-reactive protein  
 HsCRP was assessed using a high-sensitivity particle enhanced immunoturbidimetric 
assay with a coefficient of variation of 2.8% (Roche Diagnostics, Mannheim, 
Germany).28 The natural log of hsCRP (ln(hsCRP + 1)) was used for simple and 
multiple linear regression analysis due to the skewed nature of the data. 
hsCRP < 1.0 mg/L is considered to be normal.90 
3.2.5.3.3 Fibrinogen  
Fibrinogen was measured using a fully automated cap piercing coagulation analyser on 
a Sysmex CA-1500 (Mahberg, Germany).91 
The reference interval for fibrinogen is 1.5 - 4.0 g/L.90 
 Interleukin-6  
IL-6 was measured on a molecular device (Sunnyvale, CA) SpectraMax plus 384 
Microplate reader using R&D Systems (Minneapolis, MN) Quantikine High sensitivity 
Elisa kit HS600B. 
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The reference range is 0.428 – 8.87 pg/ml, with a mean value of 1.49 pg/ml determined 
by the manufacturer in 35 normal healthy individuals. The natural log of IL-6 (ln(IL-6 
+ 1)) was used for simple and multiple linear regression analysis due to the skewed 
nature of the data. 
  
3.2.6 Endothelial function 
Participants’ endothelial function was assessed in the morning in a non-fasting state. 
After lying supine for 10 minutes in a 20 ֯C temperature controlled room, a PAT device 
was placed on the index finger of each hand (Endo-PAT2000, Itamar Medical Ltd, 
Caesarea, Israel). A blood pressure cuff was placed on the right upper arm and baseline 
measurements obtained over 2 minutes. The blood pressure cuff was subsequently 
inflated to 200 mmHg or 60 mmHg above systolic blood pressure, whichever was 
higher and occlusion of flow was confirmed. After 5 minutes, the cuff was deflated and 
recording continued for another 5 minutes. Pulse amplitude was recorded from both 
fingers and analysed by a computerised, automated algorithm (Itamar Medical Ltd), 
which provided the mean pulse amplitude for each 30 second interval after cuff 
deflation for up to 5 minutes. Hence PAT measured the digital pulse volume after 
reactive hyperaemia induced by brachial artery occlusion. The F-RHI was the ratio of 
hyperaemic to baseline pulse amplitudes (F-RHI = ln(Rho / RHc), where RHo and RHc 
were the mean pulse amplitudes between the period 90 and 120s after cuff deflation 
divided by the mean baseline amplitudes in the occluded and control arm respectively). 
Impaired endothelial function was indicated by a lower value of F-RHI. 
 
3.2.7 Cardiorespiratory fitness 
Cardiorespiratory fitness was assessed by the participants completing a submaximal 
exercise test on a friction-braked cycle ergometer (Monark, Vansbro, Sweden). The 
work load was adjusted to elicit a heart rate in the range of 130 to 170 beats per minute, 
depending on the extent the heart rate increased during a 2 minute 50 W warm-up 
period. After the participants were on the bike for a further 6 minutes at a constant 
power output stage, the maximal heart rate was recorded and used to calculate the 





3.2.8 Retinal vessel calibre 
RVC was measured at phase 38 using digital fundus photos of both right and left eyes 
taken at the Dunedin Research Unit after 5 minutes of dark adaptation. The camera 
used was a Canon NMR-45 with a 20 D single-lens reflex backing; Canon, Tokyo, 
Japan. Retinal photographs were graded at the Singapore Eye Research Institute, 
National University of Singapore, using semi-automated computer software, Singapore 
I Vessel Assessment (SIVA) Version 3.0. Trained graders, blind to participants’ 
characteristics used the SIVA programme to measure retinal vessel calibre or diameter 
(internal width of the lumen of vessel) based on a standardised protocol with high 
intergrader reliability. Measurements were recorded for arterioles and venules when 
they passed through region located 0.50 to 2.00 disc diameters from the optic disc 
margin. RVC was based on the mean of the six largest arteriole and venule calibre in 
this region. (Figure 3.1) A mean of the measurements from both eyes was used for 
arteriolar and venular calibre. This was denoted as CRAE for the arteriole calibre and 
CRVE for the venular calibre; using the revised Knudtson-Parr-Hubbard formula.33 932 





Figure 3-1: Illustration showing assessment of retinal vessel calibre.  
Measurements of vessel calibre were made for six largest arterioles (red) and six largest 
venules (blue) that passed through the region of 0.50 to 2.00 disc diameters from the 
disc margin.92 
 
3.2.9 Socioeconomic status 
Childhood SES was recorded from birth to age 15 on a six-point scale (1 = 
professional, 6 = unskilled labour) based on the education level and income associated 
with the parents’ self-reported occupation in New Zealand census. The variable used in 
our analysis (SES 0-15) was a mean of the highest SES level of either parent of the 
child for each of the phases from birth to age 15.28  
Age 38 SES was coded from a similar, but inverse six-point scale (1 = unskilled labour, 
6 = professional) based on the education level and income associated with the 
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occupation in the New Zealand census. The SES of homemakers and those unemployed 
were estimated from their education.33 
 Statistical methods 
Associations between cardiovascular risk factors and RVC were evaluated using the 
statistics package: IBM SPSS Statistics 24 by the MMedSc candidate. All statistical 
analysis was age and sex stratified. Analysis was sex stratified based on significant sex 
interaction between BP and RVC at age 38. Firstly, descriptive statistics was conducted 
for all variables. Statistical tests (Analysis of variance (ANOVA) and post hoc analysis 
using Games Howell) were used to determine significant change over time in variables 
measured over multiple phases (BP, BMI and VO2 max). Independent sample t-test was 
used to analyse difference in variables between sexes. 
Linear regression was used to evaluate for associations between cardiovascular risk 
factors and RVC. HsCRP and IL-6 were skewed data, hence they were logarithmically 
transformed to make the distribution normal before analysis.  
Simple linear regression analysis was done between cardiovascular risk factors at each 
phase (3 through to 38) and RVC, with and without adjustment for fellow RVC, 
stratified by age and sex. Following on from this multiple linear regression analysis was 
done for each variable from phases 3 through to 38 and RVC adjusted for fellow RVC 
and stratified by age and sex. Multiple linear regression analysis additionally adjusted 
for age 38 covariates: MABP, BMI, waist-hip ratio, HbA1c, total cholesterol, HDL, 
WBC, hsCRP, fibrinogen, IL-6, total pack years smoked, VO2 Max, F-RHI and SES 
(childhood and age 38) without adjusting for the same or similar variable to avoid high 
collinearity. (i.e. BP measurements would not get adjusted for MABP at age 38 and 
non-HDL cholesterol was not adjusted for total cholesterol at age 38.) 
Finally, simple linear regression with and without adjustment for fellow RVC and 
multiple linear analysis adjusting for multiple covariates as above, stratified by sex, was 
done on group-based trajectory modelling on SBP, with dependent variable as CRAE 
and CRVE. This was based on SBP measured from phase 7 to 38 for 975 individuals. 
Group based trajectory modelling was performed by Theodore et al. in the Dunedin 
study.20 SBP data was used from phases 7, 11, 18, 26, 32 and 38, all ages at which there 
more than 1 BP measurement. ‘Proc Traj, a statistical analysis software macro was used 
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to estimate the model parameters using a censored normal model appropriate for 
continuous normally distributed data.’20To determine the best model 12 models were 
fitted. The best model was a 4-trajectory group model chosen on the following 
criteria:20 
(i) A prior knowledge of SBP development over time 
(ii) Tendency towards a parsimonious model 
(iii) The Bayesian Information Criterion as a statistic of model fit with larger 
values indicating better fit 
(iv) Each trajectory group having a mean posterior probability of group 







4 Results - Overview  
This chapter will outline a summary of descriptive statistics for age 38 variables, 
difference in variables between sexes, trends in variables (BMI, BP and VO2 Max) over 
time, sex interaction analysis, simple linear regression analysis, multiple linear 
regression analysis and linear regression analysis of SBP trajectories from the Dunedin 
study. More detailed results are presented in table format in chapter 8 – appendix B, 
chapter 9 – appendix C, chapter 10 – appendix D, chapter 11 – appendix E and chapter 
12 – appendix F. 
 
4.1 Descriptive statistics  
RVC was measured at age 38 along with many cardiovascular risk factors, including 
blood pressure, anthropometry, blood glucose, lipids, inflammatory markers, smoking, 
cardiorespiratory fitness and endothelial function. 465 females and 467 males had their 
RVC measured at age 38. The mean CRAE was 137.88 µm in females and 136.61 µm 
in males with a standard deviation of 11.40 µm and 10.87 µm respectively. The mean 
CRVE was 195.05 µm in females and 197.01 µm in males with a standard deviation of 
15.56 µm and 14.86 µm respectively. Descriptive data for these variables is 
demonstrated in table 4.1, sex stratified. Many of these variables were also measured in 
other preceding phases (Table 3.2). Descriptive data for all variables across phase 3 





Table 4-1: Descriptive statistics for variables measured at age 38. 
Variable Sex N Min. Max. µ σ 
CRAE (µm) F 465 57.74 170.19 137.88 11.40 
M 467 106.11 179.47 136.61 10.87 
CRVE (µm) F 465 86.65 245.68 195.05 15.56 
M 467 141.07 242.36 197.01 14.86 
AVR (ratio) F 465 .56 .84 .708 .045 
M 467 .56 .80 .695 .042 
SBP (mmHg) F 460 86.67 161.33 116.37 11.25 
M 474 96.67 180.67 124.04 11.80 
DBP (mmHg) F 460 55.33 122.67 75.61 9.04 
M 474 59.33 137.33 80.64 10.15 
MABP (mmHg) F 460 67.78 134.89 89.20 9.20 
M 474 73.56 151.78 95.11 10.05 
BMI (Kg/m2) F 460 16.01 54.42 26.92 5.92 
M 474 18.86 49.47 27.45 4.62 
Waist – hip ratio F 458 .63 1.08 .80 .06 
M 473 .69 1.14 .91 .07 
HbA1c (%) F 451 4.16 9.47 5.34 .42 
M 450 4.26 13.50 5.48 .63 
Total Cholesterol 
(mmol/L) 
F 455 2.4 11.3 5.0 1.0 
M 456 2.7 8.9 5.4 1.0 
HDL cholesterol 
(mmol/L) 
F 455 .59 3.54 1.61 .43 
M 456 .40 3.13 1.29 .35 
Non-HDL 
cholesterol (mmol/L) 
F 455 .8 9.8 3.4 1.0 
M 456 1.7 8.2 4.1 1.1 
WBC (x109/L) F 449 3.7 16.7 8.1 1.8 
M 456 3.8 14.8 7.7 1.8 
hsCRP (mg/L) F 453 .10 33.20 2.97 4.34 
M 454 .10 39.00 1.93 3.14 
Fibrinogen (g/L) F 446 1.3 5.3 2.8 .6 
M 450 1.2 4.9 2.6 .5 
IL-6 (pg/ml) F 394 .0778 18.4897 1.7900 1.8187 
M 401 .0857 15.8244 1.3161 1.3343 
Smoking (pack-
years) 
F 476 .00 35.75 5.59 7.94 
M 477 .00 46.13 6.69 9.29 
Vo2 Max 
(mL/min/kg) 
F 437 11.55 46.86 23.72 4.94 
M 463 18.15 53.43 34.70 6.23 
F-RHI (quotient) F 458 -.137 1.924 .709 .385 
M 460 -.148 1.710 .502 .347 





4.2 Difference in variables between sex 
Independent sample t-test was used to determine statistically significant difference 
between sexes at a p-value < 0.05. The main results are summarised below with 
specific detail tabulated in chapter 9 – appendix C, p. 139. 
4.2.1 Retinal vessel calibre 
CRAE in women was 137.88 ± 11.40 µm (µ ± σ) was not significantly different from 
men at 136.61 ± 10.87 µm (difference 1.27 µm, 95% CI: -0.16 to 2.70, p = 0.082). 
Females had a significantly narrower CRVE, 195.05 ± 15.56 (difference of -1.96 µm, 
95% CI: -3.92 to -0.01, p = 0.049) and a greater arteriovenous ratio (CRAE/ CRVE) of 
0.014 (95% CI 0.008 to 0.019, p < 0.001).  
 
4.2.2 Anthropometry  
There was no statistically significant difference in BMI between sexes at ages 7, 9, 11, 
18, 21, 26, 32 and 38. However, at ages 3 and 5, females had a significantly lower BMI 
than males (difference -0.26, 95% CI: -0.43 to -0.10, p=0.002 at age 3 and difference of 
-0.20, 95% CI: -0.37 to -0.04) at age 5). At ages 13 and 15, females had a significantly 
greater BMI than males (difference of 0.76, 95% CI: 0.40 to 1.12, p < 0.001 at age 13 
and difference of 0.91, 95% CI: 0.56 to 1.25, p < 0.001 at age 15).   
Waist-hip ratio was measured at ages 26, 32 and 38, with females having significantly 
lower waist-hip ratio than males at all ages, p < 0.001 (difference of -0.10 at ages 26 
and 32 and difference of -0.11, 95% CI: -0.11 to -0.10, at age 38). 
 
4.2.3 Blood pressure 
At younger ages there was mostly no statistically significant difference in BP between 
sexes. More specifically SBP was not significantly different at ages 7,9 and 11; DBP 
was not significantly different at ages 7, 9, 11, 13, 18; and MABP was not significantly 
different at ages 7,9,11,13 and 15. At all other ages, females had significantly lower BP 
than males (i.e. age 13 for SBP, p =0.015; ages 15, 18, 26, 32 and 38 for SBP, p < 
0.001; ages 15, 18, 26, 32 and 38 for DBP, p < 0.001; and ages 18, 26, 32 and 38 for 
MABP, p < 0.001). Hence, adult females had lower BP than males with statistical 
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significance and a clinically meaningful difference (e.g. females at age 38 had a mean 
difference for SBP of -7.7 mmHg with a 95% CI: -9.1 to -6.2). 
 
4.2.4 Cardiorespiratory fitness   
VO2 Max was assessed at ages 15, 26, 32 and 38, with females having significantly 
lower VO2 Max than males at all ages, p < 0.001. VO2 Max at age 38 for females was 
23.72 mL/min/kg ± 4.94 (µ ± σ) and for males 34.70 ± 6.23, with a difference of -10.98 
for females, 95% CI: -11.71 to -10.24. 
 
4.2.5 Lipids 
Lipid levels were measured at ages 26, 32 and 38. Total cholesterol was not 
significantly different at age 26 between males and females. At ages 32 and 38, total 
cholesterol was significantly lower in females, p < 0.001. Similarly, non-HDL 
cholesterol was significantly lower in females, p < 0.001 at ages 26, 32 and 38. HDL 
was significantly greater in females at ages 26, 32 and 38, p < 0.001. At age 38 total 
cholesterol in females had a difference of -0.4, 95% CI: -0.6 to -0.3, non-HDL 
cholesterol a difference of -0.7, 95% CI: -0.9 to -0.6 and HDL a difference of 0.32, 
95% CI: 0.27 to 0.37. 
 
4.2.6 Inflammatory markers 
WBC count and hsCRP were measured at ages 26, 32 and 38; fibrinogen was measured 
at age 32 and 38; and IL-6 was measured at age 38. There was no statistically 
significant difference in hsCRP between the sexes at age 32. WBC at age 32 was 
significantly greater in females, p = 0.004. All other inflammatory markers were 
significantly greater in females in the respective measured phases with a p < 0.001. 
 
4.2.7 Blood glucose 
HbA1c was measured at age 32 and 38. In both these ages females had statistically 
significant lower HbA1c than males. At age 32 females had a difference of -0.05, 95% 




4.2.8 Cigarettes smoked 
The cumulative total of cigarettes smoked was quantified at ages 18, 21, 26, 32 and 38 
as total pack years smoked. There was no statistically significant difference at ages 18, 
21, 26 and 32. At age 38 females smoked -1.10 pack years, 95% CI: -2.20 to -0.003 
compared with males, p = 0.049. 
 
4.2.9 Endothelial function 
Females had a significantly greater F-RHI (0.709 ± 0.347) than males (0.502 ± 0.385) 
at age 38, p < 0.001. A difference of 0.206, 95% CI: 0.159 to 0.254. 
 
4.2.10 Socioeconomic status 
A mean socioeconomic status was obtained from ages 0 to 15 and socioeconomic status 
was assessed at age 38. There was no significant difference in the SES in the mean 
value from age 0 to 15. At age 38 SES was significantly greater in females, p <0.001 




4.3 Trends over time 
Variables which were measured over multiple phases (BMI, VO2 max and BP) was 
plotted over time. 
4.3.1 Body mass index 
BMI increased with age in both females and males. (Figures 4-1 and 4-2.) ANOVA 
showed a statistically significant difference in BMI with age in both sexes, p <0.001. 
The post-hoc analysis for the difference in BMI between ages is presented in appendix 
D – 10.1, p. 144. 
 
Figure 4-1: Trend in BMI with age in females.  




Figure 4-2: Trend in BMI with age in males.  




4.3.2 Blood pressure 
SBP at ages 15, 18, 26, 32 and 38 was significantly greater than SBP at ages 7, 9, 11 
and 13 for both sexes, p < 0.001. (Figures 4-5 and 4-6.) DBP (measured with Korotkoff 
5) at ages 26, 32 and 38 was significantly greater than DBP at ages 7, 9, 11 and 13, p < 
0.001. (Figures 4-7 and 4-8.) MABP (calculated with SBP and DBP measured at 
Korotkoff 5) at ages 26, 32 and 38 was significantly greater than MABP at age 7, 9, 11 
and 13, p < 0.001. (Figures 4-9 and 4-10.) The post-hoc analysis is presented in 
appendix D - 10.2, 10.3, 10.4, p. 152 for the difference in BP between ages. 
 
 
Figure 4-3: Trend in SBP with age in females.  




Figure 4-4: Trend in SBP with age in males.  







Figure 4-5: Trend in DBP with age in females.  






Figure 4-6: Trend in DBP with age in males.  







Figure 4-7: Trend in MABP with age in females.  
(Use of DBP measured at Korotkoff 5 in calculation for MABP. MABP = 1/3 SBP + 




Figure 4-8: Trend in MABP with age in females.  
(Use of DBP measured at Korotkoff 5 in calculation for MABP. MABP = 1/3 SBP + 




4.3.3 Cardiorespiratory fitness 
VO2 max decreased with age in both males and females. (Figures 4-3 and 4-4.) 
ANOVA showed a statistically significant difference in VO2 max between ages in both 
sexes. (See post-hoc analysis in appendix D - 10.5, p. 164 for difference in VO2 max 
between ages). 
 
Figure 4-9: Trend in VO2 max with age in females.  





Figure 4-10: Trend in VO2 max with age in males.  





4.4 Sex interaction analysis 
Regression analysis was carried out for sex interaction between BP and RVC at age 38, 
with and without adjustment for fellow RVC. There was statistically significant sex 
interaction between SBP and CRAE with adjustment for fellow RVC and statistically 
significant sex interaction between DBP and CRAE with and without adjustment for 
fellow RVC. There were no other interactions of statistical significance. Results are 
shown in table 4-2 and 4-3. 
Table 4-2: Regression analysis for sex interaction between BP and RVC at age 38. 
Dependent variable = CRAE 




SBP*sex Nil .087 1.48 .139 -.028 .203 
CRVE .087 2.03 .043* .003 .170 
DBP*sex Nil .185 2.59 .010* .045 .325 
CRVE .145 2.86 .004** .045 .244 
* 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
Table 4-3: Regression analysis for sex interaction between BP and RVC at age 38. 
Dependent variable = CRVE. 




SBP*sex Nil .001 0.01 .989 -.166 .169 
CRAE -.086 -1.39 .165 -.208 .036 
DBP*sex Nil .082 .80 .425 -.120 .285 
CRAE -.106 -1.44 .151 -.251 .039 
* 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
 
4.5 Simple linear regression analysis 
Simple linear regression analysis was carried out unadjusted and adjusted for fellow 
RVC. Presented in this chapter are the summarised results for simple linear regression 
analysis unadjusted and adjusted for fellow RVC. More specific detail on the simple 
linear regression analysis results is presented in chapter 11 – appendix E, p. 165. 
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4.5.1 Central retinal artery equivalent (unadjusted for fellow retinal vessel 
calibre) 
4.5.1.1 Females 
In simple linear regression analysis unadjusted for fellow RVC in females, elevated 
levels of the following variables measured at the respective phases were statistically 
significantly associated with narrower CRAE: SBP (38, 32, 26, 18, 15, 11, 9), DBP K-5 
(38, 32, 26), MABP calculated with DBP K-5 (38, 32, 26, 15, 11, 9), MABP calculated 
with DBP K-4 (11, 9), BMI (38, 32, 21), waist-hip ratio (38, 32), hsCRP (32, 26), and 
fibrinogen (32). Elevated levels of the following variables measured at the respective 
phases were statistically significantly associated with wider CRAE: WBC (26), total 
pack years of cigarettes smoked (38, 32, 26) and VO2 Max (38, 32, 26). There were no 





Table 4-4: Summary of association between variables and CRAE at different ages 
for females (simple linear regression analysis unadjusted). 
Variable Age 
38 32 26 21 18 15 13 11 9 7 5 3 
SBP *** *** ** - * ** n.s ** ** n.s - - 
DBP K-5 *** *** *** - n.s n.s n.s n.s n.s n.s - - 
DBP K-4 - - - - - - n.s n.s n.s n.s - - 
MABP K-5 *** *** *** - n.s * n.s * * n.s - - 
MABP K-4 - - - - - - n.s * * n.s - - 
BMI  *** ** n.s * n.s n.s n.s n.s n.s n.s n.s n.s 
Waist-Hip * ** n.s - - - - - - - - - 
HbA1c * n.s - - - - - - - - - - 
Tot. Chol. n.s n.s n.s - - - - - - - - - 
HDL  n.s n.s n.s - - - - - - - - - 
Non-HDL n.s n.s n.s - - - - - - - - - 
WBC n.s n.s * - - - - - - - - - 
hsCRP n.s * * - - - - - - - - - 
Fibrinogen n.s * - - - - - - - - - - 
IL-6 n.s - - - - - - - - - - - 
Tot. Smk. ** * * n.s n.s - - - - - - - 
VO2 Max ** * * - - n.s - - - - - - 
F-RHI n.s - - - - - - - - - - - 
- = not measured, n.s = not significant, * = significant at p < 0.05, ** = significant at p 
< 0.01, *** = significant at p < 0.001, green = significant increase in RVC, red = 




In simple linear regression analysis unadjusted for fellow RVC in males, elevated levels 
of the following variables measured at the respective phases were statistically 
significantly associated with narrower CRAE: SBP (38, 32, 26, 18, 13, 11, 9, 7), DBP 
K-5 (38, 32, 26), DBP K-4 (11, 9, 7), MABP K-5 (38, 32, 26, 18, 13, 11, 7), MABP K-
4 (13, 11, 9, 7), BMI (38), total cholesterol (38), non-HDL cholesterol (38, 32) and IL-6 
(38). Elevated levels of the following variables measured at the respective phases were 
statistically significantly associated with wider CRAE: BMI (7), total pack years of 
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cigarettes smoked (38, 32, 26, 21) and VO2 Max (38). There were no other associations 
of statistical significance. A summary of the results is presented below in table 4-5. 
Table 4-5: Summary of association between variables and CRAE at different ages 
for males (simple linear regression analysis unadjusted). 
Variable Age 
38 32 26 21 18 15 13 11 9 7 5 3 
SBP *** *** *** - ** n.s *** *** ** * - - 
DBP K-5 *** *** *** - n.s n.s n.s n.s n.s n.s - - 
DBP K-4 - - - - - - n.s ** * * - - 
MABP K-5 *** *** *** - * n.s ** ** n.s * - - 
MABP K-4 - - - - - - ** *** ** * - - 
BMI  ** n.s n.s n.s n.s n.s n.s n.s n.s * n.s n.s 
Waist-Hip n.s n.s n.s - - - - - - - - - 
HbA1c n.s n.s - - - - - - - - - - 
Tot. Chol. * n.s n.s - - - - - - - - - 
HDL  n.s n.s n.s - - - - - - - - - 
Non-HDL * * n.s - - - - - - - - - 
WBC n.s n.s n.s - - - - - - - - - 
hsCRP n.s n.s n.s - - - - - - - - - 
Fibrinogen n.s n.s - - - - - - - - - - 
IL-6 * - - - - - - - - - - - 
Tot. Smk. ** ** * * n.s - - - - - - - 
VO2 Max ** n.s n.s - - n.s - - - - - - 
F-RHI n.s - - - - - - - - - - - 
- = not measured, n.s = not significant, * = significant at p < 0.05, ** = significant at p 
< 0.01, *** = significant at p < 0.001, green = significant increase in RVC, red = 
significant decrease in RVC. IL-6 and hsCRP were logarithmically transformed for 
analysis. 
 
4.5.2 Central retinal vein equivalent (unadjusted for fellow retinal vessel calibre) 
4.5.2.1 Females 
In simple linear regression analysis unadjusted for fellow RVC in females, elevated 
levels of the following variables measured at the respective phases were statistically 
significantly associated with narrower CRVE: SBP (38, 15), DBP K-5 (32), MABP K-5 
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(32) and HDL (26). Elevated levels of the following variables measured at the 
respective phases were statistically significantly associated with wider CRVE: DBP K-
5 (18, 11), HbA1c (38, 32), WBC (38, 32, 26) and total pack years of cigarettes smoked 
(38, 32, 26, 21, 18). There were no other associations of statistical significance. A 
summary of the results is presented below in table 4-6. 
Table 4-6: Summary of association between variables and CRVE at different ages 
for females (simple linear regression analysis unadjusted). 
Variable Age 
38 32 26 21 18 15 13 11 9 7 5 3 
SBP * n.s n.s - n.s * n.s n.s n.s n.s - - 
DBP K-5 n.s * n.s - * n.s n.s * n.s n.s - - 
DBP K-4 - - - - - - n.s n.s n.s n.s - - 
MABP K-5 n.s * n.s - n.s n.s n.s n.s n.s n.s - - 
MABP K-4 - - - - - - n.s n.s n.s n.s - - 
BMI  n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
Waist-Hip n.s n.s n.s - - - - - - - - - 
HbA1c * * - - - - - - - - - - 
Tot. Chol. n.s n.s n.s - - - - - - - - - 
HDL  n.s n.s * - - - - - - - - - 
Non-HDL n.s n.s n.s - - - - - - - - - 
WBC ** * ** - - - - - - - - - 
hsCRP n.s n.s n.s - - - - - - - - - 
Fibrinogen n.s n.s - - - - - - - - - - 
IL-6 n.s - - - - - - - - - - - 
Tot. Smk. *** *** *** ** * - - - - - - - 
VO2 Max n.s n.s n.s - - n.s - - - - - - 
F-RHI n.s - - - - - - - - - - - 
- = not measured, n.s = not significant, * = significant at p < 0.05, ** = significant at p 
< 0.01, *** = significant at p < 0.001, green = significant increase in RVC, red = 






In simple linear regression analysis unadjusted for fellow RVC in males, elevated SBP 
at age 38 was statistically significantly associated with narrower CRVE. Elevated levels 
of following variables measured at the respective phases were statistically significantly 
associated with wider CRVE: BMI (15, 13, 11, 7), waist-hip ratio (38, 32), HbA1c (38, 
32), WBC (38, 32), hsCRP (38), fibrinogen (38), F-RHI (38) and total pack years of 
cigarettes smoked (38, 32, 26, 21). There were no other associations of statistical 
significance. A summary of the results is presented below in table 4-7. 
Table 4-7: Summary of association between variables and CRVE at different ages 
for males (simple linear regression analysis unadjusted). 
Variable Age 
38 32 26 21 18 15 13 11 9 7 5 3 
SBP * n.s n.s - n.s n.s n.s n.s n.s n.s - - 
DBP K-5 n.s n.s n.s - n.s n.s n.s n.s n.s n.s - - 
DBP K-4 - - - - - - n.s n.s n.s n.s - - 
MABP K-5 n.s n.s n.s - n.s n.s n.s n.s n.s n.s - - 
MABP K-4 - - - - - - n.s n.s n.s n.s - - 
BMI n.s n.s n.s n.s n.s ** * * n.s * n.s n.s 
Waist-Hip * * n.s - - - - - - - - - 
HbA1c ** * - - - - - - - - - - 
Tot. Chol. n.s n.s n.s - - - - - - - - - 
HDL n.s n.s n.s - - - - - - - - - 
Non-HDL n.s n.s n.s - - - - - - - - - 
WBC ** ** n.s - - - - - - - - - 
hsCRP * n.s n.s - - - - - - - - - 
Fibrinogen ** n.s - - - - - - - - - - 
IL-6 n.s - - - - - - - - - - - 
Tot. Smk. *** *** ** * n.s - - - - - - - 
VO2 Max n.s n.s n.s - - n.s - - - - - - 
F-RHI * - - - - - - - - - - - 
- = not measured, n.s = not significant, * = significant at p < 0.05, ** = significant at p 
< 0.01, *** = significant at p < 0.001, green = significant increase in RVC, red = 




4.5.3 Central retinal artery equivalent (adjusted for fellow retinal vessel calibre) 
4.5.3.1 Females 
In simple linear regression analysis adjusted for fellow RVC in females, elevated levels 
of the following variables measured at the respective phases were statistically 
significantly associated with narrower CRAE: SBP (38, 32, 26, 18, 15, 11, 9, 7), DBP 
K-5 (38, 32, 26, 18, 11, 9, 7), DBP K-4 (11, 9, 7), MABP K-5 (38, 32, 26, 18, 15, 13, 
11, 9, 7), MABP K-4 (13, 11, 9, 7), BMI (38, 32, 26, 21), waist-hip ratio (38, 32, 26), 
total cholesterol (38), non-HDL cholesterol (38, 32), hsCRP (38, 32, 26) and fibrinogen 
(32). Elevated levels of the following variables measured at the respective phases were 
statistically significantly associated with wider CRAE: HDL (32) and VO2 Max (38, 
32, 26). There were no other statistically significant associations. A summary of the 




Table 4-8: Summary of association between variables and CRAE at different ages 
for females (simple linear regression analysis adjusted for fellow RVC). 
Variable Age 
38 32 26 21 18 15 13 11 9 7 5 3 
SBP *** *** ** - ** * n.s *** ** * - - 
DBP K-5 *** *** *** - ** n.s n.s ** * * - - 
DBP K-4 - - - - - - n.s ** * * - - 
MABP K-5 *** *** *** - ** * * *** ** ** - - 
MABP K-4 - - - - - - * *** ** ** - - 
BMI  *** *** ** * n.s n.s n.s n.s n.s n.s n.s n.s 
Waist-Hip ** ** ** - - - - - - - - - 
HbA1c n.s n.s - - - - - - - - - - 
Tot. Chol. * n.s n.s - - - - - - - - - 
HDL  n.s * n.s - - - - - - - - - 
Non-HDL ** * n.s - - - - - - - - - 
WBC n.s n.s n.s - - - - - - - - - 
hsCRP ** * * - - - - - - - - - 
Fibrinogen n.s ** - - - - - - - - - - 
IL-6 n.s - - - - - - - - - - - 
Tot. Smk. n.s n.s n.s n.s n.s - - - - - - - 
VO2 Max *** *** ** - - n.s - - - - - - 
F-RHI n.s - - - - - - - - - - - 
- = not measured, n.s = not significant, * = significant at p < 0.05, ** = significant at p 
< 0.01, *** = significant at p < 0.001, green = significant increase in RVC, red = 




In simple linear regression analysis adjusted for fellow RVC in males, elevated levels 
of the following variables measured at the respective phases were statistically 
significantly associated with narrower CRAE: SBP (38, 32, 26, 18, 15, 13, 11, 9, 7), 
DBP K-5 (38, 32, 26, 18, 15, 13, 11, 9, 7), DBP K-4 (13, 11, 9, 7), MABP K-5 (38, 32, 
26, 18, 15, 13, 11, 9, 7), MABP K-4 (13, 11, 9, 7), BMI (38, 32), waist-hip ratio (38, 
32, 26), total cholesterol (38, 32, 26), non-HDL cholesterol (38, 32, 26), WBC (38, 32, 
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26), hsCRP (38) and IL-6 (38). Elevated levels of the following variables measured at 
the respective phases were statistically significantly associated with wider CRAE: HDL 
(32, 26) and VO2 Max (38, 32, 26). There were no other statistically significant 
associations. A summary of the results is presented below in table 4-9. 
Table 4-9: Summary of association between variables and CRAE at different ages 
for males (simple linear regression analysis adjusted for fellow RVC). 
Variable Age 
38 32 26 21 18 15 13 11 9 7 5 3 
SBP *** *** *** - *** * *** *** *** *** - - 
DBP K-5 *** *** *** - * * * * * ** - - 
DBP K-4 - - - - - - ** ** *** *** - - 
MABP K-5 *** *** *** - ** ** *** ** ** *** - - 
MABP K-4 - - - - - - *** *** *** *** - - 
BMI  *** *** n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
Waist-Hip *** ** * - - - - - - - - - 
HbA1c n.s n.s - - - - - - - - - - 
Tot. Chol. *** *** ** - - - - - - - - - 
HDL  n.s ** * - - - - - - - - - 
Non-HDL *** *** ** - - - - - - - - - 
WBC * ** * - - - - - - - - - 
hsCRP * n.s n.s - - - - - - - - - 
Fibrinogen n.s n.s - - - - - - - - - - 
IL-6 *** - - - - - - - - - - - 
Tot. Smk. n.s n.s n.s n.s n.s - - - - - - - 
VO2 Max *** *** * - - n.s - - - - - - 
F-RHI n.s - - - - - - - - - - - 
- = not measured, n.s = not significant, * = significant at p < 0.05, ** = significant at p 
< 0.01, *** = significant at p < 0.001, green = significant increase in RVC, red = 





4.5.4 Central retinal vein equivalent (adjusted for fellow retinal vessel calibre) 
4.5.4.1 Females 
In simple linear regression analysis adjusted for fellow RVC in females, elevated levels 
of the following variables measured at the respective phases were statistically 
significantly associated with narrower CRVE: HDL (38, 32, 26) and VO2 Max (38, 32). 
Elevated levels of the following variables measured at the respective phases were 
statistically significantly associated with wider CRVE: SBP (38, 32, 18, 11), DBP K-5 
(38, 32, 18, 13, 11, 9, 7), DBP K-4 (11, 7), MABP K-5 (38, 32, 18, 13, 11, 9, 7) and 
MABP K-4 (11, 7), BMI (38, 32, 26), waist-hip ratio (38, 26), non-HDL cholesterol 
(38, 32, 26), WBC (38, 32, 26), hsCRP (38), fibrinogen (38) and total pack years of 
cigarettes smoked (38, 32, 26, 21). There were no other statistically significant 




Table 4-10: Summary of association between variables and CRVE at different 
ages for females (simple linear regression analysis adjusted for fellow RVC). 
Variable Age 
38 32 26 21 18 15 13 11 9 7 5 3 
SBP *** ** n.s - * n.s n.s * n.s n.s - - 
DBP K-5 *** * n.s - *** n.s * *** * * - - 
DBP K-4 - - - - - - n.s *** n.s * - - 
MABP K-5 *** ** n.s - ** n.s * *** * ** - - 
MABP K-4 - - - - - - n.s *** n.s * - - 
BMI  * * * n.s n.s n.s n.s n.s n.s n.s n.s n.s 
Waist-Hip * n.s ** - - - - - - - - - 
HbA1c n.s n.s - - - - - - - - - - 
Tot. Chol. n.s n.s n.s - - - - - - - - - 
HDL  * * * - - - - - - - - - 
Non-HDL ** * * - - - - - - - - - 
WBC ** * * - - - - - - - - - 
hsCRP ** n.s n.s - - - - - - - - - 
Fibrinogen * n.s - - - - - - - - - - 
IL-6 n.s - - - - - - - - - - - 
Tot. Smk. *** *** ** ** n.s - - - - - - - 
VO2 Max ** ** n.s - - n.s - - - - - - 
F-RHI n.s - - - - - - - - - - - 
- = not measured, n.s = not significant, * = significant at p < 0.05, ** = significant at p 
< 0.01, *** = significant at p < 0.001, green = significant increase in RVC, red = 




In simple linear regression analysis adjusted for fellow RVC in males, elevated levels 
of the following variables measured at the respective phases were statistically 
significantly associated with narrower CRVE: HDL (32) and VO2 Max (38, 32). 
Elevated levels of the following variables measured at the respective phases were 
statistically significantly associated with wider CRVE: SBP (38, 32, 26, 18, 13, 11, 9, 
7), DBP K-5 (38, 32, 26, 15, 13, 9, 7), DBP K-4 (13, 9, 7), MABP K-5 (38, 32, 26, 18, 
15, 13, 11, 9, 7), MABP K-4 (13, 11, 9, 7), BMI (38, 32, 15, 13, 11), waist-hip ratio 
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(38, 32), HbA1c (38, 32), total cholesterol (38, 32, 26), non-HDL cholesterol (38, 32, 
26), WBC (38, 32, 26), hsCRP (38), fibrinogen (38, 32), IL-6 (38) total pack years of 
cigarettes smoked (38, 32, 26) and F-RHI (38). There were no other statistically 
significant associations. A summary of the results is presented below in table 4-11. 
 
Table 4-11: Summary of association between variables and CRVE at different 
ages for males (simple linear regression analysis adjusted for fellow RVC). 
Variable Age 
38 32 26 21 18 15 13 11 9 7 5 3 
SBP *** * ** - ** n.s *** * *** ** - - 
DBP K-5 *** ** ** - n.s ** * n.s * ** - - 
DBP K-4 - - - - - - ** n.s *** *** - - 
MABP K-5 *** ** ** - ** ** ** * ** *** - - 
MABP K-4 - - - - - - *** * *** *** - - 
BMI  *** ** n.s n.s n.s ** ** * n.s n.s n.s n.s 
Waist-Hip *** *** n.s - - - - - - - - - 
HbA1c * ** - - - - - - - - - - 
Tot. Chol. ** ** * - - - - - - - - - 
HDL  n.s * n.s - - - - - - - - - 
Non-HDL *** *** ** - - - - - - - - - 
WBC *** *** ** - - - - - - - - - 
hsCRP ** n.s n.s - - - - - - - - - 
Fibrinogen ** * - - - - - - - - - - 
IL-6 ** - - - - - - - - - - - 
Tot. Smk. ** * * n.s n.s - - - - - - - 
VO2 Max *** ** n.s - - n.s - - - - - - 
F-RHI * - - - - - - - - - - - 
- = not measured, n.s = not significant, * = significant at p < 0.05, ** = significant at p 
< 0.01, *** = significant at p < 0.001, green = significant increase in RVC, red = 






4.6 Multiple linear regression analysis 
Multiple linear regression analysis was carried out for cardiovascular risk factors at 
each age, sex stratified and adjusted for fellow RVC, SES as well as age 38 covariates: 
MABP, BMI, waist-hip ratio, HbA1c, total cholesterol, HDL, WBC, hsCRP, 
fibrinogen, IL-6, total pack years smoked, VO2 Max and F-RHI without adjusting for 
the same or similar variable to avoid high collinearity. (i.e. BP measurements were not 
adjusted for MABP at age 38 and non-HDL cholesterol was not adjusted for total 
cholesterol for age 38). IL-6 and hsCRP were logarithmically transformed for analysis. 
More details of multiple regression analysis results can be found in chapter 12 - 
appendix F, p. 195. 
4.6.1 Central retinal artery equivalent 
4.6.1.1 Females 
In multiple linear regression analysis in females, elevated levels of the following 
variables measured at the respective phases were statistically significantly associated 
with narrower CRAE: SBP (38, 32, 26, 18, 15, 11, 9, 7), DBP K-5 (38, 32, 26, 18, 11), 
DBP K-4 (11), MABP K-5 (38, 32, 26, 18, 11, 7) and MABP K-4 (11, 9, 7). Elevated 
HbA1c was significantly associated with wider CRAE at age 38. There were no other 
statistically significant associations. A summary of the results is presented below in 
table 4-12.  
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Table 4-12: Summary of association between variables and CRAE at different 
ages for females (multiple linear regression analysis). 
Variable Age 
38 32 26 21 18 15 13 11 9 7 5 3 
SBP *** *** * - * * n.s *** * * - - 
DBP K-5 *** *** * - * n.s n.s ** n.s n.s - - 
DBP K-4 - - - - - - n.s *** n.s n.s - - 
MABP K-5 *** *** ** - * n.s n.s *** n.s * - - 
MABP K-4 - - - - - - n.s *** * * - - 
BMI  n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
Waist-Hip n.s n.s n.s - - - - - - - - - 
HbA1c * n.s - - - - - - - - - - 
Tot. Chol. n.s n.s n.s - - - - - - - - - 
HDL  n.s n.s n.s - - - - - - - - - 
Non-HDL n.s n.s n.s - - - - - - - - - 
WBC n.s n.s n.s - - - - - - - - - 
hsCRP n.s n.s n.s - - - - - - - - - 
Fibrinogen n.s n.s - - - - - - - - - - 
IL-6 n.s - - - - - - - - - - - 
Tot. Smk. n.s n.s n.s n.s n.s - - - - - - - 
VO2 Max n.s n.s n.s - - n.s - - - - - - 
F-RHI n.s - - - - - - - - - - - 
- = not measured, n.s = not significant, * = significant at p < 0.05, ** = significant at p 
< 0.01, *** = significant at p < 0.001, green = significant increase in RVC, red = 




In multiple linear regression analysis in males, elevated levels of the following 
variables measured at the respective phases were statistically significantly associated 
with narrower CRAE: SBP (38, 32, 26, 18, 13, 11, 9, 7), DBP K-5 (38, 32, 26, 18, 15, 
13, 7), DBP K-4 (13, 11, 9, 7), MABP K-5 (38, 32, 26, 18, 15, 13, 11, 9, 7), MABP K-4 
(13, 11, 9, 7), HbA1c (38, 32), non-HDL cholesterol (32) and WBC (26). Elevated 
levels of following variables measured at the respective phases were statistically 
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significantly associated with wider CRAE: BMI (26, 11, 9, 7, 5) and total pack years of 
cigarettes smoked (21). There were no other statistically significant associations. A 
summary of the results is presented below in table 4-13. 
Table 4-13: Summary of association between variables and CRAE at different 
ages for males (multiple linear regression analysis). 
Variable Age 
38 32 26 21 18 15 13 11 9 7 5 3 
SBP *** ** * - ** n.s *** ** *** * - - 
DBP K-5 *** ** *** - * * * n.s n.s ** - - 
DBP K-4 - - - - - - ** * *** ** - - 
MABP K-5 *** ** *** - ** * ** * ** *** - - 
MABP K-4 - - - - - - *** ** *** *** - - 
BMI  n.s n.s * n.s n.s n.s n.s * * ** ** n.s 
Waist-Hip n.s n.s n.s - - - - - - - - - 
HbA1c * * - - - - - - - - - - 
Tot. Chol. n.s n.s n.s - - - - - - - - - 
HDL  n.s n.s n.s - - - - - - - - - 
Non-HDL n.s * n.s - - - - - - - - - 
WBC n.s n.s * - - - - - - - - - 
hsCRP n.s n.s n.s - - - - - - - - - 
Fibrinogen n.s n.s - - - - - - - - - - 
IL-6 n.s - - - - - - - - - - - 
Tot. Smk. n.s n.s n.s * n.s - - - - - - - 
VO2 Max n.s n.s n.s - - n.s - - - - - - 
F-RHI n.s - - - - - - - - - - - 
- = not measured, n.s = not significant, * = significant at p < 0.05, ** = significant at p 
< 0.01, *** = significant at p < 0.001, green = significant increase in RVC, red = 
significant decrease in RVC. IL-6 and hsCRP were logarithmically transformed for 
analysis. 
 
4.6.2 Central retinal vein equivalent 
4.6.2.1 Females 
In multiple linear regression analysis in females, elevated levels of the following 
variables measured at the respective phases were statistically significantly associated 
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with wider CRVE: SBP (38, 32, 11, 7), DBP K-5 (38, 26, 18, 11, 7), DBP K-4 (11, 7), 
MABP K-5 (38, 32, 26, 18, 11, 7), MABP K-4 (11, 7) and total pack years of cigarettes 
smoked (38). There were no other statistically significant associations. A summary of 
the results is presented below in table 4-14. 
Table 4-14: Summary of association between variables and CRVE at different 
ages for females (multiple linear regression analysis). 
Variable Age 
38 32 26 21 18 15 13 11 9 7 5 3 
SBP ** * n.s - n.s n.s n.s ** n.s * - - 
DBP K-5 *** n.s ** - ** n.s n.s ** n.s * - - 
DBP K-4 - - - - - - n.s *** n.s * - - 
MABP K-5 *** * ** - ** n.s n.s *** n.s ** - - 
MABP K-4 - - - - - - n.s *** n.s * - - 
BMI  n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s 
Waist-Hip n.s n.s n.s - - - - - - - - - 
HbA1c n.s n.s - - - - - - - - - - 
Tot. Chol. n.s n.s n.s - - - - - - - - - 
HDL  n.s n.s n.s - - - - - - - - - 
Non-HDL n.s n.s n.s - - - - - - - - - 
WBC n.s n.s n.s - - - - - - - - - 
hsCRP n.s n.s n.s - - - - - - - - - 
Fibrinogen n.s n.s - - - - - - - - - - 
IL-6 n.s - - - - - - - - - - - 
Tot. Smk. * n.s n.s n.s n.s - - - - - - - 
VO2 Max n.s n.s n.s - - n.s - - - - - - 
F-RHI n.s - - - - - - - - - - - 
- = not measured, n.s = not significant, * = significant at p < 0.05, ** = significant at p 
< 0.01, *** = significant at p < 0.001, green = significant increase in RVC, red = 




In multiple linear regression analysis in males, elevated levels of the following 
variables measured at the respective phases were statistically significantly associated 
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with wider CRVE: SBP (13, 9, 7), DBP K-5 (38, 26, 18, 15, 9, 7), DBP K-4 (13, 9, 7), 
MABP K-5 (38, 32, 26, 18, 15, 13, 9, 7), MABP K-4 (13, 9, 7), BMI (5), waist-hip ratio 
(38), HbA1c (32), WBC (32), F-RHI (38). There were no other statistically significant 
associations. A summary of the results is presented below in table 4-15. 
 
Table 4-15: Summary of association between variables and CRVE at different 
ages for males (multiple linear regression analysis). 
Variable Age 
38 32 26 21 18 15 13 11 9 7 5 3 
SBP n.s n.s n.s - n.s n.s * n.s ** ** - - 
DBP K-5 *** n.s ** - * * n.s n.s * ** - - 
DBP K-4 - - - - - - * n.s ** ** - - 
MABP K-5 ** * ** - * * * n.s ** ** - - 
MABP K-4 - - - - - - ** n.s *** ** - - 
BMI  n.s n.s n.s n.s n.s n.s n.s n.s n.s n.s * n.s 
Waist-Hip * n.s n.s - - - - - - - - - 
HbA1c n.s * - - - - - - - - - - 
Tot. Chol. n.s n.s n.s - - - - - - - - - 
HDL  n.s n.s n.s - - - - - - - - - 
Non-HDL n.s n.s n.s - - - - - - - - - 
WBC n.s * n.s - - - - - - - - - 
hsCRP n.s n.s n.s - - - - - - - - - 
Fibrinogen n.s n.s - - - - - - - - - - 
IL-6 n.s - - - - - - - - - - - 
Tot. Smk. n.s n.s n.s n.s n.s - - - - - - - 
VO2 Max n.s n.s n.s - - n.s - - - - - - 
F-RHI ** - - - - - - - - - - - 
- = not measured, n.s = not significant, * = significant at p < 0.05, ** = significant at p 
< 0.01, *** = significant at p < 0.001, green = significant increase in RVC, red = 






4.7 Blood pressure trajectory analysis 
Participants’ BP trajectories (SBP trajectories) were categorised into four groups 
(normal BP, high-normal BP, pre-HTN and HTN, total n = 975). In clinical terms, 
throughout adulthood, the normal and high-normal groups had normal SBP range (90-
120 mmHg) and the pre-HTN group had BP within the pre-HTN range (120 – 139 
mmHg). The HTN group which had the highest SBP at age 7 and displayed the steepest 
rise from childhood to adulthood had SBP at age 38 in the hypertensive range (> 140 
mmHg).20 (Figure 4-11)  
 
Figure 4-11: Plot of predicted BP trajectory lines.20  
95% CI for 4 BP trajectory groups identified. n = 975. 
A total of 922 participants of the 975 participants from the trajectory analysis had 
corresponding RVC for analysis. Table 4-16 shows the mean CRAE, CRVE and AVR 
value for each trajectory group. Mean CRAE and AVR tended to decrease with 




Table 4-16: Descriptive data of RVC in relation to BP trajectories. 
BP trajectory N (%) Mean (standard error) 
CRAE  CRVE AVR 
Normal 187 (20.3%) 141.17 (0.76) 196.75 (1.06) 0.719 (0.003) 
High-normal 407 (44.1%) 138.45 (0.53) 196.67 (0.77) 0.705 (0.002) 
Pre-hypertensive 293 (31.8%) 133.90 (0.65) 194.84 (0.90) 0.688 (0.002) 
Hypertensive 35 (3.8%) 131.01 (2.01) 196.41 (2.44) 0.668 (0.009) 
Units for CRAE and CVRE = µm. AVR = CRAE/ CRVE, a dimensionless quotient. 
Statistical analysis was subsequently conducted to quantify these differences. The non-
normal groups were compared with normal groups with linear regression analysis, 
unadjusted, adjusted for fellow RVC, and adjusted for fellow RVC, SES and age 38 
covariates (BMI, waist-hip ratio, HbA1c, total cholesterol, HDL, WBC, hsCRP, 
fibrinogen, IL-6, total pack years smoked, VO2 Max and F-RHI). IL-6 and hsCRP were 
logarithmically transformed for analysis. AVR was not adjusted for fellow RVC. 
 
4.7.1 Central retinal artery equivalent 
4.7.1.1 Female 
Simple linear regression analysis (unadjusted and adjusted for fellow RVC) for female 
BP trajectory groups against CRAE, showed high-normal, pre-HTN and HTN groups to 
have statistically significantly narrower CRAE than the normal BP group with 
increasingly narrower CRAE in that order. This significant association persisted when 
adjusted for CRVE. (Tables 4-17 and 4-18) 
During multiple linear regression analysis, the pre-HTN and HTN groups had 
significantly narrower CRAE than the normal BP group with increasingly narrower 





Table 4-17: Simple linear regression analysis of BP trajectory groups for females 
against CRAE unadjusted.  
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal -2.86* -2.488 .013 -5.11 -.60 
Pre-Hypertension -8.94*** -5.756 <.001 -11.99 -5.89 
Hypertension -21.37** -2.735 .006 -36.72 -6.01 
Dependent variable: CRAE. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001.  
Table 4-18: Simple linear regression analysis of BP trajectory groups for females 
against CRAE adjusted for CRVE. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal -2.40** -2.906 .004 -4.03 -.78 
Pre-Hypertension -6.87*** -6.123 <.001 -9.08 -4.67 
Hypertension -17.72** -3.148 .002 -28.78 -6.66 
Dependent variable: CRAE. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
Table 4-19: Multiple linear regression analysis of BP trajectory groups for females 
against CRAE.  
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal -1.77 -1.901 .058 -3.61 .06 
Pre-Hypertension -5.41*** -4.287 <.001 -7.89 -2.93 
Hypertension -15.20* -2.605 .010 -26.68 -3.72 
Dependent variable: CRAE. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
4.7.1.2 Male 
Simple linear regression analysis for male BP trajectory groups against CRAE 
unadjusted, showed pre-HTN and HTN groups to have statistically significantly 
narrower CRAE than normal groups, with increasingly narrower CRAE observed in the 
high-normal, pre-HTN and HTN groups in that order. When adjusted for CRVE, the 
high-normal, pre-HTN and HTN groups had significantly narrower CRAE than the 
normal BP group with increasingly narrower CRAE observed in that order. (Tables 4-
20 and 4-21) 
During multiple linear regression analysis, the pre-HTN and HTN groups had 
significantly narrower CRAE than the normal BP group with increasingly narrower 
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CRAE observed in the high-normal, pre-HTN and HTN groups in that order. (Table 4-
22) 
Table 4-20: Simple linear regression analysis for BP trajectory groups for males 
against CRAE unadjusted. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal -3.44 -1.730 .084 -7.35 .47 
Pre-Hypertension -7.84*** -3.990 <.001 -11.70 -3.98 
Hypertension -10.67*** -4.123 <.001 -15.76 -5.59 
Dependent variable: CRAE. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
Table 4-21: Simple linear regression analysis for BP trajectory groups for males 
against CRAE adjusted for CRVE. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal -3.20* -2.26 .024 -5.98 -.42 
Pre-Hypertension -6.37*** -4.55 <.001 -9.12 -3.62 
Hypertension -9.75*** -5.29 <.001 -13.37 -6.13 
Dependent variable: CRAE. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
Table 4-22: Multiple linear regression analysis for BP trajectory groups for males 
against CRAE. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal -2.06 -1.306 .192 -5.16 1.04 
Pre-Hypertension -4.21** -2.670 .008 -7.31 -1.11 
Hypertension -6.64** -3.157 .002 -10.78 -2.51 
Dependent variable: CRAE. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
4.7.2 Central retinal vein equivalent 
4.7.2.1 Female 
Simple linear regression analysis for female BP trajectory groups against CRVE had no 
statistically significant associations. When adjusted for CRAE however, the pre-HTN 
group had significantly wider CRVE than normal BP group with increasingly wider 
CRVE observed in high-normal, pre-HTN and HTN groups in that order, while not 
achieving statistical significance for the high-normal and HTN groups. In multiple 
linear regression analysis, no groups were statistically significantly different from the 
normal BP trajectory group. (Tables 4-23 to 4-25) 
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Table 4-23: Simple linear regression analysis for BP trajectory groups for females 
against CRVE unadjusted. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal -.93 -.569 .570 -4.13 2.28 
Pre-Hypertension -4.22 -1.914 .056 -8.55 .11 
Hypertension -7.46 -.673 .501 -29.27 14.34 
Dependent variable: CRVE. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
Table 4-24: Simple linear regression analysis for BP trajectory groups for females 
against CRVE adjusted for CRAE. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal 1.89 1.600 .110 -.43 4.21 
Pre-Hypertension 4.60** 2.796 .005 1.37 7.83 
Hypertension 13.62 1.691 .092 -2.21 29.45 
Dependent variable: CRVE. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
Table 4-25: Multiple linear regression analysis for BP trajectory groups for 
females against CRVE. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal 1.83 1.397 .163 -.75 4.41 
Pre-Hypertension 3.53 1.954 .051 -.02 7.08 
Hypertension 5.85 .708 .479 -10.39 22.08 
Dependent variable: CRVE. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
4.7.2.2 Male 
Simple linear regression analysis for male BP trajectory groups against CRVE had no 
statistically significant associations. However, when adjusted for CRAE, pre-HTN and 
HTN groups had significantly wider CRVE than normal group with increasingly wider 
CRVE observed in high-normal, pre-HTN and HTN groups, although statistical 
significance was not reached with the high-normal group. In multiple linear regression 
analysis, no group was statistically significantly different from the normal BP trajectory 
group. (Tables 4-26 to 4-28) 
70 
 
Table 4-26: Simple linear regression analysis for BP trajectory groups for males 
against CRVE unadjusted. 
BP group Β t Sig. Lower 95% CI Upper 95% CI 
High-Normal -.49 -.173 .863 -6.01 5.04 
Pre-Hypertension -2.95 -1.065 .287 -8.40 2.50 
Hypertension -1.86 -.508 .612 -9.04 5.33 
Dependent variable: CRVE. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
Table 4-27: Simple linear regression analysis for BP trajectory groups for males 
against CRVE adjusted for CRAE. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal 2.93 1.462 .144 -1.01 6.88 
Pre-Hypertension 4.83* 2.406 .017 .88 8.77 
Hypertension 8.75** 3.301 .001 3.54 13.95 
Dependent variable: CRVE. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
Table 4-28: Multiple linear regression analysis for BP trajectory groups for males 
against CRVE. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal 1.87 .845 .399 -2.48 6.21 
Pre-Hypertension 3.21 1.447 .149 -1.15 7.58 
Hypertension 4.75 1.600 .111 -1.09 10.60 
Dependent variable: CRVE. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
4.7.3 Arteriole-to-venule ratio 
4.7.3.1 Female 
Simple linear regression analysis for female BP trajectory groups against AVR 
(CRAE/CRVE) showed a statistically significant difference between normal BP 
trajectory group and all other groups. AVR was increasingly lower for high-normal, 
pre-HTN and HTN groups in that order. During multiple linear regression analysis, the 
order and increasing magnitude of difference persisted, however, statistically 




Table 4-29: Simple linear regression analysis for BP trajectory groups for females 
against AVR. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal -.011* -2.377 .018 -.020 -.002 
Pre-Hypertension -.031*** -4.903 <.001 -.043 -.018 
Hypertension -.086** -2.748 .006 -.148 -.025 
Dependent variable: AVR. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
Table 4-30: Multiple linear regression analysis for BP trajectory groups for 
females against AVR. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal -.010 -1.804 .072 -.020 .001 
Pre-Hypertension -.025** -3.454 .001 -.039 -.011 
Hypertension -.066* -1.987 .048 -.131 -.001 
Dependent variable: AVR. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001. 
 
4.7.3.2 Male 
Simple linear regression analysis for male BP trajectory groups against AVR showed 
statistically significant difference between normal BP trajectory group and all other 
groups. AVR was increasingly lower for high-normal, pre-HTN and HTN groups in 
that order. During multiple linear regression analysis, the order and increasing 
magnitude of difference persisted, however, statistically significant difference was only 
present for the pre-HTN and HTN groups. (Tables 4-31 and 4-32) 
Table 4-31: Simple linear regression analysis for BP trajectory groups for males 
against AVR. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal -.016* -2.145 .032 -.032 -.001 
Pre-Hypertension -.030*** -4.015 <.001 -.045 -.016 
Hypertension -.048*** -4.849 <.001 -.068 -.029 





Table 4-32: Multiple linear regression analysis for BP trajectory groups for males 
against AVR. 
BP group β t Sig. Lower 95% CI Upper 95% CI 
High-Normal -.012 -1.358 .175 -.028 .005 
Pre-Hypertension -.022 -2.534 .012 -.038 -.005 
Hypertension -.032 -2.822 .005 -.054 -.010 





The Dunedin study is a longitudinal study of an original birth cohort of 1037 children 
followed from the early 1970s with a high retention rate.11 Data up to the age of 38 was 
used for the analysis presented in this thesis. This is the first prospective longitudinal 
study to address the hypothesis that RVC in early middle age is influenced by 
preceding longitudinal cardiovascular risk factors from early childhood to early middle 
age. 
Recent evidence from the Dunedin study has shown that elevated SBP in early 
childhood (age 7 and 11) tracks onto elevated SBP into adulthood (age 18, 26, 32 and 
38) in a clinically measurable way with deleterious cardiovascular outcomes.20 The 
thesis adds to this evidence by showing statistically significant narrowing of CRAE at 
age 38 with increasing levels of SBP in a dose dependent manner independent of other 
cardiovascular risk factors.  Hence, proving the hypothesis that RVC in early middle 
age is in fact influenced by longitudinally measured cardiovascular risk factors from 
early childhood.  
This chapter is divided into a summary of the international data for associations 
between cardiovascular risk factors and RVC, the significant findings from the Dunedin 
study, how these findings compare with current evidence, the study strengths and 
limitations, the final conclusions of this thesis and future directions. 
 
 International data 
International data, a mixture of cohort and predominantly cross-sectional studies have 
shown significant associations between elevated BP and narrower retinal arterioles;39-53 
and elevated BP and wider venules. 39, 42, 45, 46, 48, 49 
Significant associations have also been found between elevated metabolic risk factors, 
inflammatory markers, smoking, F-RHI and RVC. BMI was significantly associated 
with wider CRVE,39, 42-44, 51, 53, 58-60, 62-64 and narrower CRAE.39, 42-44, 53, 58-60, 62, 64 The 
literature review showed mixed associations between blood glucose levels and RVC.  
The literature review of the impact of waist-hip ratio, lipids, inflammatory markers, 
smoking and endothelial function on RVC yielded fewer than ten studies in each 
variable category. Notable findings include the significant association of inflammatory 
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markers (CRP, WBC and fibrinogen) and smoking with wider CRVE.39, 42, 51, 53, 72, 73 
Elevated LDL was significantly associated with wider CRVE,39, 42 and increased 
brachial artery FMD was significantly associated with narrower CRVE.74 
Adult retinal microvasculature changes associated with cardiovascular risk factors is 
mirrored in the paediatrics population.8 However, there is no longitudinal data showing 
persistence of paediatric retinal microvasculature change into adulthood.8 While the 
Dunedin study is not able to address this issue directly, it is however, possible to infer 
the persistence of early childhood cardiovascular effect in the form of RVC measured 
in early middle age. Furthermore, due to the multiple strengths of the Dunedin study, 
not limited to the high retention rate, precise measurement and longitudinal nature of its 
follow up, it is possible to infer potential causal relationships. 
 
 Significant findings from the Dunedin study 
This subsection is divided into discussion of the descriptive results, linear regression 
analysis and further discussion of blood pressure and RVC. 
5.2.1 Descriptive data 
Descriptive data from the Dunedin study from chapter four provides an avenue to 
compare the validity of the data from the cohort before addressing the hypothesis that 
RVC at age 38 is influenced by longitudinally measured cardiovascular risk factors 
from early childhood. 
In the Dunedin study, the mean (± σ) CRAE at age 38 was 138 (±11) µm in females 
and 137 (± 11) µm in males; the mean CRVE was 195 (± 16) µm in females and 197 (± 
15) µm in males; and the mean AVR was 0.71 (± 0.05) in females and 0.69 (± 0.04) in 
males. These finding are similar to a study from Japan which measured RVC in 
individuals aged 40 to 74.93 The vast majority of studies in the literature looked at an 
older population group. BMES which looked at a cohort of Australian participants aged 
49+ had a mean CRAE of 199 (± 18) µm and CRVE of 229 (± 20) µm in those aged 
under 60.94 Previous evidence suggests that RVC increases dramatically from birth to 
early childhood and continues to increase, in those over middle age, before starting to 
decrease in size after the age of 60.32 
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CRAE at age 38 was not statistically significantly different between the sexes, however 
females had a significantly narrower CRVE than males (difference of -1.96 µm, 95% 
CI: -3.92 to -0.01, p = 0.049) and a greater arteriovenous ratio than males (0.014, 95% 
CI 0.008 to 0.019, p < 0.001). Few studies have specifically investigated the association 
between sex and RVC, with inconsistent findings. In BMES, CHS and MESA, 
however, both CRAE and AVR were consistently larger in women compared to men. 
Currently there is no adequate explanation for the difference in RVC between the 
sexes.34 
BMI increased with age in both females and males. In children and adolescents growth 
largely accounts for the increase in BMI.95 However, there is also the effect of a general 
increase in BMI over time since the 1970s, worldwide in children, adolescents and 
adults.96 Waist-hip ratio was significantly greater in males, at p < 0.001 at ages 26, 32 
and 38. This is consistent with the evidence that males have a relatively less limb fat 
and relative greater central deposition of fat than women.82 
In adolescence and adults, BP was lower in females compared to males, consistent with 
the existing literature.97, 98 Blood pressure in the Dunedin study, particularly SBP was 
significantly greater in adolescents and adults than children, consistent with the 
expected change in BP with age.78, 98 VO2 max was significantly lower in females 
compared to males and it decreased with age from age 15 to age 38, consistent with the 
existing literature.99, 100 Total cholesterol and non-HDL cholesterol was significantly 
greater in males and HDL cholesterol was significantly lower in males compared with 
females in the Dunedin study, similar to the findings of a European cross-section study 
of 38 year old men and women.101  
High sensitive CRP was significantly greater in females compared with males in the 
Dunedin study at ages 26 and 38 and this may be a reflection of lower cardiorespiratory 
fitness as demonstrated by lower VO2 max or a reflection of the use of oral 
contraceptive pill, with 40% of the females at age 26 having been on the combined oral 
contraceptive pill.102, 103 Cardiorespiratory fitness is inversely associated with hsCRP 
independent of multiple cardiovascular risk factors.103 and use of the oral contraceptive 
pill is associated with elevated hsCRP in the Dunedin study cohort.102 It is also thought 
that greater subcutaneous fat in pre-menopausal women contributes to their higher 
hsCRP levels.104 Blood glucose was significantly lower in females at ages 32 and 38 in 
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the Dunedin study. A large Chinese cross-sectional study of healthy subjects found 
similar sex difference in HbA1c in pre-menopausal women.105 
Females in the Dunedin study had a significantly better endothelial function than males 
as assessed by PAT, a measure of microvascular endothelial function. These findings 
are consistent with a previous large cross-sectional community study from the 
Framingham heart Study which also showed a similar higher value of PAT ratio (0.250) 
in females compared to males.106 
The similarities between the descriptive data from the Dunedin study and existing 
literature imply that the data from the Dunedin study is valid and reproducible and that 
the findings from the Dunedin study have international translatability. 
 
5.2.2 Linear regression analysis of covariates 
Simple linear regression analysis was conducted between each cardiovascular risk 
factor from age 3 to 38 as available and RVC at age 38, with and without adjustment 
for fellow RVC. Simple linear regression analysis without adjustment for fellow RVC 
produced results which were inconsistent with the existing literature demonstrating the 
limitations of analyses without adjustment for fellow RVC. For example, SBP at ages 
38 was statistically significantly associated with narrower CRVE for both sexes, at a p-
value < 0.05. However, when adjusted for fellow RVC, SBP at age 38 for both sexes 
was extremely significantly associated with wider CRVE, p < 0.001 in accordance with 
the published literature. The coefficient of correlation between CRAE and CRVE in the 
Dunedin study was r = 0.688. Hence the above effect is likely secondary to the 
confounding effect of narrower CRAE with elevated SBP at age 38 exerting a 
narrowing effect on CRVE when unadjusted.34, 107   
Simple linear regression analysis which adjusted for fellow RVC is more valid because 
as well as accounting for the confounding effect of the vessels (CRAE and CRVE) on 
each other, any effect from optical and ocular magnification (from refractive curvature 
and axial length of the eye) is also adjusted for.34 Hence, the simple linear regression 




Simple linear regression analysis (adjusting for fellow RVC) showed elevated BP to be 
consistently and significantly associated with narrower CRAE and wider CRVE across 
multiple age groups (children, adolescents and adults) for both sexes. Elevated BMI 
and waist-hip ratio in adults was significantly associated with narrower CRAE and 
wider CRVE, with elevated BMI in adolescent males also significantly associated with 
wider CRVE. Waist-hip ratio was only measured in adults from age 26. 
Blood tests were only done in adults, from age 26 upwards. Elevated blood glucose was 
significantly associated with wider CRVE in adult males. Elevated lipids (non-HDL 
cholesterol) known to increase cardiovascular risk profile17 were significantly 
associated with narrower CRAE and wider CRVE for females (ages 32, 38) and males 
(ages 26, 32, 38), however, the association was inconsistent, with elevated total 
cholesterol achieving a significant association with CRVE change in males but not 
females. Elevated HDL known to be protective against cardiovascular events,17 showed 
statistically significant association with wider CRAE (females, age 32; males, ages 26, 
32) and narrower CRVE (females, ages 26, 32, 38; males, age 32). 
Inflammatory markers measured were CRP, WBC, fibrinogen and IL-6. There were 
inconsistent significant associations between elevated inflammatory markers and 
narrower CRAE and wider CRVE in females and males. Cumulative pack years of 
cigarettes smoked was not statistically significantly associated with CRAE, however, 
greater total pack years of cigarettes smoked was significantly associated with wider 
CRVE in both females and males, with the significance and magnitude of association 
being greater at older ages, and this is likely the consequence of greater spread of 
results and the greater cumulative pack years of cigarettes smoked at older ages as one 
would expect with this measure of smoking in a population. 
VO2 max, a measure of cardiorespiratory fitness was measured in adolescence (age 15) 
and adults (age 26, 32, 38). Greater VO2 max and hence greater cardiorespiratory 
fitness is protective against adverse cardiovascular events.29, 30 Greater VO2 max was 
statistically significantly associated with wider CRAE (age 26, 32, 38) and narrower 
CRVE (age 32, 38) in adult females and males. This is a novel finding as there is 
currently no published study on the association between VO2 max and RVC. Elevated 
F-RHI (a measure of endothelial function measured at age 38) was statistically 
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significantly associated with wider CRVE in males only implying no significant 
association between these different measures of vascular function. 
Elevated BP, BMI, waist-hip ratio, HbA1c, total cholesterol, non-HDL cholesterol 
(LDL and triglycerides), inflammatory markers, pack years of cigarettes smoked have 
been associated with an increased risk of CHD.17, 18, 21-27 Whereas higher levels of 
cardiorespiratory fitness, endothelial function and HDL cholesterol have been shown to 
be protective against CHD.17, 18, 28, 29  
Several prominent studies have linked narrower CRAE and wider CRVE to CHD in 
middle and older aged participants, with stronger associations found in females.2, 9, 14, 15 
This is consistent with the findings in the simple linear regression analysis adjusted for 
fellow RVC where elevated levels of cardiovascular risk factors in adulthood 
traditionally perceived to increase risk of CHD were significantly associated with 
narrower CRAE and wider CRVE in both sexes. Conversely CHD risk protectors, 
elevated HDL and VO2 max were significantly associated with wider CRAE and 
narrower CRVE in females and males.  
An exception was the significant association (p < 0.05) of elevated F-RHI with wider 
CRVE in males. In multiple linear regression analysis, the association persisted with 
increased significance (p < 0.01). No statistically significant associations were seen 
between PAT measurements and RVC in females and CRAE in males. Higher F-RHI 
values are an indication of better endothelial function and are associated with a 
decreased risk of cardiovascular events.28 Hence, this association is inconsistent with 
the associations found between other cardiovascular risk factors, where the predicted 
association between increasing F-RHI and RVC, would be a narrowing of CRVE.  
The existing literature on endothelial function and RVC is focused on brachial FMD, a 
measure of macrovascular endothelial function. Elevated brachial FMD in the MESA 
study reported by Nguyen et al was significantly (p<0.001) associated with narrower 
CRVE after adjustment for fellow RVC and traditional cardiovascular risk factors.74 A 
study by Van Hecke et al which did not adjust for fellow RVC and hence excluded 
from the formal literature review of the thesis, showed no statistically significant 
association between brachial FMD and RVC.108 Hamburg et al 2011 showed that the 
two measures of endothelial function (brachial FMD and PAT) had different 
correlations with cardiovascular risk factors, were not necessarily correlated with each 
79 
 
other and provided different measures of vascular function (larger conduit vs smaller 
digital vessels respectively), with potential for different cardiovascular risk profiling.106 
There were no prior studies comparing PAT to RVC and no other studies comparing 
brachial FMD to RVC. The findings from the Dunedin study are therefore novel and 
further research is needed to validate the associations of PAT ratio and RVC in 
participants at phase 38 of the Dunedin study. Phase 45 of the Dunedin study, expected 
to be completed in the year 2018, may provide this opportunity.11 
In simple linear regression analysis adjusted for fellow RVC, BMI in adults was 
significantly associated with narrower CRAE and wider CRVE. In children, however, 
statistically significant association was only seen in males (phases 11, 13 and 15) for 
BMI and CRVE. The lack of significant association in children may be explained by 
the narrower spread of BMI at younger ages and hence the lower power to find 
statistically significant findings from the Dunedin study. However, the above 
statistically significant findings lost significance in multiple linear regression analysis. 
BMI is significantly and positively correlated with elevated SBP and DBP,109 and is 
known to be associated with multiple other cardiovascular risk factors102 Hence once 
adjusted for BP and other covariates in multiple linear regression analysis, there was no 
longer an association between BMI and RVC in adulthood and males aged 11, 13 and 
15 where statistical significance was present in simple linear regression analysis 
adjusted for fellow RVC.  
In multiple linear regression analysis in males, elevated BMI at ages 26, 11 and 9 was 
significantly (p < 0.05) associated with wider CRAE; BMI at ages 7 and 5 was very 
significantly (p < 0.01) associated with wider CRAE; and BMI at age 5 was 
significantly associated with wider CRVE. There were no significant associations of 
BMI with either CRAE or CRVE in females. In simple linear regression analysis 
adjusted for fellow RVC, however, BMI was not associated with RVC at any of these 
ages for males; and therefore, the above findings appear likely to be spurious and a 
result of over adjustment in the multiple regression analysis. Moreover, in the literature 
review of this thesis, in no study was elevated BMI significantly associated with wider 
CRAE. 
High sensitive CRP at age 38 was significantly associated with narrower CRAE and 
wider CRVE in both sexes in simple linear regression analysis adjusted for fellow 
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RVC. While measured at ages 32 and 26 as well, significant association was only found 
in females in these phases, with elevated hsCRP associated with narrower CRAE. One 
possible explanation for the significant association with females and CRAE at younger 
adult ages may be the independent and positive significant association of combined oral 
contraceptive use and elevated hsCRP, with 40% of females in the Dunedin study being 
on the combined oral contraceptive pill at age 26.102 The spread of hsCRP at age 26 for 
females is also large with a standard deviation of 9.67 mg/L and may have provided 
sufficient statistical power to find significant association with narrowing of CRAE with 
elevated hsCRP. However, the significant association persisted at age 32 despite the use 
of oral contraceptive in females halving at this age,110 along with the halving of 
standard deviation of CRP (4.68 mg/L). Once multiple linear regression analysis was 
conducted, there was no longer a statistically significant association between hsCRP 
and RVC in both sexes. High sensitive CRP is independently and positively associated 
with BMI in young adults and independently and positively associated with SBP and 
oral contraceptive use in females and negatively associated with SBP in males.102 High 
sensitive CRP is also independently and inversely associated with cardiorespiratory 
fitness in young adults.103 Hence, in multiple linear regression analysis when these 
variables (excluding oral contraceptive use) as well as other cardiovascular risk factors 
were adjusted for, there was no longer a significant association between hsCRP and 
RVC. 
Many of the significant associations between lipids and RVC dissipated in multiple 
linear regression analysis. Dyslipidaemia is linked to hypertension and once adjusted 
for blood pressure, there was loss of significance and magnitude of association with 
RVC.111 However, elevated non-HDL cholesterol at age 32 for males was significantly 
associated with narrower CRAE of -0.734 µm per mmol/L of non-HDL cholesterol, 
95% C.I: -1.449 to -0.018, p = 0.045, in multiple linear regression analysis. This 
parallels the extremely significant (p <0.001) association with narrower CRAE of -
1.529 µm per mmol/L of non-HDL cholesterol, 95% C.I: -2.214 to -0.844 in simple 
linear regression analysis adjusted for fellow RVC. This isolated finding of significant 
association between non-HDL cholesterol (LDL cholesterol, lipoprotein(a), triglyceride 
rich lipoproteins: very low density lipoprotein cholesterol, intermediate density 
cholesterol) is consistent with the study by Kifley et al, 2007, which found significant 
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associations between triglycerides and narrower CRAE after adjusting for fellow RVC 
and multiple cardiovascular risk factors including SBP and sex.53 
In simple linear regression analysis adjusted for fellow RVC, HbA1c was not 
significantly associated with CRAE for both sexes nor with CRVE for females. In 
males however HbA1c at age 32 was very significantly associated with a wider CRVE 
of + 4.208 µm per percent increase in HbA1c, 95% C.I: 1.328 to 7.088, p = 0.004; and 
HbA1c at age 38 was significantly associated with wider CRVE of + 1.615 µm per 
percent increase in HbA1c, 95% C.I: 0.052 to 3.178, p = 0.043. During multiple linear 
regression analysis, the association that persisted was for male at age 32, a wider CRVE 
of + 3.353 µm per percent increase in HbA1c, 95% C.I: 0.390 to 6.316, p = 0.027. 
Diabetes is associated with hypertension and adjustment for BP in multiple linear 
regression analysis likely contributed to the loss of significance and magnitude of effect 
of the above findings.111 A number of studies in the literature which adjusted for fellow 
RVC and multiple cardiovascular risk factors including BP and sex also found a 
significant association between elevated blood glucose states and wider CRVE.39, 65, 68, 
69 Other significant findings (p < 0.05) in multiple linear regression analysis with 
HbA1c include elevated HbA1c associated with wider CRAE in females at age 38 and 
narrower CRAE in males at ages 38 and 32. These association may be spurious as there 
were no significant associations for these variables during simple linear regression 
analysis adjusted for fellow RVC. 
WBC count, measured at all phases (26, 32 and 38), was significantly associated with 
narrower CRAE for males and wider CRVE for both sexes in simple linear analysis 
adjusted for fellow RVC. In multiple linear regression analysis, the only persistent 
significant findings were narrowing of CRAE at age 26 for males, -0.587 µm per unit 
(x109/L cell count) increase in WBC, 95% C.I: -1.072 to -0.103, p = 0.018 and 
widening of CRVE at age 32 for males, + 0.668 µm per unit (x109/L cell count) 
increase in WBC, 95% C.I: 0.038 to 1.298, p = 0.038. However, the level of 
significance and magnitude of association was smaller than in simple linear regression 
analysis adjusted fellow RVC for WBC at age 32, CRVE of + 1.291 µm, 95% C.I: 
0.724 to 1.858, p < 0.001. Whereas for age 26, similar findings were present in simple 
linear regression analysis adjusted for fellow RVC, CRAE of -0.548 µm, 95% C.I: -
1.016 to -0.079, p = 0.022. In simple linear regression analysis (adjusted for fellow 
RVC) fibrinogen was significantly associated with narrower CRAE for one of the two 
82 
 
measured phases, age 32, and wider CRVE at age 38 for females; with significant 
association with wider CRVE at both age 32 and 38 for males. In multiple linear 
regression analysis however, there was no statistically significant association between 
fibrinogen and RVC for both sexes. IL-6 was significantly associated with narrower 
CRAE for males and wider CRVE for both sexes in simple linear regression analysis 
adjusted for fellow RVC, however, this significance was lost in multiple linear 
regression analysis. The loss of significance for many of these inflammatory markers 
with multiple linear regression analysis can be explained by the link between 
inflammation and hypertension, a covariate which was adjusted for.112-118 The 
persistence of significance of WBC in multiple linear regression analysis is isolated for 
one phase with CRAE and one phase with CRVE and only for males. Nevertheless the 
association with wider CRVE is consistent with the study by Liew et al, 2008 which 
also adjusted for multiple cardiovascular risk factors including MABP and fellow 
RVC.39 While the significant finding of narrower CRAE and WBC in the Dunedin 
study is novel in relation to the reviewed literature as per the inclusion criteria, this 
finding is in isolation and in one sex only and hence may be due to chance. 
Reproducibility of this finding in phase 45 of the study may add plausibility to the 
significance of relation between elevated WBC and narrower CRAE.   
Cumulative pack years smoked (at phases 21, 26, 32 and 38 for females and phases 26, 
32 and 38 for males) was significantly associated with wider CRVE in simple linear 
regression analysis adjusted for fellow RVC, with greater significance of association in 
older ages. In multiple linear regression analysis, the only persistent statistically 
significant association from above was wider CRVE at age 38 for females. The 
significance of association was greater with increasing age due to the spread and 
magnitude of cumulative pack years of smoking increasing with age as expected by the 
type of measure used. However, smoking is associated with hypertension, as well as 
other cardiovascular risk factors with resulting loss of significance in multiple linear 
regression analysis after adjusting for hypertension and multiple other cardiovascular 
risk factors.119-121 There was also an isolated statistically significant association 
between smoking at age 21 in males and wider CRAE in multiple linear regression 
analysis, with non-significant association in simple linear regression analysis adjusted 
for fellow RVC. While there is some evidence for association between smoking and 
wider CRAE in the literature,51, 53 this isolated association is likely to be spurious and 
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due to over-adjustment in multiple linear regression analysis. The persistence of 
significance of wider CRVE and with smoking in age 38 in females in multiple linear 
regression analysis is consistent with the existing literature.39, 42 However, further 
reproducible evidence from phase 45 of the Dunedin study is required to determine the 
clinical significance of this finding. 
In simple linear regression analysis adjusted for fellow RVC, increased VO2 max (at 
ages 26, 32 and 38) was significantly associated with wider CRAE in adult females and 
males. There was also a statistically significant association between narrower CRVE 
and VO2 max in adult females and males (age 32 and 38). No association remained 
significant in multiple linear regression analysis. While the literature review yielded no 
published studies on VO2 max and RVC, the significant findings from the simple linear 
regression analysis adjusted for fellow RVC is consistent with the concept that 
predictors of adverse cardiovascular outcomes cause arteriolar narrowing and venular 
dilation.2 The corollary is that factors that are protective of cardiovascular risk, such as 
increased levels of VO2 max and HDL cholesterol are associated with wider CRAE and 
narrower CRVE. VO2 max was not significantly associated with RVC at age 15 in both 
sexes when adjusted for fellow RVC. It may be that cardiorespiratory fitness in 
adolescents does not impact RVC at middle age even when evaluated in isolation. The 
loss of significant association in multiple linear regression analysis may be due to the 
co-dependence between cardiorespiratory fitness and many of the cardiovascular risk 
variables (including hypertension) which were adjusted for.122  
Furthermore, while many of these associations (between HbA1c, non-HDL cholesterol, 
WBC, total pack years smoked, waist-hip ratio and RVC) are consistent with the 
existing literature, they did not reach significance of p < 0.01, and with the large sample 
size of the Dunedin study may have been due to chance. Hence, it is reasonable to 
conclude from the present evidence that these other cardiovascular risk factors which 
lost significance in multiple linear regression analysis are covariates rather than true 
determinants of RVC. 
 
5.2.3 Blood pressure 
In the Dunedin study after adjusting for fellow RVC and other covariates in multiple 
linear regression analysis, there was a consistent significant to extremely significant 
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association between elevated SBP, DBP, MABP and narrower CRAE and wider CRVE 
in both males and females from phase 7 to phase 38. For example, at age 7 an increase 
in SBP by 10 mmHg in females was associated with a change of -1.42 µm of CRAE, 
95% C.I: -2.65 to -0.19, p < 0.024 and a change of + 1.81 µm of CRVE, 95% CI: 0.14 
to 3.49, p = 0.034. In males a 10mmHg increase of SBP was associated with a change 
of -1.38 µm of CRAE, 95% C.I: -2.51 to -0.26, p = 0.016 and a change of + 1.66 µm 
CRVE, 95% C.I: 0.09 to 3.22, p = 0.038. The significant association was more 
consistently present with elevated BP and narrower CRAE than with wider CRVE. 
The stronger association of BP with CRAE was reflected in trajectory analysis which 
was based on group based trajectory models based on SBP data from age 7, 11, 18, 26, 
32 and 38. Across all these ages there was consistently a significant to extremely 
significant association between elevated SBP and narrower CRAE across both sexes in 
multiple linear regression analysis.  During simple linear regression analysis adjusted 
for fellow RVC comparing non-normal BP trajectory groups to normal BP trajectory 
groups, high-normal, pre-HT and HT groups were significantly to extremely 
significantly associated with narrower CRAE and wider CRVE with an increasing 
magnitude of change in that order, when compared with the normal BP trajectory 
group. In multiple linear regression trajectory group based analysis (adjusting for 
fellow RVC and other age 38 covariates) there was a significant to extremely 
significant narrowing of CRAE in pre-HTN and HTN groups compared to normal BP 
group across both sexes. While there was no statistically significant difference in 
CRAE between high-normal group and normal BP group; a dose response in the 
magnitude of CRAE narrowing was demonstrated with increasing narrowing of CRAE 
in high-normal, pre-HTN and HTN groups in that order compared to normal BP groups 
across both sexes. The persistence of a significant association between non-normal BP 
trajectories and narrower CRAE, along with a dose response (albeit a smaller 
magnitude and statistical significance than in simple linear regression analysis adjusted 
for CRVE), despite adjusting for covariates highlights the influence of BP from 
childhood to middle age on CRAE at middle age. Furthermore, these findings are also 
clinically significant. The normal and the high-normal BP trajectory groups fall within 
the SBP of 90 - 120 mmHg at age 38 (otherwise considered as normal and no increased 
cardiovascular risk). It is only the pre-HTN group falling within 120 - 139 mmHg and 
HTN groups with > 140 mmHg of SBP at age 38 which are considered to cause greater 
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cardiovascular risk in a dose dependent manner that in fact have a dose-dependent 
change in CRAE.3, 20 
The association between BP trajectory and CRVE was not as significant. In simple 
linear regression analysis adjusted for fellow RVC, the pre-HT group had significantly 
wider CRVE than the normal BP group for females and HT and pre-HT groups had 
significantly wider CRVE than normal BP group for males. However, there was no 
statistically significant association seen between BP trajectory groups and CRVE in 
multiple linear regression analysis. When AVR was analysed against RVC, simple 
linear regression analysis showed statistically significant decrease in AVR for both 
sexes with increasing magnitude of change in the order of high-normal, pre-HTN and 
HTN groups when compared to normal BP trajectory group for each sex. Once adjusted 
for other covariates, much of the significance and the order of magnitude of change 
persisted, with significant associations remaining in the pre-HTN and HTN groups. The 
individual analysis of each vessel suggests that much of the change is AVR is likely to 
relate to change in CRAE. This is demonstrated in table 4-14, where CRAE 
progressively narrows from normal to HT trajectory groups, with little change in CRVE 
and progressive narrowing of AVR. 
A recent meta-analysis by McGeechan et al demonstrated that narrower retinal 
arterioles and wider retinal venules were associated with an increased risk of CHD in 
women, but not in men, independent of traditional CHD risk factors,9 with one 
plausible explanation being the greater role of microvascular dysfunction in CHD in 
women.2 The BP trajectory analysis in this thesis which also adjusted for traditional 
CHD risk factors found significant associations in both sexes with elevated SBP and 
narrower CRAE, without this level of significance being reflected in CRVE. Future 
phases of the Dunedin study, where participants are older and more likely to encounter 
coronary events, may provide insight into whether the longitudinal relationships 
between cardiovascular risk factors, namely SBP, and CRAE in males and females are 
in fact translatable to end outcomes such as coronary events. 
 
 Study strengths 
The strengths of this study include the longitudinal nature of the data from age 3 to age 
38 with data collection at multiple phases of ageing. The Dunedin study is the first and 
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only one of its kind to have such a long reliable follow up of an original representative 
birth cohort (of the population living in South Island, New Zealand in the early 1970s), 
with high retention rate, relatively large sample size and precise measurement of 
variables at each phase of the study. The Dunedin study uses multiple data sources 
including self-reports, tests, observations, records and informant reports which enables 
the study to collect multiple avenues of information as well as cross-check information. 
All information provided by the participants is maintained in the strictest confidentiality 
with data about participants distributed to researchers in non-identifiable format. These 
features help strengthen causal inferences from the Dunedin study, although the study 
itself is of cross-sectional correlational nature.11 
Furthermore, the wide variety of variables measured including a wholistic panel of 
cardiovascular risk factors (from blood pressure to anthropometric measurements, 
biochemistry and smoking history) allows adjustment for multiple potential 
confounders in statistical analysis. 
 
 Study Limitations 
The limitations of this study include the under-representation of Maori (7.5%) and 
Pacific population with the participants being primarily white, hence potentially 
limiting generalisability to New Zealand and rest of the world.11, 12  
Antihypertensive medication use information was collected at ages 26 (n=6), 32 (n=12) 
and 38 (n=26), and the use of antihypertensive medications would likely have had some 
impact on the effect of BP on RVC at age 38.20 While this variable was not considered 
during statistical analysis, the effect is likely to be small due to the large sample size at 
each of these ages (n = 929 at age 26, n = 930 at age 32 and n = 934 at age 38). 
Trajectory analysis had certain limitations with predictive power. The BP trajectory 
model had poor accuracy (area under the ROC curve of 0.6-0.7) at age 7 and 11, 
improving to fair accuracy (area under the ROC curve of 0.7-0.8) at ages 18, 26 and 32 
for predicting hypertension at age 38. The model’s predictive power (positive 
predictive value) to predict hypertension at age 38 improved with age.20 Despite the 
cohort nature of this study enabling the use of trajectory models for variables measured 
over multiple ages such as blood pressure; the measure of RVC at age 38 was of cross-
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sectional nature. Whilst it is out of the scope of the hypothesis, nevertheless it was not 
possible to analyse the temporal association between change in cardiovascular risk 
factors with change in RVC over time. 
At ages 7, 9, 11 and 13 DBP was measured at both Korotkoff 4 and Korotkoff 5 
sounds. MABP was derived from both these sets of results (labelled MABP K-4 and 
MABP K-5 respectively) Statistical analysis was done on both sets of results (DBP K-
4/ MABP K-4 and DBP K-5/ MABP K-5). This was a form of sensitivity analysis as 
some DBP K-5 values were too low to be plausible, as low as 2 mmHg for one age 
group. This is likely to be spurious and secondary to difficulties experienced by the 
measurer in determining the end-point. The association between RVC and DBP and 
MABP was larger in magnitude and more significant with K-4 values compared with 
K-5 values and this may reflect the more robust DBP measurements from K-4 sounds 
compared with K-5 sounds at these ages. 
Regression analysis comparing associations between cardiovascular risk factors and 
RVC was sex stratified due to significant sex interaction between a cardinal variable 
(BP) and RVC and because physiological differences between the sexes require 
separate analysis in health research.123 However, the MMedSc candidate acknowledges 
that the subsequent halving of sample size may have limited study power to find 
statistically significant associations. 
During multiple linear regression analysis there was a loss of sample size due to not all 
covariates being recorded in all participants. For example, at age 38 multiple linear 
regression analysis for SBP in females had a sample size of 362 and in males a sample 
size of 381. This is in comparison to a sample size of 454 for females and 467 for males 
in univariate analysis for SBP at age 38. There is potential for bias from this loss of 
sample size in multiple linear regression analysis. 
 
 Conclusions 
There is an extensive body of literature linking cardiovascular risk factors, particularly 
blood pressure to RVC. The Dunedin study is the longest longitudinal study to date that 
adds further evidence to the importance and role of blood pressure from childhood (as 
early as age 7) to adulthood in predicting RVC in middle age. More specifically there is 
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evidence that the presence of elevated SBP even at a young age, 7 and 11, tracks 
through to early midlife, 38, and influences RVC (narrowing of CRAE) at this age in a 
clinically meaningful manner.  
This study is the first of its kind to evaluate whether there was an association between 
VO2 max and PAT to RVC. While VO2 max was no longer significantly associated 
with RVC in multiple linear regression analysis and the significant association between 
PAT and CRVE in multiple linear regression analysis was an isolated finding, these are 
never the less important results and likely to promote further research into these fields. 
Considering the ample evidence in the literature linking change in RVC to 
cardiovascular morbidity and mortality, this study provides further evidence for the role 
of hypertension at a young age having deleterious cardiovascular outcomes later in life.  
 
 Future Directions 
Future phases of the Dunedin study may reproduce the findings from phase 38 shifting 
many of the variables (particularly HbA1c, non-HDL cholesterol, WBC, total pack 
years of cigarettes smoked and waist-hip ratio which had significant associations with 
RVC in multiple linear regression analysis) from covariates to independent predictors 
of RVC. The relationship between PAT and RVC can also be further clarified in phase 
45 of the Dunedin study. 
More research is required to determine whether in fact the relationship of blood 
pressure to RVC is translatable to cardiovascular end outcomes. At age 38, it was not 
possible to determine this relationship with a sample size of 961 participants; however, 
in future phases of this study, as the participants grow older and cardiovascular events 
become more prevalent, it may be possible to address this question. Small studies over 
a short duration have shown RVC to be reversible with treatment of cardiovascular risk 
factors.124-126 Given that RVC is being measured in the current (phase 45) and future 
phases of the Dunedin study it may be possible to add supporting evidence to these 
smaller studies from the larger sample size and longer follow up of the Dunedin study. 
There is presently research on novel retinal vessel parameters (vessel tortuosity, 
branching angles and fractal dimensions) and their relationship with cardiovascular 
disease.32 Phase 45 of the Dunedin study also lends itself to research in this field. There 
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is also emerging research on the use of artificial intelligence (deep machine learning) 
on predicting cardiovascular risk factors and events from retinal fundal images.127 
Clearly this is a field of emerging novel research. Further work on the impact of 
cardiovascular risk factors such as blood pressure on RVC, has the potential to impact 
cardiovascular risk tools and primary and secondary treatment of cardiovascular risk 
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7 Appendix A: Literature Review 
7.1 Search key words 
Ovid MEDLINE 1946 to present (July 2017):  
 
1. exp Retinal Vessels/ 
2. retinal microvascular caliber.mp. 
3. retinal vascular caliber.mp. 
4. retinal microvasculature.mp. 
5. retinal vascular calibre.mp. 





11. 7 or 8 or 9 or 10 
12. 1 and 11 
13. 2 or 3 or 4 or 5 or 6 or 12 
14. exp Hypertension/ 
15. exp Blood Pressure/ 
16. 14 or 15 
17. 13 and 16 
18. exp Diabetes Mellitus/ 
19. exp Blood Glucose/ 
20. 18 or 19 
21. 13 and 20 
22. exp Body Mass Index/ or exp Obesity/ or BMI.mp. or exp Overweight/ 
23. exp Body Weight/ 
24. exp Adiposity/ 
25. exp Waist Circumference/ 
26. exp Waist-Hip Ratio/ 
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27. 22 or 23 or 24 or 25 or 26 
28. 13 and 27 
29. exp Lipids/ 
30. 13 and 29 
31. exp Smoking/ 
32. exp Tobacco/ 
33. 31 or 32 
34. 13 and 33 
35. exp Inflammation Mediators/ or exp Inflammation/ 
36. 13 and 35 
37. endothelial function.mp. 
38. 13 and 37 
39. exp Cardiorespiratory Fitness/ 
40. 13 and 39 
41. exp Sex/ 
42. gender.mp. 
43. 41 or 42 





Embase 1947 to present (September 2017): 
1. exp retina blood vessel/  
2. retinal microvascular caliber.mp.  
3. retinal vascular caliber.mp.  
4. retinal microvasculature.mp.  
5. retinal vascular calibre.mp.  
6. retinal microvascular calibre.mp.  
7. caliber.mp.  
8. calibre.mp.  
9. width.mp.  
10. diameter.mp.  
11. 7 or 8 or 9 or 10  
12. 1 and 11  
13. 2 or 3 or 4 or 5 or 6 or 12  
14. exp hypertension/  
15. exp blood pressure/  
16. 14 or 15  
17. 13 and 16  
18. exp diabetes mellitus/  
19. exp glucose blood level/  
20. 18 or 19  
21. 13 and 20  
22. exp weight/ or exp obesity/ or exp body mass/ or BMI.mp. or exp body weight/  
23. adiposity.mp.  
24. exp waist circumference/  
25. exp waist hip ratio/  
26. 22 or 23 or 24 or 25  
27. 13 and 26  
28. exp lipid/  
29. 13 and 28  
30. exp smoking/  
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31. exp tobacco/  
32. 30 or 31  
33. 13 and 32  
34. inflammation mediators.mp.  
35. exp inflammation/  
36. 34 or 35  
37. 13 and 36  
38. endothelial function.mp.  
39. 13 and 38  
40. exp cardiorespiratory fitness/  
41. 13 and 40  
42. exp sex/  
43. exp gender/  
44. 42 or 43  




7.2 Current literature on the effect of cardiovascular risk factors on RVC. 
7.2.1 Hypertension 
Table 7-1: Literature review of the effect of blood pressure on retinal vessel calibre. 
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-2.7µm per σ 
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increase in BP 
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Narrower and wider associations between variable and RVC is for p < 0.05. n.s = non-significant association.  
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7.2.2 Anthropometry and Metabolic syndrome 
Table 7-2: Literature review of the effect of body mass index, waist circumference and metabolic syndrome on retinal vessel calibre. 
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Table 7-3: Literature review of the effect of blood glucose on retinal vessel calibre. 
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Table 7-4: Literature review of the effect of lipids on retinal vessel calibre. 
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Table 7-5: Literature review of the effect of inflammatory markers on retinal vessel calibre. 
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Table 7-6: Literature review of the effect of tobacco smoking on retinal vessel calibre. 
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7.2.7 Endothelial function 
Table 7-7: Literature review of the effect of endothelial function on retinal vessel calibre. 







CRAE CRVE Covariates 
adjusted for 
Comments 
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cholesterol, 
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Narrower and wider associations between variable and RVC is for p < 0.05. n.s = non-significant association.
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8 Appendix B: Results - Descriptive statistics 
Tables of descriptive data grouped by variables (age and sex stratified) is detailed in this 
section. For each variable, there is the total number of participants from whom that variable 
was measured (n), minimum value of that variable (Min.), maximum value of that variable 
(Max.), mean (µ) and standard deviation (σ).  
 Retinal vessel calibre 
Table 8-1: Descriptive statistics for retinal vessel calibre at age 38 years. 
Variable Sex n Min. Max. µ σ 
CRAE  F 465 57.74 170.19 137.88 11.40 
M 467 106.11 179.47 136.61 10.87 
CRVE F 465 86.65 245.68 195.05 15.56 
M 467 141.07 242.36 197.01 14.86 
AVR F 465 0.56 0.84 0.71 0.045 
M 467 0.56 0.80 0.69 0.042 
Units = µm for CRAE and CRVE. AVR is a ratio. 
 Blood pressure 
Table 8-2: Descriptive statistics for systolic blood pressure. 
Age Sex n Min. Max. µ σ 
38 F 460 86.67 161.33 116.37 11.25 
M 474 96.67 180.67 124.04 11.80 
32 F 440 83.00 150.00 112.58 10.34 
M 490 88.00 153.00 122.89 10.93 
26 F 440 92.00 150.00 111.56 9.00 
M 489 84.67 164.67 121.64 10.68 
18 F 420 85.00 146.00 115.35 9.37 
M 449 99.00 154.00 125.91 9.42 
15 F 407 92.00 158.00 122.45 10.30 
M 437 97.00 164.00 127.10 11.08 
13 F 351 83.00 132.00 105.26 8.81 
M 376 83.00 134.00 106.83 8.58 
11 F 372 82.00 122.00 102.74 7.75 
M 408 82.00 122.00 102.71 7.02 
9 F 385 84.00 132.00 106.09 7.21 
M 426 85.00 140.00 107.08 7.45 
7 F 419 81.00 128.00 101.78 7.36 
M 453 80.00 127.00 102.70 7.16 
Units = mmHg. The precision of BP measurements was to whole numbers. They have been 





Table 8-3: Descriptive statistics for diastolic blood pressure. 
Age Sex K n Min. Max. µ σ 
38 F 5 460 55.33 122.67 75.61 9.04 
M 5 474 59.33 137.33 80.64 10.15 
32 F 5 440 49.00 102.00 73.84 8.27 
M 5 490 48.00 111.00 77.73 9.91 
26 F 5 440 43.33 100.00 69.85 8.19 
M 5 489 40.67 112.67 73.39 10.15 
18 F 5 409 32.00 81.00 56.77 8.92 
M 5 423 31.00 84.00 57.06 10.51 
15 F 5 407 43.00 98.00 68.65 8.23 
M 5 437 42.00 106.00 66.31 10.19 
13 F 5 351 2.00 69.00 40.12 11.65 
4 351 5.00 75.00 50.44 9.13 
M 5 376 4.00 69.00 38.69 12.44 
4 376 17.00 76.00 50.61 9.76 
11 F 5 372 35.00 80.00 58.30 7.94 
4 372 49.00 90.00 67.76 7.47 
M 5 408 21.00 81.00 57.35 8.68 
4 408 42.00 91.00 66.91 7.47 
9 F 5 382 28.00 80.00 54.36 9.17 
4 384 49.00 95.00 68.41 7.04 
M 5 420 3.00 83.00 53.15 9.75 
4 425 48.00 91.00 68.76 6.84 
7 F 5 419 25.00 77.00 55.15 7.60 
4 419 44.00 82.00 61.08 6.56 
M 5 453 12.00 82.00 54.38 7.93 
4 453 30.00 85.00 61.29 6.98 
Units = mmHg, K = Korotkoff phase. The precision of BP measurements was to whole 
numbers. They have been reported to 2 decimal places as some ages had multiple BP 





Table 8-4: Descriptive statistics for mean arterial blood pressure. 
Age Sex K n Min. Max. µ σ 
38 F 5 460 67.78 134.89 89.20 9.20 
M 5 474 73.56 151.78 95.11 10.05 
32 F 5 440 62.00 114.89 86.76 8.15 
M 5 490 66.22 121.56 92.78 9.19 
26 F 5 440 64.89 113.33 83.75 7.51 
M 5 489 58.44 126.67 89.47 9.20 
18 F 5 409 53.83 97.33 76.34 7.39 
M 5 423 56.50 101.00 79.93 8.24 
15 F 5 407 61.33 111.67 86.59 7.45 
M 5 437 66.67 123.33 86.58 8.66 
13 F 5 351 37.67 83.33 61.83 8.24 
4 351 47.33 87.33 68.71 7.06 
M 5 376 37.00 83.33 61.41 8.72 
4 376 46.33 93.33 69.35 7.38 
11 F 5 372 54.33 91.67 73.12 6.52 
4 372 63.67 99.00 79.42 6.55 
M 5 408 52.33 94.67 72.47 6.72 
4 408 60.00 101.33 78.84 6.30 
9 F 5 382 52.67 95.33 71.61 7.04 
4 384 63.33 102.67 80.98 6.12 
M 5 420 41.67 99.33 71.10 7.21 
4 425 64.67 106.00 81.54 6.15 
7 F 5 419 52.33 90.00 70.69 6.26 
4 419 60.33 92.67 74.64 5.84 
M 5 453 39.00 92.67 70.48 6.42 
4 453 51.00 94.67 75.10 6.08 
Units = mmHg, K = Korotkoff phase of DBP used for deriving MABP. The precision of BP 
measurements was to whole numbers. They have been reported to 2 decimal places as some 





Table 8-5: Descriptive statistics for body mass index. 
Age Sex n Min. Max. µ σ 
38 F 460 16.01 54.42 26.92 5.92 
M 474 18.86 49.47 27.45 4.62 
32 F 441 16.65 51.87 25.93 5.60 
M 489 18.57 50.21 26.40 4.33 
26 F 445 16.58 48.70 24.91 4.95 
M 494 18.02 48.84 25.15 3.86 
21 F 460 17.10 44.30 23.78 3.73 
M 482 17.11 42.70 23.93 3.35 
18 F 422 16.54 38.43 22.90 3.25 
M 450 16.38 44.58 22.75 3.19 
15 F 464 15.50 30.96 20.93 2.62 
M 498 13.78 35.35 20.02 2.83 
13 F 355 14.27 28.73 20.04 2.64 
M 381 14.94 29.12 19.28 2.34 
11 F 339 11.05 27.51 17.56 2.22 
M 372 13.40 29.59 17.49 2.15 
9 F 384 12.51 26.50 16.42 1.78 
M 427 12.92 24.69 16.34 1.57 
7 F 418 12.53 22.66 15.84 1.39 
M 450 12.95 24.01 15.88 1.33 
5 F 436 12.00 21.10 15.80 1.22 
M 457 12.76 24.35 16.00 1.24 
3 F 459 12.58 20.28 16.23 1.33 
M 466 12.81 21.85 16.49 1.27 
Units = Kg/m2. 
Table 8-6: Descriptive statistics for waist-hip ratio. 
Age Sex n Min. Max. µ σ 
38 F 458 0.63 1.08 0.80 0.06 
M 473 0.69 1.14 0.91 0.07 
32 F 442 0.66 1.13 0.78 0.06 
M 489 0.75 1.10 0.88 0.05 
26 F 438 0.64 0.94 0.74 0.05 
M 489 0.75 1.03 0.85 0.04 





8.4.1 Blood glucose 
Table 8-7: Descriptive statistics for glycated haemoglobin. 
Age Sex n Min. Max. µ σ 
38 F 451 4.16 9.47 5.34 0.42 
M 450 4.26 13.50 5.48 0.63 
32 F 433 4.30 9.10 5.24 0.37 
M 454 4.30 8.60 5.29 0.37 
Units = %. Precision of age 32 HbA1c was only to one decimal place. 
8.4.2 Lipids 
Table 8-8: Descriptive statistics for total cholesterol. 
Age Sex n Min. Max. µ σ 
38 F 455 2.4 11.3 5.0 1.0 
M 456 2.7 8.9 5.4 1.0 
32 F 435 2.7 9.6 4.8 1.0 
M 456 3.0 8.9 5.1 1.0 
26 F 399 2.9 9.1 5.0 1.0 
M 452 2.8 8.6 5.0 1.0 
Units = mmol/L. 
Table 8-9: Descriptive statistics for HDL cholesterol. 
Age Sex n Min. Max. µ σ 
38 F 455 0.59 3.54 1.61 0.43 
M 456 0.40 3.13 1.29 0.35 
32 F 435 0.50 3.38 1.63 0.42 
M 456 0.66 2.91 1.31 0.35 
26 F 399 0.33 3.11 1.51 0.38 
M 452 0.44 2.88 1.25 0.31 
Units = mmol/L. 
 
Table 8-10: Descriptive statistics for non-HDL cholesterol. 
Age Sex n Min. Max. µ σ 
38 F 455 0.8 9.8 3.4 1.0 
M 456 1.7 8.2 4.1 1.1 
32 F 435 1.1 7.9 3.2 1.0 
M 456 1.5 7.7 3.8 1.1 
26 F 399 1.1 7.8 3.5 1.0 
M 452 1.3 7.4 3.8 1.0 
Units = mmol/L. 
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8.4.3 Inflammatory markers 
Table 8-11: Descriptive statistics for white blood cell count. 
Age Sex n Min. Max. µ σ 
38 F 449 3.7 16.7 8.1 1.8 
M 456 3.8 14.8 7.7 1.8 
32 F 435 3.4 16.1 7.8 1.8 
M 457 3.8 17.4 7.5 1.8 
26 F 429 4.3 17.4 8.3 2.1 
M 452 4.5 16.2 7.5 1.7 
Units = x109/L. 
Table 8-12: Descriptive statistics for high sensitive C-reactive protein. 
Age Sex n Min. Max. µ σ 
38 F 453 .10 33.20 2.97 4.34 
M 454 .10 39.00 1.93 3.14 
32 F 433 .10 42.00 3.12 4.68 
M 455 .10 118.00 2.65 9.17 
26 F 421 .00 148.00 5.81 9.67 
M 451 .00 83.00 2.85 5.76 
Units = mg/L. hsCRP at age 26 was measured to zero decimal places, hsCRP at age 32 was 
measured to two decimal places and hsCRP at age 38 was measured to one decimal place.  
 
Table 8-13: Descriptive statistics for fibrinogen. 
Age Sex n Min. Max. µ σ 
38 F 446 1.3 5.3 2.8 0.6 
M 450 1.2 4.9 2.6 0.5 
32 F 434 1.3 5.0 2.8 0.6 
M 456 1.2 5.9 2.5 0.5 
Units = g/L. 
Table 8-14: Descriptive statistics for interleukin-6. 
Age Sex n Min. Max. µ σ 
38 F 394 .0778 18.4897 1.7900 1.8187 
M 401 .0857 15.8244 1.3161 1.3343 




Table 8-15: Descriptive statistics for smoking. 
Age Sex n Min. Max. µ σ 
38 F 476 0.00 35.75 5.59 7.94 
M 477 0.00 46.13 6.69 9.29 
32 F 476 0.00 26.00 4.43 5.98 
M 495 0.00 36.25 5.17 7.06 
26 F 481 0.00 22.00 3.02 4.04 
M 499 0.00 22.75 3.28 4.65 
21 F 481 0.00 15.00 1.61 2.40 
M 504 0.00 15.00 1.65 2.75 
18 F 483 0.00 11.25 0.73 1.37 
M 511 0.00 19.50 0.80 1.89 
Units = pack years. Cumulative pack years smoked up to age 18, 21, 26, 32 and 38 was 
skewed data, however, natural logarithmic transformation still leaves it skewed, hence this has 
not been log transformed. 
 
 Cardiorespiratory fitness 
Table 8-16: Descriptive statistics for VO2 max. 
Age Sex n Min. Max. µ σ 
38 F 437 11.55 46.86 23.72 4.94 
M 463 18.15 53.43 34.70 6.23 
32 F 407 11.87 48.60 26.38 5.50 
M 466 17.91 63.30 39.17 6.54 
26 F 393 15.30 42.78 29.04 5.00 
M 460 20.25 59.48 43.45 6.16 
15 F 403 34.20 61.70 44.07 4.46 
M 436 36.50 71.30 49.21 5.74 
Units = mL/min/kg. 
 Endothelial function 
Table 8-17: Descriptive statistics for Framingham-reactive hyperaemic index. 
Age Sex n Min. Max. µ σ 
38 F 458 -0.137 1.924 0.709 0.385 
M 460 -0.148 1.710 0.502 0.347 




 Socioeconomic status 
Table 8-18: Descriptive statistics for socioeconomic status. 
Age Sex n Min. Max. µ σ 
38 F 474 1 6 3.94 1.37 
M 479 1 6 3.54 1.47 
0 - 15 F 499 1.00 6.00 3.76 1.14 
M 532 1.00 6.00 3.75 1.14 
Age 38 SES is a categorical variable, whereas childhood SES (average of age 0-15 SES is a 




9 Appendix C: Results - Difference in variables between sex 
This section is tables of difference between sexes for variables including: RVC, BMI, SBP, 
DBP, MABP, VO2 max, waist-hip ratio, lipids, inflammatory markers, HbA1c, cigarettes 
smoked, endothelial function and SES. Statistical test used was independent sample t-test. 
 Retinal vessel calibre 
Table 9-1: Difference in retinal vessel calibre between sex 




95% Confidence Interval 
of the Difference 
Lower Upper 
CRAE 1.740 .082 1.27 -.16 2.70 
CRVE -1.968 .049 -1.96 -3.92 -.01 
AVR 4.783 <.001 .014 .01 .02 
Mean difference = variable for female – variable for male. 
 
 Body mass index 
Table 9-2: Difference in body mass index between sex stratified by age. 




95% Confidence Interval 
of the Difference 
Lower Upper 
3 -3.086 .002 -0.26 -0.43 -0.10 
5 -2.491 .013 -0.20 -0.37 -0.04 
7 -.439 .661 -0.04 -0.22 0.14 
9 .670 .503 0.08 -0.15 0.31 
11 .443 .658 0.07 -0.25 0.39 
13 4.121 <.001 0.76 0.40 1.12 
15 5.143 <.001 0.91 0.56 1.25 
18 .707 .480 0.15 -0.27 0.58 
21 -.655 .512 -0.15 -0.60 0.30 
26 -.831 .406 -0.24 -0.82 0.33 
32 -1.407 .160 -0.47 -1.11 0.18 
38 -1.521 .129 -0.53 -1.21 0.15 




 Systolic blood pressure 
Table 9-3: Difference in systolic blood pressure between sex stratified by age. 




95% Confidence Interval 
of the Difference 
Lower Upper 
7 -1.888 .059 -0.93 -1.89 0.04 
9 -1.907 .057 -0.98 -2.00 0.03 
11 .069 .945 0.04 -1.00 1.07 
13 -2.429 .015 -1.57 -2.83 -0.30 
15 -6.299 <.001 -4.65 -6.10 -3.20 
18 -16.559 <.001 -10.56 -11.81 -9.31 
26 -15.615 <.001 -10.09 -11.36 -8.82 
32 -14.737 <.001 -10.31 -11.69 -8.94 
38 -10.164 <.001 -7.67 -9.15 -6.19 
Mean difference = variable for female – variable for male. Units = mmHg. 
 
 Diastolic blood pressure 
Table 9-4: Difference in diastolic blood pressure between sex stratified by age. 




95% Confidence Interval 
of the Difference 
Lower Upper 
7 1.471 .142 0.78 -0.26 1.81 
9 1.807 .071 1.21 -0.10 2.53 
11 1.595 .111 0.95 -0.22 2.13 
13 1.592 .112 1.43 -0.33 3.18 
15 3.683 <.001 2.34 1.09 3.59 
18 -.428 .669 -0.29 -1.61 1.04 
26 -5.862 <.001 -3.53 -4.72 -2.35 
32 -6.510 <.001 -3.88 -5.05 -2.71 
38 -8<.001 <.001 -5.03 -6.26 -3.79 
Mean difference = variable for female – variable for male. DBP measured at Korotkoff 5. 




 Mean arterial blood pressure 
Table 9-5: Difference in mean arterial blood pressure between sex stratified by age. 




95% Confidence Interval 
of the Difference 
Lower Upper 
7 .482 .630 0.21 -0.64 1.05 
9 1.003 .316 0.51 -0.48 1.50 
11 1.364 .173 0.65 -0.28 1.58 
13 .679 .497 0.43 -0.81 1.67 
15 .019 .985 0.01 -1.08 1.10 
18 -6.621 <.001 -3.59 -4.65 -2.52 
26 -10.422 <.001 -5.72 -6.80 -4.64 
32 -10.602 <.001 -6.03 -7.14 -4.91 
38 -9.371 <.001 -5.91 -7.14 -4.67 
Mean difference = variable for female – variable for male. Units = mmHg. 
 
 Cardiorespiratory fitness 
Table 9-6: Difference in VO2 max between sex stratified by age. 




95% Confidence Interval 
of the Difference 
Lower Upper 
15 -14.544 <.001 -5.14 -5.84 -4.45 
26 -37.688 <.001 -14.41 -15.16 -13.66 
32 -31.389 <.001 -12.79 -13.59 -11.99 
38 -29.385 <.001 -10.98 -11.71 -10.24 
Mean difference = variable for female – variable for male. Units = mL/min/Kg. 
 
 Waist-hip ratio 
Table 9-7: Difference in waist-hip ratio between sex stratified by age. 




95% Confidence Interval 
of the Difference 
Lower Upper 
26 -34.684 <.001 -0.10 -0.11 -0.10 
32 -28.339 <.001 -0.10 -0.11 -0.09 
38 -25.804 <.001 -0.11 -0.11 -0.10 
















95% Confidence Interval 




26 -.479 .632 0.0 -0.2 0.1 
32 -4.096 <.001 -0.3 -0.4 -0.1 
38 -6.423 <.001 -0.4 -0.6 -0.3 
HDL 
cholesterol 
26 11.045 <.001 0.27 0.22 0.31 
32 12.091 <.001 0.31 0.26 0.36 
38 12.338 <.001 0.32 0.27 0.37 
Non- HDL 
cholesterol 
26 -4.274 <.001 -0.3 -0.4 -0.2 
32 -8.510 <.001 -0.6 -0.7 -0.5 
38 -10.923 <.001 -0.7 -0.9 -0.6 
Mean difference = variable for female – variable for male. Units = mmol/L. 
 
 Inflammatory markers 
Table 9-9: Difference in inflammatory markers between sex stratified by age. 
Variable Ag
e 





95% Confidence Interval 
of the Difference 
Lower Upper 
WBC 26 6.252 <.001 0.8 0.6 1.1 
32 2.861 .004 0.3 0.1 0.6 
38 3.431 .001 0.4 0.2 0.6 
CRP 26 5.432 <.001 2.95 1.89 4.02 
32 .975 .330 0.47 -0.48 1.43 
38 4.106 <.001 1.03 0.54 1.53 
Fibrinogen 32 7.284 <.001 0.3 0.2 0.4 
38 5.802 <.001 0.2 0.1 0.3 
IL-6 38 4.182 <.001 0.4738 0.2514 0.6962 
Mean difference = variable for female – variable for male. Units = WBC: x109/L, hsCRP: 




 Glycated haemoglobin 
Table 9-10: Difference in glycated haemoglobin between sex stratified by age. 




95% Confidence Interval 
of the Difference 
Lower Upper 
32 -2.157 .031 -0.05 -0.10 0.00 
38 -3.928 <.001 -0.14 -0.21 -0.07 
Mean difference = variable for female – variable for male. Units = %. 
 
 Cigarettes smoked 
Table 9-11: Difference in cigarettes smoked between sex stratified by age. 




95% Confidence Interval 
of the Difference 
Lower Upper 
18 -.642 .521 -0.07 -0.27 0.14 
21 -.231 .817 -0.04 -0.36 0.29 
26 -.954 .340 -0.27 -0.81 0.28 
32 -1.771 .077 -0.74 -1.57 0.08 
38 -1.968 .049 -1.10 -2.20 0.00 
Mean difference = variable for female – variable for male. Unites = total pack years. 
 
 Endothelial function 
Table 9-12: Difference in Framingham-reactive hyperaemia index between sex at age 38. 




95% Confidence Interval 
of the Difference 
Lower Upper 
38 8.528 <.001 0.206 0.159 0.254 
Mean difference = variable for female – variable for male. No units as it is a dimensionless 
quotient. 
 
 Socioeconomic status 




95% Confidence Interval 
of the Difference 
Lower Upper 
0 – 15 .153 .879 0.01 -0.13 0.15 
38 4.351 <.001 0.40 0.22 0.58 




10 Appendix D: Results - Trends in cardiovascular risk factors 
with time 
This section explores the trends in variables measured over multiple phase (BMI, BP and VO2 
max) with time. Tables provided for post hoc Games Howell analysis for difference between 
age groups.  
 Body mass index 
Statistical analysis using ANOVA showed statistically significant difference between age 
groups at p < 0.001 for both females and males. 














3 5 0.43 <.001 0.15 0.71 
7 0.39 .002 0.09 0.69 
9 -0.19 .837 -0.56 0.17 
11 -1.33 <.001 -1.78 -0.89 
13 -3.81 <.001 -4.31 -3.31 
15 -4.70 <.001 -5.15 -4.25 
18 -6.67 <.001 -7.23 -6.12 
21 -7.55 <.001 -8.16 -6.94 
26 -8.68 <.001 -9.47 -7.88 
32 -9.70 <.001 -10.60 -8.81 
38 -10.69 <.001 -11.62 -9.76 
5 3 -0.43 <.001 -0.71 -0.15 
7 -0.04 1.000 -0.33 0.25 
9 -0.62 <.001 -0.98 -0.27 
11 -1.76 <.001 -2.20 -1.32 
13 -4.24 <.001 -4.74 -3.74 
15 -5.13 <.001 -5.57 -4.69 
18 -7.10 <.001 -7.66 -6.55 
21 -7.98 <.001 -8.58 -7.38 
26 -9.11 <.001 -9.90 -8.31 
32 -10.13 <.001 -11.03 -9.24 
38 -11.12 <.001 -12.05 -10.19 
7 3 -0.39 .002 -0.69 -0.09 
5 0.04 1.000 -0.25 0.33 
9 -0.58 <.001 -0.96 -0.21 
11 -1.72 <.001 -2.18 -1.27 
13 -4.20 <.001 -4.71 -3.69 
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15 -5.09 <.001 -5.55 -4.63 
18 -7.06 <.001 -7.63 -6.50 
21 -7.94 <.001 -8.55 -7.32 
26 -9.07 <.001 -9.87 -8.26 
32 -10.09 <.001 -11.00 -9.19 
38 -11.08 <.001 -12.01 -10.15 
9 3 0.19 .837 -0.17 0.56 
5 0.62 <.001 0.27 0.98 
7 0.58 <.001 0.21 0.96 
11 -1.14 <.001 -1.64 -0.64 
13 -3.62 <.001 -4.16 -3.07 
15 -4.51 <.001 -5.01 -4.01 
18 -6.48 <.001 -7.08 -5.88 
21 -7.35 <.001 -8.00 -6.71 
26 -8.48 <.001 -9.31 -7.66 
32 -9.51 <.001 -10.43 -8.59 
38 -10.50 <.001 -11.45 -9.54 
11 3 1.33 <.001 0.89 1.78 
5 1.76 <.001 1.32 2.20 
7 1.72 <.001 1.27 2.18 
9 1.14 <.001 0.64 1.64 
13 -2.48 <.001 -3.08 -1.87 
15 -3.37 <.001 -3.93 -2.81 
18 -5.34 <.001 -5.99 -4.69 
21 -6.21 <.001 -6.91 -5.52 
26 -7.34 <.001 -8.21 -6.48 
32 -8.37 <.001 -9.33 -7.41 
38 -9.36 <.001 -10.34 -8.37 
13 3 3.81 <.001 3.31 4.31 
5 4.24 <.001 3.74 4.74 
7 4.20 <.001 3.69 4.71 
9 3.62 <.001 3.07 4.16 
11 2.48 <.001 1.87 3.08 
15 -0.89 <.001 -1.50 -0.28 
18 -2.86 <.001 -3.56 -2.17 
21 -3.74 <.001 -4.47 -3.01 
26 -4.87 <.001 -5.76 -3.97 
32 -5.89 <.001 -6.88 -4.91 
38 -6.88 <.001 -7.89 -5.86 
15 3 4.70 <.001 4.25 5.15 
5 5.13 <.001 4.69 5.57 
7 5.09 <.001 4.63 5.55 
9 4.51 <.001 4.01 5.01 
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11 3.37 <.001 2.81 3.93 
13 0.89 <.001 0.28 1.50 
18 -1.97 <.001 -2.63 -1.32 
21 -2.85 <.001 -3.54 -2.15 
26 -3.97 <.001 -4.84 -3.11 
32 -5.00 <.001 -5.96 -4.04 
38 -5.99 <.001 -6.98 -5.00 
18 3 6.67 <.001 6.12 7.23 
5 7.10 <.001 6.55 7.66 
7 7.06 <.001 6.50 7.63 
9 6.48 <.001 5.88 7.08 
11 5.34 <.001 4.69 5.99 
13 2.86 <.001 2.17 3.56 
15 1.97 <.001 1.32 2.63 
21 -0.88 .011 -1.65 -0.10 
26 -2.00 <.001 -2.93 -1.08 
32 -3.03 <.001 -4.05 -2.01 
38 -4.02 <.001 -5.06 -2.97 
21 3 7.55 <.001 6.94 8.16 
5 7.98 <.001 7.38 8.58 
7 7.94 <.001 7.32 8.55 
9 7.35 <.001 6.71 8.00 
11 6.21 <.001 5.52 6.91 
13 3.74 <.001 3.01 4.47 
15 2.85 <.001 2.15 3.54 
18 0.88 .011 0.10 1.65 
26 -1.13 .007 -2.08 -0.17 
32 -2.16 <.001 -3.20 -1.11 
38 -3.14 <.001 -4.21 -2.07 
26 3 8.68 <.001 7.88 9.47 
5 9.11 <.001 8.31 9.90 
7 9.07 <.001 8.26 9.87 
9 8.48 <.001 7.66 9.31 
11 7.34 <.001 6.48 8.21 
13 4.87 <.001 3.97 5.76 
15 3.97 <.001 3.11 4.84 
18 2.00 <.001 1.08 2.93 
21 1.13 .007 0.17 2.08 
32 -1.03 .144 -2.19 0.14 
38 -2.01 <.001 -3.20 -0.83 
32 3 9.70 <.001 8.81 10.60 
5 10.13 <.001 9.24 11.03 
7 10.09 <.001 9.19 11.00 
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9 9.51 <.001 8.59 10.43 
11 8.37 <.001 7.41 9.33 
13 5.89 <.001 4.91 6.88 
15 5.00 <.001 4.04 5.96 
18 3.03 <.001 2.01 4.05 
21 2.16 <.001 1.11 3.20 
26 1.03 .144 -0.14 2.19 
38 -0.99 .299 -2.24 0.27 
38 3 10.69 <.001 9.76 11.62 
5 11.12 <.001 10.19 12.05 
7 11.08 <.001 10.15 12.01 
9 10.50 <.001 9.54 11.45 
11 9.36 <.001 8.37 10.34 
13 6.88 <.001 5.86 7.89 
15 5.99 <.001 5.00 6.98 
18 4.02 <.001 2.97 5.06 
21 3.14 <.001 2.07 4.21 
26 2.01 <.001 0.83 3.20 
32 0.99 .299 -0.27 2.24 





Table 10-2: Difference in body mass index with age for males. 
(I) Age (J) Age Mean 
Difference 
(I-J) 






3 5 0.49 <.001 0.22 0.76 
7 0.61 <.001 0.33 0.90 
9 0.15 0.924 -0.17 0.46 
11 -1.00 <.001 -1.41 -0.58 
13 -2.79 <.001 -3.22 -2.35 
15 -3.53 <.001 -3.99 -3.07 
18 -6.26 <.001 -6.79 -5.72 
21 -7.44 <.001 -7.97 -6.90 
26 -8.65 <.001 -9.26 -8.05 
32 -9.91 <.001 -10.58 -9.23 
38 -10.96 <.001 -11.68 -10.23 
5 3 -0.49 <.001 -0.76 -0.22 
7 0.12 0.951 -0.16 0.40 
9 -0.34 0.02 -0.65 -0.03 
11 -1.49 <.001 -1.90 -1.07 
13 -3.28 <.001 -3.71 -2.84 
15 -4.02 <.001 -4.48 -3.56 
18 -6.74 <.001 -7.27 -6.22 
21 -7.92 <.001 -8.46 -7.39 
26 -9.14 <.001 -9.74 -8.54 
32 -10.39 <.001 -11.06 -9.72 
38 -11.44 <.001 -12.17 -10.72 
7 3 -0.61 <.001 -0.90 -0.33 
5 -0.12 0.951 -0.40 0.16 
9 -0.46 <.001 -0.79 -0.14 
11 -1.61 <.001 -2.03 -1.19 
13 -3.40 <.001 -3.84 -2.96 
15 -4.14 <.001 -4.61 -3.68 
18 -6.87 <.001 -7.40 -6.33 
21 -8.05 <.001 -8.59 -7.51 
26 -9.27 <.001 -9.87 -8.66 
32 -10.52 <.001 -11.19 -9.84 
38 -11.57 <.001 -12.29 -10.84 
9 3 -0.15 0.924 -0.46 0.17 
5 0.34 0.02 0.03 0.65 
7 0.46 <.001 0.14 0.79 
11 -1.15 <.001 -1.59 -0.70 
13 -2.94 <.001 -3.40 -2.47 
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15 -3.68 <.001 -4.16 -3.20 
18 -6.40 <.001 -6.96 -5.85 
21 -7.58 <.001 -8.14 -7.03 
26 -8.80 <.001 -9.43 -8.18 
32 -10.05 <.001 -10.74 -9.37 
38 -11.10 <.001 -11.84 -10.36 
11 3 1.00 <.001 0.58 1.41 
5 1.49 <.001 1.07 1.90 
7 1.61 <.001 1.19 2.03 
9 1.15 <.001 0.70 1.59 
13 -1.79 <.001 -2.33 -1.25 
15 -2.53 <.001 -3.09 -1.98 
18 -5.26 <.001 -5.87 -4.64 
21 -6.44 <.001 -7.06 -5.82 
26 -7.66 <.001 -8.33 -6.98 
32 -8.91 <.001 -9.65 -8.17 
38 -9.96 <.001 -10.74 -9.17 
13 3 2.79 <.001 2.35 3.22 
5 3.28 <.001 2.84 3.71 
7 3.40 <.001 2.96 3.84 
9 2.94 <.001 2.47 3.40 
11 1.79 <.001 1.25 2.33 
15 -0.74 0.001 -1.32 -0.17 
18 -3.47 <.001 -4.10 -2.84 
21 -4.65 <.001 -5.28 -4.01 
26 -5.87 <.001 -6.56 -5.18 
32 -7.12 <.001 -7.87 -6.37 
38 -8.17 <.001 -8.97 -7.37 
15 3 3.53 <.001 3.07 3.99 
5 4.02 <.001 3.56 4.48 
7 4.14 <.001 3.68 4.61 
9 3.68 <.001 3.20 4.16 
11 2.53 <.001 1.98 3.09 
13 0.74 0.001 0.17 1.32 
18 -2.72 <.001 -3.37 -2.08 
21 -3.91 <.001 -4.55 -3.26 
26 -5.12 <.001 -5.83 -4.42 
32 -6.37 <.001 -7.14 -5.61 
38 -7.42 <.001 -8.24 -6.61 
18 3 6.26 <.001 5.72 6.79 
5 6.74 <.001 6.22 7.27 
7 6.87 <.001 6.33 7.40 
9 6.40 <.001 5.85 6.96 
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11 5.26 <.001 4.64 5.87 
13 3.47 <.001 2.84 4.10 
15 2.72 <.001 2.08 3.37 
21 -1.18 <.001 -1.88 -0.48 
26 -2.40 <.001 -3.15 -1.65 
32 -3.65 <.001 -4.46 -2.84 
38 -4.70 <.001 -5.55 -3.85 
21 3 7.44 <.001 6.90 7.97 
5 7.92 <.001 7.39 8.46 
7 8.05 <.001 7.51 8.59 
9 7.58 <.001 7.03 8.14 
11 6.44 <.001 5.82 7.06 
13 4.65 <.001 4.01 5.28 
15 3.91 <.001 3.26 4.55 
18 1.18 <.001 0.48 1.88 
26 -1.22 <.001 -1.98 -0.46 
32 -2.47 <.001 -3.28 -1.66 
38 -3.52 <.001 -4.38 -2.66 
26 3 8.65 <.001 8.05 9.26 
5 9.14 <.001 8.54 9.74 
7 9.27 <.001 8.66 9.87 
9 8.80 <.001 8.18 9.43 
11 7.66 <.001 6.98 8.33 
13 5.87 <.001 5.18 6.56 
15 5.12 <.001 4.42 5.83 
18 2.40 <.001 1.65 3.15 
21 1.22 <.001 0.46 1.98 
32 -1.25 <.001 -2.11 -0.39 
38 -2.30 <.001 -3.20 -1.40 
32 3 9.91 <.001 9.23 10.58 
5 10.39 <.001 9.72 11.06 
7 10.52 <.001 9.84 11.19 
9 10.05 <.001 9.37 10.74 
11 8.91 <.001 8.17 9.65 
13 7.12 <.001 6.37 7.87 
15 6.37 <.001 5.61 7.14 
18 3.65 <.001 2.84 4.46 
21 2.47 <.001 1.66 3.28 
26 1.25 <.001 0.39 2.11 
38 -1.05 0.015 -2.00 -0.10 
38 3 10.96 <.001 10.23 11.68 
5 11.44 <.001 10.72 12.17 
7 11.57 <.001 10.84 12.29 
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9 11.10 <.001 10.36 11.84 
11 9.96 <.001 9.17 10.74 
13 8.17 <.001 7.37 8.97 
15 7.42 <.001 6.61 8.24 
18 4.70 <.001 3.85 5.55 
21 3.52 <.001 2.66 4.38 
26 2.30 <.001 1.40 3.20 
32 1.05 0.015 0.10 2.00 





 Systolic blood pressure 
Statistical analysis using ANOVA showed statistically significant difference between age 
groups at p < 0.001 for both females and males. 
Table 10-3: Difference in systolic blood pressure with age for females. 
(I) 
Age 
(J) Age Mean 
Difference 
(I-J) 






7 9 -4.32 <.001 -5.92 -2.72 
11 -0.97 0.684 -2.65 0.71 
13 -3.49 <.001 -5.33 -1.65 
15 -20.68 <.001 -22.62 -18.73 
18 -13.57 <.001 -15.38 -11.76 
26 -9.78 <.001 -11.52 -8.04 
32 -10.80 <.001 -12.70 -8.91 
38 -14.59 <.001 -16.57 -12.62 
9 7 4.32 <.001 2.72 5.92 
11 3.35 <.001 1.66 5.04 
13 0.83 0.902 -1.03 2.69 
15 -16.36 <.001 -18.32 -14.40 
18 -9.25 <.001 -11.08 -7.43 
26 -5.46 <.001 -7.22 -3.71 
32 -6.49 <.001 -8.40 -4.57 
38 -10.28 <.001 -12.27 -8.28 
11 7 0.97 0.684 -0.71 2.65 
9 -3.35 <.001 -5.04 -1.66 
13 -2.52 0.002 -4.44 -0.60 
15 -19.71 <.001 -21.73 -17.69 
18 -12.60 <.001 -14.50 -10.71 
26 -8.81 <.001 -10.64 -6.98 
32 -9.84 <.001 -11.81 -7.86 
38 -13.62 <.001 -15.68 -11.57 
13 7 3.49 <.001 1.65 5.33 
9 -0.83 0.902 -2.69 1.03 
11 2.52 0.002 0.60 4.44 
15 -17.19 <.001 -19.35 -15.03 
18 -10.08 <.001 -12.12 -8.04 
26 -6.29 <.001 -8.27 -4.31 
32 -7.32 <.001 -9.44 -5.20 
38 -11.10 <.001 -13.30 -8.91 
15 7 20.68 <.001 18.73 22.62 
9 16.36 <.001 14.40 18.32 
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11 19.71 <.001 17.69 21.73 
13 17.19 <.001 15.03 19.35 
18 7.10 <.001 4.97 9.24 
26 10.90 <.001 8.82 12.97 
32 9.87 <.001 7.66 12.08 
38 6.08 <.001 3.81 8.36 
18 7 13.57 <.001 11.76 15.38 
9 9.25 <.001 7.43 11.08 
11 12.60 <.001 10.71 14.50 
13 10.08 <.001 8.04 12.12 
15 -7.10 <.001 -9.24 -4.97 
26 3.79 <.001 1.84 5.74 
32 2.77 0.001 0.68 4.86 
38 -1.02 0.87 -3.18 1.14 
26 7 9.78 <.001 8.04 11.52 
9 5.46 <.001 3.71 7.22 
11 8.81 <.001 6.98 10.64 
13 6.29 <.001 4.31 8.27 
15 -10.90 <.001 -12.97 -8.82 
18 -3.79 <.001 -5.74 -1.84 
32 -1.02 0.823 -3.06 1.01 
38 -4.81 <.001 -6.92 -2.71 
32 7 10.80 <.001 8.91 12.70 
9 6.49 <.001 4.57 8.40 
11 9.84 <.001 7.86 11.81 
13 7.32 <.001 5.20 9.44 
15 -9.87 <.001 -12.08 -7.66 
18 -2.77 0.001 -4.86 -0.68 
26 1.02 0.823 -1.01 3.06 







7 14.59 <.001 12.62 16.57 
9 10.28 <.001 8.28 12.27 
11 13.62 <.001 11.57 15.68 
13 11.10 <.001 8.91 13.30 
15 -6.08 <.001 -8.36 -3.81 
18 1.02 0.87 -1.14 3.18 
26 4.81 <.001 2.71 6.92 
32 3.79 <.001 1.55 6.03 





Table 10-4: Difference in systolic blood pressure with age for males. 
(I) Age (J) Age Mean 
Difference 
(I-J) 






7 9 -4.37 <.001 -5.91 -2.84 
11 0.00 <.001 -1.51 1.50 
13 -4.13 <.001 -5.86 -2.40 
15 -24.40 <.001 -26.35 -22.44 
18 -23.20 <.001 -24.94 -21.47 
26 -18.94 <.001 -20.77 -17.11 
32 -20.19 <.001 -22.05 -18.33 
38 -21.33 <.001 -23.32 -19.35 
9 7 4.37 <.001 2.84 5.91 
11 4.37 <.001 2.81 5.93 
13 0.25 <.001 -1.53 2.02 
15 -20.02 <.001 -22.02 -18.03 
18 -18.83 <.001 -20.61 -17.05 
26 -14.57 <.001 -16.44 -12.69 
32 -15.81 <.001 -17.72 -13.91 
38 -16.96 <.001 -18.99 -14.94 
11 7 0.00 <.001 -1.50 1.51 
9 -4.37 <.001 -5.93 -2.81 
13 -4.12 <.001 -5.87 -2.37 
15 -24.39 <.001 -26.36 -22.42 
18 -23.20 <.001 -24.95 -21.44 
26 -18.94 <.001 -20.79 -17.09 
32 -20.18 <.001 -22.06 -18.31 
38 -21.33 <.001 -23.33 -19.33 
13 7 4.13 <.001 2.40 5.86 
9 -0.25 1 -2.02 1.53 
11 4.12 <.001 2.37 5.87 
15 -20.27 <.001 -22.42 -18.12 
18 -19.07 <.001 -21.02 -17.12 
26 -14.81 <.001 -16.85 -12.77 
32 -16.06 <.001 -18.12 -14.00 
38 -17.21 <.001 -19.38 -15.03 
15 7 24.40 <.001 22.44 26.35 
9 20.02 <.001 18.03 22.02 
11 24.39 <.001 22.42 26.36 
13 20.27 <.001 18.12 22.42 
18 1.19 0.73 -0.96 3.35 
26 5.46 <.001 3.23 7.69 
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32 4.21 <.001 1.96 6.46 
38 3.06 0.002 0.71 5.42 
18 7 23.20 <.001 21.47 24.94 
9 18.83 <.001 17.05 20.61 
11 23.20 <.001 21.44 24.95 
13 19.07 <.001 17.12 21.02 
15 -1.19 0.73 -3.35 0.96 
26 4.26 <.001 2.22 6.30 
32 3.01 <.001 0.95 5.08 
38 1.87 0.161 -0.31 4.05 
26 7 18.94 <.001 17.11 20.77 
9 14.57 <.001 12.69 16.44 
11 18.94 <.001 17.09 20.79 
13 14.81 <.001 12.77 16.85 
15 -5.46 <.001 -7.69 -3.23 
18 -4.26 <.001 -6.30 -2.22 
32 -1.25 0.677 -3.39 0.90 
38 -2.39 0.028 -4.65 -0.14 
32 7 20.19 <.001 18.33 22.05 
9 15.81 <.001 13.91 17.72 
11 20.18 <.001 18.31 22.06 
13 16.06 <.001 14.00 18.12 
15 -4.21 <.001 -6.46 -1.96 
18 -3.01 <.001 -5.08 -0.95 
26 1.25 0.677 -0.90 3.39 
38 -1.15 0.825 -3.42 1.13 
38 7 21.33 <.001 19.35 23.32 
9 16.96 <.001 14.94 18.99 
11 21.33 <.001 19.33 23.33 
13 17.21 <.001 15.03 19.38 
15 -3.06 0.002 -5.42 -0.71 
18 -1.87 0.161 -4.05 0.31 
26 2.39 0.028 0.14 4.65 
32 1.15 0.825 -1.13 3.42 





 Diastolic blood pressure 
Statistical analysis using ANOVA showed statistically significant difference between age 
groups at p < 0.001 for both females and males. 
Table 10-5: Difference in diastolic blood pressure with age for females. 
(I) 
Age 
(J) Age Mean 
Difference 
(I-J) 






7 9 0.79 0.927 -1.08 2.65 
11 -3.15 <.001 -4.88 -1.43 
13 15.03 <.001 12.78 17.29 
15 -13.50 <.001 -15.22 -11.79 
18 -1.62 0.113 -3.41 0.17 
26 -14.70 <.001 -16.38 -13.03 
32 -18.69 <.001 -20.38 -17.01 
38 -20.46 <.001 -22.21 -18.72 
9 7 -0.79 0.927 -2.65 1.08 
11 -3.94 <.001 -5.88 -2.00 
13 14.24 <.001 11.82 16.67 
15 -14.29 <.001 -16.22 -12.36 
18 -2.41 0.006 -4.41 -0.41 
26 -15.49 <.001 -17.39 -13.59 
32 -19.48 <.001 -21.39 -17.57 
38 -21.25 <.001 -23.21 -19.29 
11 7 3.15 <.001 1.43 4.88 
9 3.94 <.001 2.00 5.88 
13 18.18 <.001 15.86 20.51 
15 -10.35 <.001 -12.15 -8.55 
18 1.53 0.215 -0.34 3.41 
26 -11.55 <.001 -13.31 -9.78 
32 -15.54 <.001 -17.31 -13.77 
38 -17.31 <.001 -19.14 -15.48 
13 7 -15.03 <.001 -17.29 -12.78 
9 -14.24 <.001 -16.67 -11.82 
11 -18.18 <.001 -20.51 -15.86 
15 -28.53 <.001 -30.85 -26.22 
18 -16.65 <.001 -19.03 -14.28 
26 -29.73 <.001 -32.02 -27.45 
32 -33.72 <.001 -36.02 -31.43 
38 -35.49 <.001 -37.83 -33.16 
15 7 13.50 <.001 11.79 15.22 
9 14.29 <.001 12.36 16.22 
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11 10.35 <.001 8.55 12.15 
13 28.53 <.001 26.22 30.85 
18 11.88 <.001 10.01 13.75 
26 -1.20 0.457 -2.96 0.56 
32 -5.19 <.001 -6.95 -3.43 
38 -6.96 <.001 -8.78 -5.14 
18 7 1.62 0.113 -0.17 3.41 
9 2.41 0.006 0.41 4.41 
11 -1.53 0.215 -3.41 0.34 
13 16.65 <.001 14.28 19.03 
15 -11.88 <.001 -13.75 -10.01 
26 -13.08 <.001 -14.91 -11.25 
32 -17.07 <.001 -18.91 -15.23 
38 -18.84 <.001 -20.74 -16.94 
26 7 14.70 <.001 13.03 16.38 
9 15.49 <.001 13.59 17.39 
11 11.55 <.001 9.78 13.31 
13 29.73 <.001 27.45 32.02 
15 1.20 0.457 -0.56 2.96 
18 13.08 <.001 11.25 14.91 
32 -3.99 <.001 -5.72 -2.27 
38 -5.76 <.001 -7.55 -3.97 
32 7 18.69 <.001 17.01 20.38 
9 19.48 <.001 17.57 21.39 
11 15.54 <.001 13.77 17.31 
13 33.72 <.001 31.43 36.02 
15 5.19 <.001 3.43 6.95 
18 17.07 <.001 15.23 18.91 
26 3.99 <.001 2.27 5.72 
38 -1.77 0.057 -3.56 0.02 
38 7 20.46 <.001 18.72 22.21 
9 21.25 <.001 19.29 23.21 
11 17.31 <.001 15.48 19.14 
13 35.49 <.001 33.16 37.83 
15 6.96 <.001 5.14 8.78 
18 18.84 <.001 16.94 20.74 
26 5.76 <.001 3.97 7.55 
32 1.77 0.057 -0.02 3.56 





Table 10-6: Difference in diastolic blood pressure with age for males. 
(I) Age (J) Age Mean 
Difference 
(I-J) 






7 9 1.22 0.527 -0.66 3.10 
11 -2.98 <.001 -4.74 -1.21 
13 15.68 <.001 13.37 17.99 
15 -11.94 <.001 -13.85 -10.03 
18 -2.69 0.001 -4.65 -0.72 
26 -19.01 <.001 -20.85 -17.17 
32 -23.35 <.001 -25.16 -21.54 
38 -26.26 <.001 -28.12 -24.41 
9 7 -1.22 0.527 -3.10 0.66 
11 -4.20 <.001 -6.19 -2.20 
13 14.46 <.001 11.97 16.94 
15 -13.16 <.001 -15.28 -11.04 
18 -3.91 <.001 -6.08 -1.74 
26 -20.23 <.001 -22.29 -18.18 
32 -24.57 <.001 -26.61 -22.54 
38 -27.49 <.001 -29.56 -25.42 
11 7 2.98 <.001 1.21 4.74 
9 4.20 <.001 2.20 6.19 
13 18.66 <.001 16.25 21.06 
15 -8.96 <.001 -10.98 -6.94 
18 0.29 1 -1.79 2.37 
26 -16.04 <.001 -17.99 -14.08 
32 -20.38 <.001 -22.31 -18.45 
38 -23.29 <.001 -25.26 -21.32 
13 7 -15.68 <.001 -17.99 -13.37 
9 -14.46 <.001 -16.94 -11.97 
11 -18.66 <.001 -21.06 -16.25 
15 -27.62 <.001 -30.13 -25.11 
18 -18.37 <.001 -20.92 -15.82 
26 -34.69 <.001 -37.15 -32.24 
32 -39.03 <.001 -41.47 -36.60 
38 -41.95 <.001 -44.41 -39.48 
15 7 11.94 <.001 10.03 13.85 
9 13.16 <.001 11.04 15.28 
11 8.96 <.001 6.94 10.98 
13 27.62 <.001 25.11 30.13 
18 9.25 <.001 7.06 11.45 
26 -7.07 <.001 -9.16 -4.99 
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32 -11.41 <.001 -13.47 -9.36 
38 -14.33 <.001 -16.42 -12.23 
18 7 2.69 0.001 0.72 4.65 
9 3.91 <.001 1.74 6.08 
11 -0.29 1 -2.37 1.79 
13 18.37 <.001 15.82 20.92 
15 -9.25 <.001 -11.45 -7.06 
26 -16.33 <.001 -18.46 -14.19 
32 -20.67 <.001 -22.78 -18.55 
38 -23.58 <.001 -25.73 -21.43 
26 7 19.01 <.001 17.17 20.85 
9 20.23 <.001 18.18 22.29 
11 16.04 <.001 14.08 17.99 
13 34.69 <.001 32.24 37.15 
15 7.07 <.001 4.99 9.16 
18 16.33 <.001 14.19 18.46 
32 -4.34 <.001 -6.33 -2.35 
38 -7.25 <.001 -9.29 -5.22 
32 7 23.35 <.001 21.54 25.16 
9 24.57 <.001 22.54 26.61 
11 20.38 <.001 18.45 22.31 
13 39.03 <.001 36.60 41.47 
15 11.41 <.001 9.36 13.47 
18 20.67 <.001 18.55 22.78 
26 4.34 <.001 2.35 6.33 
38 -2.91 <.001 -4.92 -0.90 
38 7 26.26 <.001 24.41 28.12 
9 27.49 <.001 25.42 29.56 
11 23.29 <.001 21.32 25.26 
13 41.95 <.001 39.48 44.41 
15 14.33 <.001 12.23 16.42 
18 23.58 <.001 21.43 25.73 
26 7.25 <.001 5.22 9.29 
32 2.91 <.001 0.90 4.92 





 Mean arterial blood pressure 
Statistical analysis using ANOVA showed statistically significant difference between age 
groups at p < 0.001 for both females and males. 
Table 10-7: Difference in mean arterial blood pressure with age for females. 
(I) 
Age 
(J) Age Mean 
Difference 
(I-J) 






7 9 -0.92 0.586 -2.39 0.55 
11 -2.43 <.001 -3.84 -1.01 
13 8.86 <.001 7.19 10.52 
15 -15.89 <.001 -17.39 -14.40 
18 -5.65 <.001 -7.13 -4.17 
26 -13.06 <.001 -14.53 -11.60 
32 -16.06 <.001 -17.60 -14.53 
38 -18.51 <.001 -20.15 -16.87 
9 7 0.92 0.586 -0.55 2.39 
11 -1.51 0.059 -3.05 0.03 
13 9.77 <.001 8.01 11.54 
15 -14.98 <.001 -16.58 -13.37 
18 -4.73 <.001 -6.33 -3.14 
26 -12.15 <.001 -13.72 -10.57 
32 -15.15 <.001 -16.79 -13.50 
38 -17.59 <.001 -19.33 -15.85 
11 7 2.43 <.001 1.01 3.84 
9 1.51 0.059 -0.03 3.05 
13 11.28 <.001 9.56 13.01 
15 -13.47 <.001 -15.03 -11.91 
18 -3.22 <.001 -4.77 -1.67 
26 -10.64 <.001 -12.17 -9.11 
32 -13.64 <.001 -15.24 -12.04 
38 -16.08 <.001 -17.78 -14.38 
13 7 -8.86 <.001 -10.52 -7.19 
9 -9.77 <.001 -11.54 -8.01 
11 -11.28 <.001 -13.01 -9.56 
15 -24.75 <.001 -26.54 -22.97 
18 -14.51 <.001 -16.28 -12.73 
26 -21.92 <.001 -23.68 -20.16 
32 -24.92 <.001 -26.75 -23.10 
38 -27.36 <.001 -29.27 -25.45 
15 7 15.89 <.001 14.40 17.39 
9 14.98 <.001 13.37 16.58 
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11 13.47 <.001 11.91 15.03 
13 24.75 <.001 22.97 26.54 
18 10.25 <.001 8.63 11.86 
26 2.83 <.001 1.23 4.43 
32 -0.17 1 -1.84 1.50 
38 -2.61 <.001 -4.37 -0.85 
18 7 5.65 <.001 4.17 7.13 
9 4.73 <.001 3.14 6.33 
11 3.22 <.001 1.67 4.77 
13 14.51 <.001 12.73 16.28 
15 -10.25 <.001 -11.86 -8.63 
26 -7.41 <.001 -9.00 -5.82 
32 -10.42 <.001 -12.07 -8.76 
38 -12.86 <.001 -14.61 -11.11 
26 7 13.06 <.001 11.60 14.53 
9 12.15 <.001 10.57 13.72 
11 10.64 <.001 9.11 12.17 
13 21.92 <.001 20.16 23.68 
15 -2.83 <.001 -4.43 -1.23 
18 7.41 <.001 5.82 9.00 
32 -3.00 <.001 -4.64 -1.36 
38 -5.44 <.001 -7.18 -3.71 
32 7 16.06 <.001 14.53 17.60 
9 15.15 <.001 13.50 16.79 
11 13.64 <.001 12.04 15.24 
13 24.92 <.001 23.10 26.75 
15 0.17 1 -1.50 1.84 
18 10.42 <.001 8.76 12.07 
26 3.00 <.001 1.36 4.64 
38 -2.44 0.001 -4.24 -0.64 
38 7 18.51 <.001 16.87 20.15 
9 17.59 <.001 15.85 19.33 
11 16.08 <.001 14.38 17.78 
13 27.36 <.001 25.45 29.27 
15 2.61 <.001 0.85 4.37 
18 12.86 <.001 11.11 14.61 
26 5.44 <.001 3.71 7.18 
32 2.44 0.001 0.64 4.24 
Post hoc analysis using Games Howell test. Dependent variable is MABP. MABP is an 
average of SBP and DBP measured at Korotkoff 5 with 2/3 weighting given to DBP and 1/3 




Table 10-8: Difference in mean arterial blood pressure with age for males. 
(I) Age (J) Age Mean 
Difference 
(I-J) 






7 9 -0.62 0.921 -2.06 0.82 
11 -1.98 <.001 -3.38 -0.59 
13 9.08 <.001 7.39 10.76 
15 -16.09 <.001 -17.68 -14.50 
18 -9.44 <.001 -11.00 -7.88 
26 -18.99 <.001 -20.59 -17.39 
32 -22.30 <.001 -23.89 -20.70 
38 -24.62 <.001 -26.34 -22.91 
9 7 0.62 0.921 -0.82 2.06 
11 -1.37 0.111 -2.87 0.14 
13 9.70 <.001 7.92 11.47 
15 -15.47 <.001 -17.16 -13.78 
18 -8.83 <.001 -10.48 -7.17 
26 -18.37 <.001 -20.06 -16.68 
32 -21.68 <.001 -23.37 -19.99 
38 -24.00 <.001 -25.81 -22.20 
11 7 1.98 <.001 0.59 3.38 
9 1.37 0.111 -0.14 2.87 
13 11.06 <.001 9.32 12.80 
15 -14.11 <.001 -15.76 -12.45 
18 -7.46 <.001 -9.08 -5.84 
26 -17.00 <.001 -18.66 -15.35 
32 -20.31 <.001 -21.97 -18.66 
38 -22.64 <.001 -24.41 -20.87 
13 7 -9.08 <.001 -10.76 -7.39 
9 -9.70 <.001 -11.47 -7.92 
11 -11.06 <.001 -12.80 -9.32 
15 -25.17 <.001 -27.07 -23.27 
18 -18.52 <.001 -20.40 -16.65 
26 -28.07 <.001 -29.97 -26.16 
32 -31.38 <.001 -33.28 -29.47 
38 -33.70 <.001 -35.70 -31.69 
15 7 16.09 <.001 14.50 17.68 
9 15.47 <.001 13.78 17.16 
11 14.11 <.001 12.45 15.76 
13 25.17 <.001 23.27 27.07 
18 6.65 <.001 4.86 8.44 
26 -2.90 <.001 -4.72 -1.07 
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32 -6.21 <.001 -8.03 -4.38 
38 -8.53 <.001 -10.46 -6.60 
18 7 9.44 <.001 7.88 11.00 
9 8.83 <.001 7.17 10.48 
11 7.46 <.001 5.84 9.08 
13 18.52 <.001 16.65 20.40 
15 -6.65 <.001 -8.44 -4.86 
26 -9.54 <.001 -11.34 -7.75 
32 -12.85 <.001 -14.65 -11.06 
38 -15.18 <.001 -17.08 -13.28 
26 7 18.99 <.001 17.39 20.59 
9 18.37 <.001 16.68 20.06 
11 17.00 <.001 15.35 18.66 
13 28.07 <.001 26.16 29.97 
15 2.90 <.001 1.07 4.72 
18 9.54 <.001 7.75 11.34 
32 -3.31 <.001 -5.14 -1.48 
38 -5.63 <.001 -7.56 -3.70 
32 7 22.30 <.001 20.70 23.89 
9 21.68 <.001 19.99 23.37 
11 20.31 <.001 18.66 21.97 
13 31.38 <.001 29.47 33.28 
15 6.21 <.001 4.38 8.03 
18 12.85 <.001 11.06 14.65 
26 3.31 <.001 1.48 5.14 
38 -2.32 0.006 -4.25 -0.39 
38 7 24.62 <.001 22.91 26.34 
9 24.00 <.001 22.20 25.81 
11 22.64 <.001 20.87 24.41 
13 33.70 <.001 31.69 35.70 
15 8.53 <.001 6.60 10.46 
18 15.18 <.001 13.28 17.08 
26 5.63 <.001 3.70 7.56 
32 2.32 0.006 0.39 4.25 
Post hoc analysis using Games Howell test. Dependent variable is MABP. MABP is an 
average of SBP and DBP measured at Korotkoff 5 with 2/3 weighting given to DBP and 1/3 




 Cardiorespiratory fitness 
Statistical analysis using ANOVA showed statistically significant difference between age 
groups at p < 0.001 for both females and males. 
Table 10-9: Difference in VO2 max with age in females. 
(I) Age (J) Age Mean 
Difference 
(I-J) 






15 26 15.02 <.001 14.16 15.89 
32 17.69 <.001 16.78 18.59 
38 20.35 <.001 19.51 21.18 
26 15 -15.02 <.001 -15.89 -14.16 
32 2.66 <.001 1.71 3.62 
38 5.33 <.001 4.44 6.21 
32 15 -17.69 <.001 -18.59 -16.78 
26 -2.66 <.001 -3.62 -1.71 
38 2.66 <.001 1.73 3.59 
38 15 -20.35 <.001 -21.18 -19.51 
26 -5.33 <.001 -6.21 -4.44 
32 -2.66 <.001 -3.59 -1.73 
Post hoc analysis using Games Howell test. Dependent variable is VO2 max. 
 
Table 10-10: Difference in VO2 max with age for males. 
(I) Age (J) Age Mean 
Difference 
(I-J) 






15 26 5.76 <.001 4.74 6.78 
32 10.04 <.001 8.99 11.09 
38 14.51 <.001 13.49 15.54 
26 15 -5.76 <.001 -6.78 -4.74 
32 4.28 <.001 3.20 5.35 
38 8.75 <.001 7.70 9.80 
32 15 -10.04 <.001 -11.09 -8.99 
26 -4.28 <.001 -5.35 -3.20 
38 4.47 <.001 3.40 5.55 
38 15 -14.51 <.001 -15.54 -13.49 
26 -8.75 <.001 -9.80 -7.70 
32 -4.47 <.001 -5.55 -3.40 
Post hoc analysis using Games Howell test. Dependent variable is VO2 max.
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11 Appendix E: Results - Simple linear regression analysis 
This section explores the simple linear regression relationship between CVD risk factor and RVC (CRAE and CRVE). Simple linear regression 
analysis is done per age group, stratified by sex, unadjusted and then adjusted for fellow RVC. Logarithmic transformation was undertaken for the 




 Age 38 
11.1.1 Dependent variable: central retinal artery equivalent 
Table 11-1: Simple linear regression analysis for age 38 variables. Dependent variable: CRAE. 















SBP -.375 -.384*** -8.840 <.001 -.459 -.292 -.288 -.312*** -7.070 <.001 -.368 -.208 
DBP -.480 -.394*** -9.108 <.001 -.583 -.376 -.295 -.276*** -6.196 <.001 -.388 -.201 
MABP -.497 -.415*** -9.695 <.001 -.598 -.396 -.332 -.308*** -6.974 <.001 -.426 -.239 
BMI  -.318 -.163*** -3.517 <.001 -.495 -.140 -.325 -.139** -3.016 .003 -.537 -.113 
Waist-Hip -23.454 -.122* -2.604 .010 -41.156 -5.751 -11.205 -.068 -1.476 .141 -26.122 3.712 
HbA1c 2.755 .107* 2.272 .024 .372 5.139 1.395 .081 1.718 .086 -.200 2.991 
Tot. Chol. -.679 -.061 -1.301 .194 -1.703 .346 -1.065 -.100* -2.138 .033 -2.044 -.086 
HDL  -.312 -.013 -.267 .790 -2.610 1.987 .149 .005 .103 .918 -2.701 2.999 
Non-HDL -.570 -.054 -1.136 .257 -1.556 .416 -1.016 -.099* -2.105 .036 -1.965 -.068 
WBC .456 .078 1.639 .102 -.091 1.003 .163 .027 .570 .569 -.399 .725 
hsCRP -1.087 -.073 -1.542 .124 -2.471 .298 -.159 -.008 -.170 .865 -1.993 1.676 
Fibrinogen -.296 -.017 -.351 .726 -1.955 1.363 1.377 .066 1.400 .162 -.556 3.310 
IL-6 -.189 -.008 -.151 .880 -2.647 2.270 -3.608 -.122* -2.443 .015 -6.510 -.705 
Tot. Smk. .212 .147** 3.196 .001 .082 .343 .153 .130** 2.832 .005 .047 .258 
VO2 Max .332 .154** 3.241 .001 .131 .534 .285 .165*** 3.584 <.001 .129 .442 
F-RHI .436 .016 .334 .739 -2.129 3.001 1.299 .042 .903 .367 -1.526 4.123 





Table 11-2: Simple linear regression analysis for age 38 variables adjusted for fellow RVC. Dependent variable: CRAE. 















SBP -.318 -.325*** -10.101 <.001 -.380 -.256 -.227 -.246*** -7.800 <.001 -.285 -.170 
DBP -.428 -.352*** -11.161 <.001 -.503 -.353 -.280 -.263*** -8.456 <.001 -.346 -.215 
MABP -.435 -.363*** -11.636 <.001 -.509 -.362 -.295 -.273*** -8.822 <.001 -.360 -.229 
BMI  -.277 -.142*** -4.266 <.001 -.404 -.149 -.401 -.171*** -5.262 <.001 -.551 -.251 
Waist-Hip -21.933 -.114** -3.401 .001 -34.607 -9.259 -23.784 -.145*** -4.377 <.001 -34.461 -13.107 
HbA1c 1.129 .044 1.226 .221 -.680 2.939 -.100 -.006 -.168 .866 -1.262 1.063 
Tot. Chol. -.840 -.076* -2.148 .032 -1.609 -.071 -1.323 -.124*** -3.719 <.001 -2.022 -.624 
HDL  1.208 .049 1.369 .172 -.526 2.941 1.372 .045 1.313 .190 -.682 3.425 
Non-HDL -1.001 -.094** -2.664 .008 -1.739 -.262 -1.396 -.136*** -4.062 <.001 -2.072 -.721 
WBC -.182 -.031 -.857 .392 -.599 .235 -.418 -.069* -2.017 .044 -.825 -.011 
hsCRP -1.706 -.114** -3.241 .001 -2.740 -.671 -1.459 -.074* -2.154 .032 -2.789 -.128 
Fibrinogen -1.122 -.063 -1.766 .078 -2.372 .127 -.947 -.046 -1.310 .191 -2.368 .474 
IL-6 -1.300 -.053 -1.343 .180 -3.203 .603 -3.830 -.129*** -3.605 <.001 -5.919 -1.741 
Tot. Smk. -.030 -.021 -.603 .547 -.128 .068 .000 <.001 -.003 .998 -.078 .078 
VO2 Max .337 .156*** 4.347 <.001 .185 .489 .321 .186*** 5.699 <.001 .210 .431 
F-RHI 1.207 .043 1.217 .224 -.743 3.156 -.838 -.027 -.799 .424 -2.897 1.222 




11.1.2 Dependent variable: central retinal vein equivalent 
Table 11-3: Simple linear regression analysis for age 38 variables. Dependent variable: CRVE. 















SBP -.125 -.094* -2.000 .046 -.247 -.002 -.124 -.098* -2.119 .035 -.238 -.009 
DBP -.111 -.067 -1.422 .156 -.264 .042 -.028 -.019 -.420 .674 -.161 .105 
MABP -.134 -.082 -1.749 .081 -.284 .017 -.076 -.051 -1.107 .269 -.210 .059 
BMI  -.082 -.031 -.655 .513 -.328 .164 .147 .046 .990 .323 -.145 .440 
Waist-Hip -2.993 -.011 -.242 .809 -27.345 21.359 24.610 .109* 2.356 .019 4.081 45.139 
HbA1c 3.419 .097* 2.045 .041 .133 6.705 2.918 .125** 2.662 .008 .764 5.071 
Tot. Chol. .336 .022 .467 .641 -1.077 1.749 .499 .035 .737 .462 -.832 1.830 
HDL  -3.148 -.092 -1.964 .050 -6.299 .002 -2.376 -.057 -1.212 .226 -6.228 1.475 
Non-HDL .891 .061 1.291 .197 -.465 2.247 .734 .053 1.120 .263 -.554 2.023 
WBC 1.315 .163** 3.469 .001 .570 2.060 1.118 .136** 2.915 .004 .364 1.871 
hsCRP 1.278 .062 1.317 .188 -.629 3.185 2.555 .094* 2.010 .045 .057 5.053 
Fibrinogen 1.722 .071 1.482 .139 -.561 4.004 4.579 .160** 3.431 .001 1.957 7.202 
IL-6 2.368 .071 1.397 .163 -.966 5.701 .440 .011 .217 .828 -3.553 4.434 
Tot. Smk. .474 .241*** 5.327 <.001 .299 .649 .300 .188*** 4.116 <.001 .157 .444 
VO2 Max -.010 -.003 -.067 .946 -.289 .270 -.070 -.029 -.631 .528 -.288 .148 
F-RHI -1.625 -.043 -.906 .365 -5.147 1.898 4.226 .100* 2.157 .032 .376 8.076 




Table 11-4: Simple linear regression analysis for age 38 variables adjusted for fellow RVC. Dependent variable: CRVE. 















SBP .248 .186*** 4.968 <.001 .150 .346 .166 .132*** 3.804 <.001 .080 .252 
DBP .377 .227*** 6.122 <.001 .256 .498 .273 .187*** 5.554 <.001 .176 .369 
MABP .376 .230*** 6.142 <.001 .256 .496 .265 .180*** 5.274 <.001 .166 .364 
BMI  .225 .085* 2.476 .014 .046 .403 .466 .145*** 4.390 <.001 .257 .674 
Waist-Hip 19.560 .074* 2.189 .029 1.996 37.124 35.457 .157*** 4.759 <.001 20.816 50.099 
HbA1c .927 .026 .730 .466 -1.571 3.425 1.615 .069* 2.031 .043 .052 3.178 
Tot. Chol. .956 .063 1.769 .078 -.106 2.017 1.515 .105** 3.119 .002 .560 2.470 
HDL  -2.866 -.084* -2.381 .018 -5.231 -.500 -2.516 -.060* -1.785 .075 -5.287 .254 
Non-HDL 1.413 .097** 2.735 .006 .397 2.428 1.705 .122*** 3.639 <.001 .784 2.626 
WBC .905 .112** 3.165 .002 .343 1.466 .965 .117** 3.506 .001 .424 1.506 
hsCRP 2.277 .111** 3.138 .002 .851 3.702 2.705 .100** 2.947 .003 .901 4.509 
Fibrinogen 1.991 .082* 2.281 .023 .275 3.706 3.292 .115** 3.391 .001 1.384 5.200 
IL-6 2.530 .075 1.932 .054 -.044 5.105 3.892 .096** 2.643 .009 .996 6.787 
Tot. Smk. .279 .142*** 4.256 <.001 .150 .408 .158 .099** 2.958 .003 .053 .263 
VO2 Max -.311 -.105** -2.868 .004 -.525 -.098 -.351 -.148*** -4.420 <.001 -.507 -.195 
F-RHI -2.015 -.053 -1.480 .140 -4.689 .660 3.006 .071* 2.113 .035 .211 5.802 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001.  
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 Age 32 
11.2.1 Dependent variable: central retinal artery equivalent 
Table 11-5: Simple linear regression analysis for age 32 variables. Dependent variable: CRAE. 















SBP -.265 -.246*** -5.236 <.001 -.364 -.165 -.203 -.203*** -4.457 <.001 -.292 -.113 
DBP -.370 -.275*** -5.878 <.001 -.494 -.246 -.191 -.175*** -3.814 <.001 -.289 -.092 
MABP -.395 -.289*** -6.225 <.001 -.519 -.270 -.242 -.206*** -4.515 <.001 -.347 -.137 
BMI  -.308 -.151** -3.145 .002 -.500 -.115 -.200 -.080 -1.717 .087 -.429 .029 
Waist-Hip -29.990 -.143** -2.971 .003 -49.830 -10.149 -4.259 -.020 -.433 .665 -23.598 15.079 
HbA1c 2.682 .095 1.944 .053 -.030 5.394 -.174 -.006 -.116 .908 -3.111 2.764 
Tot. Chol. -.324 -.028 -.570 .569 -1.439 .792 -.994 -.094 -1.949 .052 -1.996 .008 
HDL  1.180 .044 .903 .367 -1.389 3.749 1.868 .061 1.258 .209 -1.050 4.787 
Non-HDL -.523 -.046 -.942 .347 -1.614 .568 -1.105 -.109* -2.276 .023 -2.059 -.151 
WBC .202 .033 .674 .501 -.387 .791 -.026 -.004 -.088 .930 -.613 .561 
hsCRP -1.464 -.096* -1.984 .048 -2.914 -.013 -.654 -.040 -.826 .409 -2.211 .902 
Fibrinogen -2.048 -.112* -2.301 .022 -3.798 -.298 -.056 -.003 -.057 .954 -1.965 1.854 
Tot. Smk. .224 .118* 2.549 .011 .051 .397 .187 .120** 2.606 .009 .046 .328 
VO2 Max .229 .118* 2.368 .018 .039 .419 .154 .092 1.948 .052 -.001 .309 






















SBP -.208 -.193*** -5.644 <.001 -.280 -.135 -.158 -.159*** -4.821 <.001 -.223 -.094 
DBP -.273 -.203*** -5.919 <.001 -.364 -.183 -.177 -.163*** -4.963 <.001 -.248 -.107 
MABP -.299 -.219*** -6.437 <.001 -.390 -.207 -.211 -.180*** -5.500 <.001 -.287 -.136 
BMI  -.268 -.132*** -3.793 <.001 -.408 -.129 -.305 -.122*** -3.657 <.001 -.469 -.141 
Waist-Hip -24.526 -.117** -3.335 .001 -38.979 -10.073 -21.579 -.102** -3.048 .002 -35.491 -7.668 
HbA1c .785 .028 .744 .457 -1.289 2.859 -2.237 -.072* -2.054 .041 -4.378 -.097 
Tot. Chol. -.611 -.052 -1.496 .135 -1.415 .192 -1.374 -.129*** -3.736 <.001 -2.097 -.651 
HDL  2.121 .079* 2.259 .024 .275 3.967 2.581 .084* 2.395 .017 .463 4.698 
Non-HDL -.970 -.085* -2.433 .015 -1.753 -.186 -1.529 -.151*** -4.384 <.001 -2.214 -.844 
WBC -.278 -.045 -1.282 .201 -.705 .148 -.681 -.110** -3.131 .002 -1.109 -.254 
hsCRP -1.183 -.078* -2.223 .027 -2.228 -.137 -1.106 -.067 -1.923 .055 -2.237 .025 
Fibrinogen -1.671 -.091** -2.607 .009 -2.931 -.411 -1.223 -.061 -1.728 .085 -2.615 .168 
Tot. Smk. -.040 -.021 -.617 .537 -.169 .088 .002 .002 .046 .964 -.102 .107 
VO2 Max .291 .150*** 3.991 <.001 .148 .435 .206 .123*** 3.661 <.001 .095 .317 




11.2.2 Dependent variable: central retinal vein equivalent 

















SBP -.118 -.079 -1.635 .103 -.260 .024 -.089 -.065 -1.406 .160 -.213 .035 
DBP -.203 -.108* -2.244 .025 -.380 -.025 -.026 -.018 -.376 .707 -.162 .110 
MABP -.202 -.107* -2.207 .028 -.381 -.022 -.062 -.038 -.823 .411 -.208 .085 
BMI  -.079 -.028 -.578 .564 -.349 .190 .205 .060 1.287 .199 -.108 .517 
Waist-Hip -11.155 -.038 -.788 .431 -38.969 16.658 33.725 .116* 2.513 .012 7.350 60.100 
HbA1c 4.034 .103* 2.115 .035 .284 7.783 4.046 .096* 2.003 .046 .076 8.017 
Tot. Chol. .571 .036 .729 .466 -.968 2.110 .746 .052 1.074 .284 -.619 2.110 
HDL  -1.861 -.050 -1.032 .303 -5.405 1.683 -1.405 -.034 -.696 .487 -5.373 2.563 
Non-HDL .883 .056 1.153 .250 -.622 2.387 .829 .060 1.253 .211 -.472 2.130 
WBC .948 .112* 2.307 .022 .140 1.756 1.267 .151** 3.163 .002 .480 2.054 
hsCRP -.561 -.027 -.549 .583 -2.571 1.448 .891 .040 .829 .408 -1.223 3.005 
Fibrinogen -.753 -.030 -.610 .542 -3.182 1.676 2.295 .084 1.746 .082 -.288 4.879 
Tot. Smk. .522 .201*** 4.396 <.001 .289 .755 .364 .172*** 3.746 <.001 .173 .555 
VO2 Max -.131 -.049 -.972 .332 -.395 .134 -.102 -.045 -.941 .347 -.314 .111 





















SBP .142 .095** 2.632 .009 .036 .249 .107 .079* 2.295 .022 .015 .198 
DBP .161 .086* 2.355 .019 .027 .296 .159 .107** 3.153 .002 .060 .258 
MABP .189 .100** 2.727 .007 .053 .326 .174 .109** 3.191 .002 .067 .282 
BMI  .219 .077* 2.180 .030 .021 .416 .396 .116** 3.472 .001 .172 .620 
Waist-Hip 17.708 .061 1.702 .090 -2.747 38.163 37.794 .131*** 3.940 <.001 18.945 56.643 
HbA1c 1.623 .041 1.113 .266 -1.242 4.488 4.208 .100** 2.872 .004 1.328 7.088 
Tot. Chol. .881 .055 1.564 .119 -.226 1.989 1.686 .117** 3.355 .001 .698 2.673 
HDL  -2.997 -.081* -2.314 .021 -5.542 -.451 -3.156 -.075* -2.152 .032 -6.039 -.273 
Non-HDL 1.386 .088* 2.523 .012 .306 2.466 1.880 .137*** 3.937 <.001 .942 2.819 
WBC .756 .089* 2.552 .011 .174 1.338 1.291 .154*** 4.473 <.001 .724 1.858 
hsCRP .846 .040 1.143 .254 -.609 2.302 1.503 .067 1.924 .055 -.033 3.039 
Fibrinogen 1.223 .048 1.367 .172 -.536 2.982 2.347 .086* 2.459 .014 .471 4.223 
Tot. Smk. .315 .121*** 3.608 <.001 .143 .486 .190 .090** 2.669 .008 .050 .330 
VO2 Max -.340 -.127** -3.340 .001 -.541 -.140 -.250 -.110** -3.231 .001 -.402 -.098 






 Age 26 
11.3.1 Dependent Variable: central retinal artery equivalent 

















SBP -.199 -.162** -3.378 .001 -.314 -.083 -.209 -.205*** -4.460 <.001 -.301 -.117 
DBP -.255 -.189*** -3.969 <.001 -.382 -.129 -.199 -.188*** -4.083 <.001 -.295 -.103 
MABP -.298 -.203*** -4.259 <.001 -.436 -.161 -.256 -.218*** -4.756 <.001 -.362 -.150 
BMI  -.169 -.071 -1.476 .141 -.393 .056 -.101 -.035 -.749 .454 -.365 .164 
Waist-Hip -15.891 -.067 -1.385 .167 -38.446 6.663 -21.432 -.081 -1.728 .085 -45.812 2.949 
Tot. Chol. .136 .012 .235 .815 -1.004 1.276 -.782 -.072 -1.490 .137 -1.813 .250 
HDL  -.523 -.018 -.353 .725 -3.439 2.393 2.125 .061 1.256 .210 -1.201 5.452 
Non-HDL .216 .019 .372 .710 -.923 1.355 -.914 -.088 -1.811 .071 -1.905 .078 
WBC .602 .113* 2.311 .021 .090 1.114 -.190 -.028 -.583 .561 -.830 .451 
hsCRP -1.430 -.113* -2.301 .022 -2.652 -.208 -1.076 -.072 -1.486 .138 -2.500 .347 
Tot. Smk. .281 .100* 2.158 .031 .025 .536 .280 .120* 2.598 .010 .068 .491 
VO2 Max .249 .111* 2.186 .029 .025 .472 .129 .074 1.530 .127 -.037 .295 
























SBP -.141 -.115** -3.260 .001 -.226 -.056 -.175 -.172*** -5.182 <.001 -.242 -.109 
DBP -.193 -.143*** -4.086 <.001 -.285 -.100 -.176 -.166*** -5.013 <.001 -.245 -.107 
MABP -.221 -.150*** -4.300 <.001 -.322 -.120 -.222 -.189*** -5.740 <.001 -.298 -.146 
BMI  -.217 -.092** -2.621 .009 -.379 -.054 -.169 -.059 -1.733 .084 -.360 .023 
Waist-Hip -24.361 -.103** -2.942 .003 -40.636 -8.086 -22.295 -.084* -2.486 .013 -39.922 -4.668 
Tot. Chol. -.239 -.021 -.575 .566 -1.055 .578 -1.019 -.094** -2.659 .008 -1.772 -.266 
HDL  1.561 .054 1.467 .143 -.532 3.654 2.452 .070* 1.979 .048 .017 4.887 
Non-HDL -.478 -.042 -1.149 .251 -1.295 .340 -1.163 -.112** -3.164 .002 -1.885 -.440 
WBC .018 .003 .093 .926 -.354 .389 -.548 -.082* -2.296 .022 -1.016 -.079 
hsCRP -1.054 -.084* -2.369 .018 -1.928 -.179 -.632 -.042 -1.181 .238 -1.684 .420 
Tot. Smk. -.048 -.017 -.500 .618 -.238 .141 .027 .012 .346 .730 -.129 .183 
VO2 Max .243 .109** 2.942 .003 .081 .406 .150 .085* 2.453 .015 .030 .270 







11.3.2 Dependent variable: central retinal vein equivalent 

















SBP -.120 -.070 -1.443 .150 -.282 .043 -.067 -.049 -1.037 .300 -.195 .060 
DBP -.130 -.069 -1.424 .155 -.309 .049 -.046 -.032 -.680 .497 -.178 .087 
MABP -.161 -.078 -1.615 .107 -.356 .035 -.067 -.042 -.901 .368 -.214 .079 
BMI  .095 .029 .607 .544 -.214 .405 .134 .034 .732 .465 -.226 .495 
Waist-Hip 16.738 .052 1.063 .288 -14.205 47.682 1.704 .005 .101 .920 -31.598 35.007 
Tot. Chol. .749 .047 .924 .356 -.844 2.343 .464 .032 .659 .510 -.920 1.848 
HDL  -4.141 -.102* -2.005 .046 -8.203 -.080 -.642 -.014 -.283 .777 -5.104 3.820 
Non-HDL 1.381 .087 1.709 .088 -.208 2.971 .487 .035 .719 .472 -.845 1.819 
WBC 1.154 .156** 3.216 .001 .449 1.860 .698 .078 1.604 .110 -.158 1.553 
hsCRP -.750 -.043 -.865 .387 -2.455 .954 -.882 -.044 -.908 .364 -2.791 1.027 
Tot. Smk. .653 .170*** 3.697 <.001 .306 1<.001 .501 .157** 3.416 .001 .213 .789 
VO2 Max .011 .003 .067 .947 -.300 .321 -.041 -.017 -.352 .725 -.269 .188 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001.  
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SBP .071 .042 1.155 .249 -.050 .192 .133 .096** 2.793 .005 .040 .227 
DBP .117 .062 1.725 .085 -.016 .250 .145 .101** 2.944 .003 .048 .242 
MABP .128 .063 1.726 .085 -.018 .274 .180 .113** 3.275 .001 .072 .288 
BMI  .256 .079* 2.246 .025 .032 .480 .229 .058 1.726 .085 -.032 .490 
Waist-Hip 31.874 .099** 2.803 .005 9.524 54.224 21.954 .061 1.786 .075 -2.202 46.110 
Tot. Chol. .616 .039 1.062 .289 -.524 1.757 1.182 .082* 2.295 .022 .170 2.195 
HDL  -3.631 -.089* -2.461 .014 -6.531 -.730 -2.587 -.055 -1.554 .121 -5.859 .685 
Non-HDL 1.171 .074* 2.025 .044 .034 2.307 1.330 .095** 2.685 .008 .356 2.303 
WBC .575 .078* 2.221 .027 .066 1.085 .871 .097** 2.743 .006 .247 1.495 
hsCRP .647 .037 1.036 .301 -.580 1.873 .093 .005 .129 .898 -1.320 1.506 
Tot. Smk. .392 .102** 3.026 .003 .138 .647 .240 .075* 2.226 .026 .028 .451 
VO2 Max -.227 -.074 -1.961 .051 -.454 .001 -.164 -.068 -1.945 .052 -.329 .002 








 Age 21 
11.4.1 Dependent variable: central retinal artery equivalent 

















BMI  -.298 -.102* -2.148 .032 -.571 -.025 -.103 -.033 -.702 .483 -.392 .185 
Tot. Smk. .411 .087 1.880 .061 -.019 .841 .390 .100* 2.166 .031 .036 .745 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 

















BMI  -.263 -.090* -2.452 .015 -.473 -.052 -.200 -.064 -1.859 .064 -.412 .011 
Tot. Smk. -.083 -.018 -.512 .609 -.400 .235 .077 .020 .581 .562 -.183 .336 






11.4.2 Dependent variable: central retinal vein equivalent 

















BMI  -.077 -.019 -.403 .687 -.454 .300 .195 .046 .969 .333 -.200 .589 
Tot. Smk. .981 .152** 3.297 .001 .396 1.565 .624 .117* 2.530 .012 .139 1.108 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 

















BMI  .185 .046 1.247 .213 -.107 .478 .291 .068* 1.976 .049 .002 .580 
Tot. Smk. .598 .093** 2.744 .006 .170 1.026 .256 .048 1.425 .155 -.097 .610 






 Age 18 
11.5.1 Dependent variable: central retinal artery equivalent 

















SBP -.142 -.121* -2.443 .015 -.256 -.028 -.170 -.152** -3.115 .002 -.277 -.063 
DBP -.042 -.034 -.677 .499 -.164 .080 -.070 -.069 -1.360 .175 -.170 .031 
MABP -.111 -.074 -1.480 .140 -.259 .036 -.145 -.113* -2.238 .026 -.272 -.018 
BMI  -.041 -.012 -.236 .813 -.383 .301 -.006 -.002 -.033 .974 -.338 .327 
Tot. Smk. .689 .083 1.796 .073 -.065 1.444 .404 .063 1.355 .176 -.182 .990 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 

















SBP -.126 -.107** -2.924 .004 -.210 -.041 -.176 -.158*** -4.439 <.001 -.254 -.098 
DBP -.133 -.108** -2.895 .004 -.224 -.043 -.085 -.084* -2.276 .023 -.159 -.012 
MABP -.189 -.127** -3.426 .001 -.298 -.081 -.165 -.128** -3.499 .001 -.258 -.072 
BMI  -.190 -.054 -1.471 .142 -.444 .064 -.129 -.037 -1.027 .305 -.374 .117 
Tot. Smk. .033 .004 .117 .907 -.521 .587 .057 .009 .263 .792 -.368 .481 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
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11.5.2 Dependent variable: central retinal vein equivalent 

















SBP -.033 -.020 -.409 .683 -.192 .126 .013 .009 .174 .862 -.132 .158 
DBP .186 .108* 2.156 .032 .016 .355 .031 .023 .446 .656 -.105 .166 
MABP .160 .077 1.530 .127 -.046 .365 .039 .023 .451 .652 -.133 .212 
BMI  .306 .063 1.273 .204 -.166 .778 .241 .053 1.074 .283 -.200 .682 
Tot. Smk. 1.310 .116* 2.497 .013 .279 2.340 .685 .078 1.681 .093 -.116 1.485 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 

















SBP .100 .061 1.651 .100 -.019 .218 .170 .114** 3.135 .002 .063 .277 
DBP .226 .131*** 3.556 <.001 .101 .350 .095 .070 1.875 .061 -.005 .194 
MABP .265 .128** 3.448 .001 .114 .416 .174 .101** 2.713 .007 .048 .300 
BMI  .344 .071 1.932 .054 -.006 .694 .246 .054 1.486 .138 -.079 .572 
Tot. Smk. .664 .059 1.730 .084 -.090 1.419 .303 .034 1.027 .305 -.277 .882 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
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 Age 15 
11.6.1 Dependent variable: central retinal artery equivalent 

















SBP -.185 -.168** -3.354 .001 -.294 -.077 -.074 -.078 -1.559 .120 -.168 .019 
DBP -.062 -.045 -.881 .379 -.201 .077 -.032 -.031 -.624 .533 -.133 .069 
MABP -.170 -.111* -2.197 .029 -.323 -.018 -.070 -.058 -1.157 .248 -.190 .049 
BMI  -.186 -.041 -.862 .389 -.609 .237 .301 .080 1.703 .089 -.046 .649 
VO2 Max  .086 .034 .659 .510 -.171 .344 .060 .032 .640 .522 -.125 .245 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 

















SBP -.104 -.094* -2.564 .011 -.183 -.024 -.084 -.088* -2.418 .016 -.153 -.016 
DBP -.092 -.066 -1.805 .072 -.192 .008 -.097 -.095* -2.595 .010 -.171 -.024 
MABP -.141 -.092* -2.516 .012 -.251 -.031 -.137 -.113** -3.096 .002 -.225 -.050 
BMI  -.239 -.053 -1.550 .122 -.543 .064 -.127 -.034 -.980 .328 -.382 .128 
VO2 Max  .064 .025 .672 .502 -.122 .250 .110 .059 1.599 .111 -.025 .246 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
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11.6.2 Dependent variable: central retinal vein equivalent 

















SBP -.162 -.108* -2.151 .032 -.311 -.014 .020 .015 .308 .758 -.107 .147 
DBP .058 .031 .607 .544 -.130 .247 .129 .093 1.862 .063 -.007 .265 
MABP -.058 -.028 -.548 .584 -.266 .150 .132 .080 1.604 .109 -.030 .294 
BMI  .105 .017 .358 .721 -.470 .680 .849 .163** 3.503 .001 .373 1.325 
VO2 Max  .045 .013 .250 .802 -.305 .394 -.100 -.039 -.782 .435 -.351 .151 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 

















SBP .012 .008 .208 .836 -.098 .121 .089 .069 1.870 .062 -.005 .182 
DBP .117 .062 1.688 .092 -.019 .253 .159 .114** 3.139 .002 .059 .258 
MABP .103 .049 1.341 .181 -.048 .254 .198 .120** 3.293 .001 .080 .316 
BMI  .281 .046 1.336 .182 -.132 .694 .564 .109** 3.205 .001 .218 .910 
VO2 Max  -.037 -.010 -.285 .776 -.289 .216 -.155 -.061 -1.661 .098 -.339 .029 




 Age 13 
11.7.1 Dependent variable: central retinal artery equivalent 

















SBP -.122 -.090 -1.646 .101 -.269 .024 -.281 -.227*** -4.315 <.001 -.409 -.153 
DBP K-5 -.012 -.011 -.208 .835 -.122 .099 -.073 -.083 -1.554 .121 -.166 .019 
DBP K-4 -.058 -.044 -.814 .416 -.199 .083 -.115 -.104 -1.948 .052 -.231 .001 
MABP K-5 -.063 -.043 -.786 .433 -.221 .095 -.188 -.153** -2.868 .004 -.317 -.059 
MABP K-4 -.130 -.076 -1.395 .164 -.314 .053 -.255 -.178** -3.354 .001 -.405 -.106 
BMI  -.240 -.052 -.959 .338 -.731 .252 .073 .016 .298 .766 -.408 .554 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 

















SBP -.077 -.056 -1.459 .145 -.180 .027 -.273 -.220*** -5.727 <.001 -.367 -.179 
DBP K-5 -.075 -.073 -1.895 .059 -.153 .003 -.088 -.101* -2.525 .012 -.157 -.020 
DBP K-4 -.084 -.064 -1.676 .095 -.184 .015 -.143 -.130** -3.280 .001 -.229 -.057 
MABP K-5 -.131 -.089* -2.332 .020 -.242 -.021 -.205 -.167*** -4.252 <.001 -.300 -.110 
MABP K-4 -.136 -.079* -2.070 .039 -.265 -.007 -.283 -.198*** -5.094 <.001 -.393 -.174 
BMI  -.266 -.058 -1.505 .133 -.613 .081 -.337 -.074 -1.837 .067 -.698 .024 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
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11.7.2 Dependent variable: central retinal vein equivalent 

















SBP -.084 -.047 -.867 .387 -.276 .107 -.016 -.010 -.180 .857 -.193 .161 
DBP K-5 .115 .086 1.577 .116 -.028 .259 .030 .026 .477 .633 -.095 .155 
DBP K-4 .048 .028 .512 .609 -.136 .232 .056 .038 .708 .480 -.100 .213 
MABP K-5 .124 .065 1.189 .235 -.081 .329 .034 .021 .387 .699 -.141 .210 
MABP K-4 .010 .005 .083 .934 -.230 .250 .057 .029 .545 .586 -.148 .261 
BMI  .048 .008 .147 .883 -.597 .694 .818 .133* 2.506 .013 .176 1.461 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 

















SBP .029 .016 .425 .671 -.106 .165 .249 .149*** 3.678 <.001 .116 .382 
DBP K-5 .126 .094* 2.460 .014 .025 .227 .097 .082* 2.042 .042 .004 .190 
DBP K-4 .102 .060 1.552 .122 -.027 .231 .161 .109** 2.722 .007 .045 .278 
MABP K-5 .183 .096* 2.499 .013 .039 .327 .208 .126** 3.131 .002 .077 .338 
MABP K-4 .131 .059 1.529 .127 -.038 .300 .295 .153*** 3.817 <.001 .143 .447 
BMI  .271 .045 1.169 .243 -.185 .728 .753 .123** 3.099 .002 .275 1.231 




 Age 11 
11.8.1 Dependent variable: central retinal artery equivalent 

















SBP -.267 -.179** -3.419 .001 -.421 -.114 -.280 -.187*** -3.669 <.001 -.430 -.130 
DBP K-5 -.064 -.044 -.819 .413 -.219 .090 -.106 -.086 -1.667 .096 -.230 .019 
DBP K-4 -.091 -.058 -1.091 .276 -.255 .073 -.197 -.141** -2.741 .006 -.338 -.056 
MABP K-5 -.191 -.107* -2.017 .044 -.377 -.005 -.219 -.139** -2.707 .007 -.377 -.060 
MABP K-4 -.204 -.115* -2.173 .030 -.389 -.019 -.299 -.181*** -3.534 <.001 -.466 -.133 
BMI  -.034 -.006 -.112 .911 -.624 .557 .377 .076 1.407 .160 -.150 .904 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 

















SBP -.221 -.148*** -3.983 <.001 -.331 -.112 -.233 -.156*** -4.251 <.001 -.341 -.125 
DBP K-5 -.188 -.128** -3.381 .001 -.297 -.079 -.106 -.086* -2.312 .021 -.196 -.016 
DBP K-4 -.196 -.125** -3.320 .001 -.312 -.080 -.167 -.120** -3.223 .001 -.269 -.065 
MABP K-5 -.289 -.162*** -4.352 <.001 -.420 -.159 -.201 -.128** -3.469 .001 -.316 -.087 
MABP K-4 -.272 -.153*** -4.106 <.001 -.402 -.141 -.252 -.152*** -4.140 <.001 -.372 -.132 
BMI  -.132 -.025 -.615 .539 -.555 .291 -.072 -.015 -.367 .714 -.457 .314 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
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11.8.2 Dependent variable: central retinal vein equivalent 

















SBP -.089 -.044 -.834 .405 -.298 .121 -.095 -.045 -.876 .382 -.309 .119 
DBP K-5 .232 .117* 2.215 .027 .026 .438 .001 <.001 -.001 .999 -.176 .175 
DBP K-4 .197 .094 1.771 .077 -.022 .417 -.061 -.031 -.601 .548 -.262 .139 
MABP K-5 .185 .077 1.450 .148 -.066 .435 -.035 -.016 -.308 .759 -.260 .190 
MABP K-4 .127 .053 1.003 .316 -.122 .376 -.096 -.041 -.799 .425 -.334 .141 
BMI  .189 .026 .470 .638 -.601 .979 .909 .131* 2.430 .016 .173 1.644 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 

















SBP .168 .084* 2.185 .030 .017 .319 .183 .087* 2.294 .022 .026 .339 
DBP K-5 .293 .148*** 3.973 <.001 .148 .438 .103 .060 1.598 .111 -.024 .230 
DBP K-4 .284 .135*** 3.608 <.001 .129 .439 .133 .068 1.790 .074 -.013 .278 
MABP K-5 .368 .154*** 4.110 <.001 .192 .545 .181 .082* 2.174 .030 .017 .344 
MABP K-4 .323 .136*** 3.609 <.001 .147 .500 .201 .086* 2.274 .024 .027 .374 
BMI  .220 .031 .766 .444 -.346 .786 .546 .079* 2.007 .046 .011 1.081 




 Age 9 
11.9.1 Dependent variable: central retinal artery equivalent 

















SBP -.246 -.150** -2.886 .004 -.413 -.078 -.245 -.173** -3.448 .001 -.385 -.105 
DBP K-5 -.093 -.073 -1.382 .168 -.225 .039 -.021 -.019 -.375 .708 -.130 .088 
DBP K-4 -.147 -.088 -1.684 .093 -.318 .025 -.174 -.113* -2.228 .026 -.328 -.020 
MABP K-5 -.191 -.114* -2.175 .030 -.364 -.018 -.110 -.075 -1.472 .142 -.257 .037 
MABP K-4 -.245 -.127* -2.435 .015 -.443 -.047 -.262 -.152** -3.025 .003 -.432 -.092 
BMI  -.159 -.023 -.428 .669 -.889 .572 .450 .067 1.317 .189 -.222 1.122 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 

















SBP -.186 -.114** -3.041 .003 -.307 -.066 -.254 -.179*** -5.071 <.001 -.352 -.155 
DBP K-5 -.115 -.090* -2.387 .018 -.209 -.020 -.078 -.072* -1.984 .048 -.156 -.001 
DBP K-4 -.152 -.091* -2.429 .016 -.274 -.029 -.249 -.161*** -4.550 <.001 -.357 -.142 
MABP K-5 -.196 -.117** -3.117 .002 -.319 -.072 -.182 -.125** -3.453 .001 -.286 -.079 
MABP K-4 -.221 -.115** -3.070 .002 -.362 -.079 -.327 -.190*** -5.425 <.001 -.445 -.208 
BMI  -.198 -.028 -.743 .458 -.721 .325 -.010 -.001 -.039 .969 -.495 .476 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
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11.9.2 Dependent variable: central retinal vein equivalent 

















SBP -.116 -.053 -1.004 .316 -.344 .111 .018 .009 .173 .863 -.182 .217 
DBP K-5 .042 .025 .465 .642 -.136 .220 .114 .075 1.467 .143 -.039 .266 
DBP K-4 .009 .004 .077 .938 -.223 .241 .148 .068 1.337 .182 -.069 .364 
MABP K-5 .009 .004 .072 .942 -.225 .243 .142 .069 1.353 .177 -.064 .348 
MABP K-4 -.047 -.018 -.341 .733 -.315 .222 .128 .053 1.039 .299 -.114 .369 
BMI  .074 .008 .149 .882 -.906 1.055 .919 .098 1.933 .054 -.016 1.854 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 
 

















SBP .117 .053 1.390 .165 -.048 .282 .266 .134*** 3.671 <.001 .123 .408 
DBP K-5 .130 .076* 1.997 .047 .002 .258 .134 .089* 2.442 .015 .026 .242 
DBP K-4 .148 .066 1.748 .081 -.018 .314 .324 .149*** 4.173 <.001 .171 .476 
MABP K-5 .190 .084* 2.222 .027 .022 .358 .252 .123** 3.403 .001 .106 .397 
MABP K-4 .186 .072 1.892 .059 -.007 .379 .395 .164*** 4.578 <.001 .225 .565 
BMI  .223 .024 .626 .532 -.479 .925 .484 .051 1.411 .159 -.190 1.157 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
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 Age 7 
11.10.1 Dependent variable: central retinal artery equivalent 

















SBP -.132 -.083 -1.659 .098 -.288 .024 -.150 -.101* -2.052 .041 -.294 -.006 
DBP K-5 -.053 -.034 -.672 .502 -.208 .102 -.102 -.076 -1.529 .127 -.233 .029 
DBP K-4 -.075 -.041 -.823 .411 -.254 .104 -.163 -.106* -2.145 .033 -.312 -.014 
MABP K-5 -.115 -.061 -1.204 .229 -.302 .073 -.168 -.100* -2.034 .043 -.329 -.006 
MABP K-4 -.135 -.067 -1.323 .187 -.335 .066 -.212 -.121* -2.451 .015 -.382 -.042 
BMI  .177 .021 .411 .681 -.669 1.023 .892 .108* 2.179 .030 .087 1.696 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 

















SBP -.142 -.090* -2.518 .012 -.253 -.031 -.199 -.134*** -3.760 <.001 -.302 -.095 
DBP K-5 -.117 -.075* -2.089 .037 -.227 -.007 -.147 -.109** -3.040 .003 -.242 -.052 
DBP K-4 -.137 -.076* -2.113 .035 -.264 -.010 -.233 -.152*** -4.268 <.001 -.340 -.126 
MABP K-5 -.182 -.096** -2.698 .007 -.315 -.049 -.234 -.140*** -3.942 <.001 -.351 -.117 
MABP K-4 -.192 -.095** -2.660 .008 -.334 -.050 -.296 -.169*** -4.774 <.001 -.418 -.174 
BMI  -.112 -.013 -.367 .713 -.711 .487 .237 .029 .782 .435 -.359 .832 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
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11.10.2 Dependent variable: central retinal vein equivalent 

















SBP .019 .009 .183 .855 -.189 .228 .098 .047 .957 .339 -.103 .298 
DBP K-5 .121 .058 1.152 .250 -.085 .327 .091 .048 .977 .329 -.092 .273 
DBP K-4 .117 .048 .963 .336 -.122 .356 .141 .066 1.331 .184 -.067 .348 
MABP K-5 .127 .050 1.003 .317 -.122 .377 .134 .058 1.166 .244 -.092 .360 
MABP K-4 .108 .040 .797 .426 -.159 .376 .168 .069 1.393 .164 -.069 .406 
BMI  .543 .048 .949 .343 -.582 1.667 1.332 .117* 2.357 .019 .221 2.443 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 

















SBP .144 .068 1.898 .058 -.005 .292 .243 .118** 3.282 .001 .097 .388 
DBP K-5 .170 .082* 2.291 .023 .024 .317 .189 .101** 2.799 .005 .056 .321 
DBP K-4 .187 .078* 2.172 .030 .018 .357 .298 .140*** 3.911 <.001 .148 .448 
MABP K-5 .235 .093** 2.614 .009 .058 .412 .296 .128*** 3.563 <.001 .133 .459 
MABP K-4 .236 .087* 2.439 .015 .046 .425 .375 .154*** 4.310 <.001 .204 .546 
BMI  .376 .033 .930 .353 -.419 1.172 .496 .044 1.187 .236 -.326 1.317 




 Age 5 
11.11.1 Dependent variable: central retinal artery equivalent 

















BMI  .506 .052 1.053 .293 -.439 1.451 .776 .088 1.778 .076 -.082 1.635 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 

















BMI  .180 .018 .525 .600 -.494 .854 .569 .064 1.793 .074 -.055 1.192 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 
11.11.2 Dependent variable: central retinal vein equivalent 

















BMI  .616 .048 .965 .335 -.638 1.870 .424 .034 .691 .490 -.782 1.629 





















BMI  .144 .011 .316 .752 -.751 1.039 -.327 -.026 -.732 .465 -1.206 .552 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 Age 3 
11.12.1 Dependent variable: central retinal artery equivalent 

















BMI  .530 .063 1.297 .195 -.274 1.334 .719 .082 1.645 .101 -.140 1.578 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 

















BMI  .398 .047 1.366 .173 -.175 .972 .438 .050 1.399 .162 -.177 1.054 





11.12.2 Dependent variable: central retinal vein equivalent 

















BMI  .261 .022 .460 .646 -.855 1.377 .548 .046 .919 .359 -.624 1.720 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 

















BMI  -.256 -.022 -.632 .528 -1.053 .541 -.138 -.012 -.322 .748 -.980 .704 









12 Appendix F: Results - Multiple linear regression analysis 
 Introduction 
Multiple linear regression analysis was done on age 38 variables, including all relevant variables. Non-HDL cholesterol was assessed separately from 
total cholesterol. MABP, SBP and DBP were analysed separately from each other. Stratification was done by sex and adjustment was also made for 
fellow RVC and SES (childhood SES and age 38 SES). Logarithmic transformation was done for the following variables for analysis: hsCRP to 




 Age 38 
12.2.1 Dependent variable: central retinal artery equivalent 
Table 12-1: Multiple linear regression analysis for age 38. Dependent variable: CRAE. 















MABP -.380 -.326*** -8.232 <.001 -.470 -.289 -.274 -.246*** -6.454 <.001 -.358 -.191 
BMI  -.016 -.008 -.131 .896 -.252 .220 .066 .029 .486 .627 -.202 .335 
Waist-Hip -4.077 -.022 -.533 .594 -19.115 10.962 -13.540 -.084 -1.938 .053 -27.282 .202 
HbA1c 2.176 .089* 2.358 .019 .361 3.990 -2.137 -.077* -2.091 .037 -4.145 -.128 
Tot. Chol. -.408 -.038 -.968 .334 -1.236 .421 -.448 -.043 -1.148 .252 -1.216 .320 
HDL  .330 .014 .308 .758 -1.779 2.440 1.071 .035 .910 .363 -1.243 3.386 
WBC .110 .018 .449 .654 -.373 .594 -.069 -.012 -.306 .760 -.515 .376 
hsCRP -.978 -.064 -1.203 .230 -2.577 .621 .980 .050 1.085 .279 -.797 2.757 
Fibrinogen .362 .021 .398 .691 -1.429 2.154 .090 .004 .103 .918 -1.630 1.810 
IL-6 1.532 .062 1.244 .214 -.890 3.953 -1.347 -.045 -1.095 .274 -3.764 1.071 
Tot. Smk. .003 .002 .053 .958 -.112 .118 .047 .039 .958 .339 -.049 .143 
VO2 Max .168 .077 1.292 .197 -.087 .423 .117 .068 1.209 .227 -.073 .307 
F-RHI .262 .009 .242 .809 -1.862 2.385 -1.695 -.055 -1.507 .133 -3.906 .516 
CRVE .442 .598*** 15.591 <.001 .386 .497 .496 .680*** 19.294 <.001 .446 .547 
Child SES .075 .008 .201 .841 -.657 .807 -.626 -.067 -1.849 .065 -1.292 .040 
Age 38 SES .060 .008 .199 .842 -.533 .653 .270 .036 .948 .344 -.289 .829 




Table 12-2: Multiple linear regression analysis for other age 38 variables. Dependent Variable: CRAE. 















SBP -.265 -.277*** -6.894 <.001 -.340 -.189 -.181 -.194*** -5.006 <.001 -.252 -.110 
DBP  -.378 -.318*** -8.064 <.001 -.470 -.286 -.265 -.241*** -6.424 <.001 -.346 -.184 
Non-HDL  -.408 -.039 -.968 .334 -1.236 .421 -.448 -.044 -1.148 .252 -1.216 .320 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 




12.2.2 Dependent variable: central retinal vein equivalent 
Table 12-3: Multiple linear regression linear regression analysis for age 38. Dependent variable: CRVE. 















MABP .271 .172*** 3.772 <.001 .130 .413 .194 .127** 3.064 .002 .070 .319 
BMI  .056 .021 .318 .750 -.288 .399 -.009 -.003 -.046 .964 -.394 .376 
Waist-Hip -4.956 -.020 -.445 .656 -26.845 16.934 23.058 .104* 2.307 .022 3.403 42.713 
HbA1c -.731 -.022 -.540 .589 -3.392 1.930 2.246 .059 1.530 .127 -.641 5.134 
Tot. Chol. .054 .004 .089 .929 -1.153 1.262 .467 .032 .833 .405 -.635 1.568 
HDL  -1.244 -.038 -.798 .426 -4.311 1.823 -1.557 -.037 -.923 .357 -4.875 1.761 
WBC .289 .035 .809 .419 -.414 .993 .299 .037 .923 .357 -.339 .937 
hsCRP 2.096 .101 1.775 .077 -.226 4.417 -1.286 -.048 -.992 .322 -3.833 1.262 
Fibrinogen -.401 -.017 -.303 .762 -3.009 2.207 1.484 .052 1.186 .236 -.976 3.945 
IL-6 -1.420 -.042 -.792 .429 -4.949 2.108 .884 .021 .501 .617 -2.586 4.354 
Tot. Smk. .168 .091* 1.994 .047 .002 .334 .090 .054 1.282 .201 -.048 .227 
VO2 Max -.037 -.013 -.194 .846 -.409 .335 -.109 -.046 -.789 .430 -.382 .163 
F-RHI -.128 -.003 -.082 .935 -3.219 2.962 4.403 .105** 2.752 .006 1.257 7.550 
CRAE .936 .691*** 15.591 <.001 .818 1.054 1.019 .743*** 19.294 <.001 .915 1.123 
Child SES -.997 -.079 -1.850 .065 -2.057 .063 .151 .012 .310 .757 -.808 1.110 
Age 38 SES -.295 -.028 -.673 .501 -1.157 .567 -.160 -.016 -.392 .695 -.962 .642 





Table 12-4: Multiple linear regression analysis for other age 38 variables. Dependent Variable: CRVE. 















SBP .158 .122** 2.714 .007 .043 .272 .078 .061 1.478 .140 -.026 .182 
DBP  .288 .179*** 3.979 <.001 .145 .430 .219 .145*** 3.584 <.001 .099 .339 
Non-HDL  .054 .004 .089 .929 -1.153 1.262 .467 .033 .833 .405 -.635 1.568 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 




 Age 32 
12.3.1 Dependent variable: central retinal artery equivalent 
Table 12-5: Multiple linear regression analysis for age 32 variables. Dependent Variable: CRAE. 















SBP -.152 -.154*** -3.649 <.001 -.234 -.070 -.104 -.110** -2.997 .003 -.173 -.036 
DBP -.220 -.173*** -4.138 <.001 -.325 -.116 -.104 -.098** -2.677 .008 -.181 -.028 
MABP -.234 -.184*** -4.380 <.001 -.340 -.129 -.132 -.115** -3.142 .002 -.214 -.049 
BMI  -.036 -.018 -.352 .725 -.237 .165 .046 .019 .415 .678 -.173 .266 
Waist-Hip -7.710 -.039 -.909 .364 -24.388 8.969 -10.300 -.051 -1.296 .196 -25.928 5.328 
HbA1c 1.697 .064 1.626 .105 -.356 3.749 -2.250 -.076* -2.128 .034 -4.330 -.171 
Tot. Chol. -.501 -.046 -1.159 .247 -1.351 .349 -.659 -.065 -1.794 .074 -1.383 .064 
HDL  .807 .033 .775 .439 -1.240 2.854 1.938 .062 1.673 .095 -.340 4.217 
Non-HDL -.614 -.056 -1.354 .177 -1.505 .278 -.734 -.075* -2.017 .045 -1.449 -.018 
WBC -.053 -.009 -.215 .830 -.536 .430 -.389 -.065 -1.732 .084 -.830 .053 
hsCRP .252 .017 .405 .686 -.974 1.478 .131 .008 .211 .833 -1.094 1.356 
Fibrinogen -.008 <.001 -.010 .992 -1.446 1.431 .557 .027 .737 .462 -.930 2.045 
Tot. Smk. .005 .003 .067 .947 -.143 .153 .082 .052 1.307 .192 -.041 .205 
VO2 Max .126 .064 1.203 .230 -.080 .331 .026 .016 .356 .722 -.118 .170 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 





12.3.2 Dependent variable: central retinal vein equivalent 
Table 12-6: Multiple linear regression analysis for age 32 variables. Dependent variable: CRVE. 















SBP .131 .097* 2.248 .025 .016 .247 .079 .061 1.636 .103 -.016 .175 
DBP .124 .071 1.623 .106 -.026 .273 .104 .071 1.924 .055 -.002 .210 
MABP .159 .091* 2.074 .039 .008 .310 .120 .076* 2.049 .041 .005 .235 
BMI  .089 .033 .589 .556 -.207 .385 -.022 -.007 -.137 .891 -.335 .291 
Waist-Hip -11.660 -.043 -.934 .351 -36.218 12.899 19.295 .069 1.687 .092 -3.193 41.782 
HbA1c .780 .022 .515 .607 -2.198 3.759 3.353 .082* 2.226 .027 .390 6.316 
Tot. Chol. .491 .033 .781 .435 -.745 1.727 .944 .068 1.790 .074 -.093 1.981 
HDL  -.655 -.020 -.431 .666 -3.640 2.330 -2.578 -.061 -1.546 .123 -5.856 .701 
Non-HDL .421 .028 .637 .524 -.878 1.720 .991 .074 1.897 .059 -.037 2.018 
WBC .167 .021 .468 .640 -.535 .869 .668 .082* 2.084 .038 .038 1.298 
hsCRP -.074 -.004 -.082 .935 -1.850 1.703 -.390 -.016 -.437 .663 -2.148 1.367 
Fibrinogen -.153 -.006 -.145 .885 -2.235 1.929 -.603 -.021 -.555 .579 -2.739 1.533 
Tot. Smk. .152 .063 1.389 .166 -.063 .368 .071 .033 .788 .431 -.106 .247 
VO2 Max -.172 -.064 -1.120 .263 -.473 .130 -.004 -.002 -.036 .971 -.210 .203 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 





 Age 26 
12.4.1 Dependent variable: central retinal artery equivalent 
Table 12-7: Multiple linear regression analysis for age 26 variables. Dependent Variable: CRAE. 















SBP -.104 -.092* -2.153 .032 -.198 -.009 -.095 -.094* -2.548 .011 -.168 -.022 
DBP -.126 -.102* -2.421 .016 -.228 -.024 -.139 -.135*** -3.757 <.001 -.212 -.066 
MABP -.148 -.110** -2.616 .009 -.260 -.037 -.157 -.136*** -3.770 <.001 -.238 -.075 
BMI  -.076 -.034 -.700 .485 -.290 .138 .235 .084* 1.980 .048 .002 .467 
Waist-Hip -13.712 -.062 -1.469 .143 -32.081 4.657 -12.194 -.048 -1.214 .226 -31.954 7.566 
Tot. Chol. -.346 -.034 -.819 .414 -1.177 .485 -.316 -.030 -.813 .417 -1.082 .449 
HDL  .804 .032 .739 .460 -1.337 2.944 1.710 .049 1.302 .194 -.873 4.294 
Non-HDL -.449 -.044 -1.051 .294 -1.290 .392 -.375 -.037 -.974 .331 -1.132 .382 
WBC .139 .027 .612 .541 -.309 .588 -.587 -.089* -2.383 .018 -1.072 -.103 
hsCRP -.366 -.030 -.700 .484 -1.394 .662 -.151 -.011 -.284 .777 -1.197 .895 
Tot. Smk. .027 .010 .246 .806 -.187 .241 .176 .073 1.878 .061 -.008 .361 
VO2 Max .095 .046 .915 .361 -.109 .299 -.053 -.030 -.665 .506 -.210 .104 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 





12.4.2 Dependent variable: central retinal vein equivalent 
Table 12-8: Multiple linear regression analysis for age 26 variables. Dependent Variable: CRVE. 















SBP .019 .012 .272 .786 -.116 .154 .080 .057 1.526 .128 -.023 .182 
DBP .121 .070 1.633 .104 -.025 .266 .155 .109** 2.982 .003 .053 .257 
MABP .105 .056 1.298 .195 -.054 .264 .164 .103** 2.804 .005 .049 .278 
BMI  .295 .096 1.847 .066 -.019 .610 -.228 -.059 -1.323 .187 -.567 .111 
Waist-Hip 4.694 .016 .336 .737 -.22.835 32.224 4.698 .013 .321 .748 -24.094 33.490 
Tot. Chol. .191 .013 .301 .764 -1.058 1.440 .544 .039 .977 .329 -.551 1.638 
HDL  -1.741 -.049 -1.064 .288 -4.964 1.481 -1.981 -.042 -1.052 .294 -5.687 1.724 
Non-HDL .250 .017 .390 .697 -1.015 1.516 .579 .042 1.051 .294 -.505 1.662 
WBC .111 .015 .333 .740 -.547 .769 .680 .076 1.914 .056 -.019 1.379 
hsCRP .004 <.001 .005 .996 -1.504 1.512 -.840 -.044 -1.109 .268 -2.330 .650 
Tot. Smk. .156 .044 .977 .329 -.158 .470 .016 .005 .115 .909 -.252 .284 
VO2 Max <.001 <.001 -.003 .998 -.312 .311 .117 .049 1.016 .310 -.110 .344 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 





 Age 21 
12.5.1 Dependent variable: central retinal artery equivalent 
Table 12-9: Multiple linear regression analysis for age 21 variables. Dependent Variable: CRAE. 















BMI  .001 <.001 .007 .994 -.251 .253 .241 .080 1.957 .051 -.001 .483 
Tot. Smk. .068 .015 .364 .716 -.299 .435 .306 .074* 1.977 .049 .002 .610 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. Variable not 
adjusted for same variable at age 38. * significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 
12.5.2 Dependent variable: central retinal vein equivalent 
Table 12-10: Multiple linear regression analysis for age 21 variables. Dependent Variable: CRVE. 















BMI  .136 .035 .731 .465 -.230 .502 -.250 -.061 -1.417 .157 -.596 .097 
Tot. Smk. .216 .035 .788 .431 -.323 .755 -.102 -.018 -.454 .650 -.545 .340 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. Variable not 




 Age 18 
12.6.1 Dependent variable: central retinal artery equivalent 
Table 12-11: Multiple linear regression analysis for age 18 variables. Dependent Variable: CRAE. 















SBP -.119 -.107* -2.405 .017 -.216 -.022 -.121 -.110** -2.790 .006 -.207 -.036 
DBP -.105 -.091* -2.051 .041 -.206 -.004 -.091 -.093* -2.288 .023 -.170 -.013 
MABP -.161 -.114* -2.571 .011 -.285 -.038 -.148 -.119** -2.932 .004 -.247 -.049 
BMI  .041 .012 .294 .769 -.231 .312 .217 .065 1.624 .105 -.046 .481 
Tot. Smk. .279 .034 .836 .404 -.377 .935 .446 .064 1.772 .077 -.049 .941 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 
not adjusted for age 38 MABP. Variable not adjusted for same variable at age 38. * significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 
 
12.6.2 Dependent variable: central retinal vein equivalent 
Table 12-12: Multiple linear regression analysis for age 18 variables. Dependent Variable: CRVE. 















SBP .107 .070 1.553 .121 -.029 .243 .112 .075 1.902 .058 -.004 .228 
DBP .233 .146** 3.366 .001 .097 .370 .110 .083* 2.066 .040 .005 .215 
MABP .278 .142** 3.243 .001 .109 .446 .162 .096* 2.385 .018 .028 .295 
BMI  .172 .038 .832 .406 -.236 .581 -.279 -.063 -1.502 .134 -.645 .087 
Tot. Smk. .091 .008 .186 .853 -.875 1.058 -.206 -.022 -.566 .571 -.923 .510 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 
not adjusted for age 38 MABP. Variable not adjusted for same variable at age 38. * significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
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 Age 15 
12.7.1 Dependent variable: central retinal artery equivalent 
Table 12-13: Multiple linear regression analysis for age 15 variables. Dependent Variable: CRAE. 















SBP -.096 -.094* -2.089 .038 -.186 -.006 -.057 -.061 -1.503 .134 -.131 .018 
DBP -.062 -.050 -1.102 .272 -.173 .049 -.086 -.086* -2.133 .034 -.165 -.007 
MABP -.110 -.079 -1.765 .079 -.234 .013 -.109 -.093* -2.304 .022 -.202 -.016 
BMI  -.002 -.001 -.015 .988 -.328 .323 .228 .061 1.607 .109 -.051 .508 
VO2 Max -.073 -.032 -.790 .430 -.256 .109 -.008 -.004 -.117 .907 -.151 .134 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 
not adjusted for age 38 MABP. Variable not adjusted for same variable at age 38. * significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 
 
12.7.2 Dependent variable: central retinal vein equivalent 
Table 12-14: Multiple linear regression analysis for age 15 variables. Dependent Variable: CRVE. 















SBP .009 .007 .142 .887 -.115 .133 .057 .045 1.094 .275 -.046 .160 
DBP .145 .086 1.920 .056 -.004 .294 .132 .097* 2.380 .018 .023 .241 
MABP .127 .067 1.492 .137 -.040 .293 .151 .095* 2.326 .021 .023 .279 
BMI  -.032 -.006 -.134 .893 -.505 .440 .021 .004 .100 .920 -.384 .426 
VO2 Max .013 .004 .098 .922 -.251 .277 -.018 -.007 -.168 .866 -.222 .187 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 
not adjusted for age 38 MABP. Variable not adjusted for same variable at age 38. * significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
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 Age 13 
12.8.1 Dependent variable: central retinal artery equivalent 
Table 12-15: Multiple linear regression analysis for age 13 variables. Dependent Variable: CRAE. 















SBP -.052 -.044 -.920 .359 -.163 .059 -.189 -.154*** -3.602 <.001 -.293 -.086 
DBP K-5 -.063 -.068 -1.413 .159 -.151 .025 -.077 -.088* -2.052 .041 -.151 -.003 
DBP K-4 -.043 -.036 -.756 .450 -.154 .069 -.128 -.114** -2.658 .008 -.223 -.033 
MABP K-5 -.108 -.082 -1.698 .091 -.233 .017 -.164 -.133** -3.137 .002 -.268 -.061 
MABP K-4 -.078 -.051 -1.061 .290 -.223 .067 -.237 -.162*** -3.796 <.001 -.360 -.114 
BMI  -.034 -.008 -.183 .855 -.395 .328 .260 .056 1.275 .203 -.142 .662 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 




12.8.2 Dependent variable: central retinal vein equivalent 
Table 12-16: Multiple linear regression analysis for age 13 variables. Dependent Variable: CRVE. 















SBP .057 .037 .785 .433 -.086 .200 .161 .098* 2.185 .030 .016 .305 
DBP K-5 .089 .075 1.563 .119 -.023 .202 .091 .078 1.776 .077 -.010 .191 
DBP K-4 .054 .035 .740 .460 -.089 .197 .151 .101* 2.299 .022 .022 .280 
MABP K-5 .146 .086 1.790 .075 -.015 .307 .174 .106* 2.409 .017 .032 .316 
MABP K-4 .094 .047 .988 .324 -.093 .281 .252 .129** 2.913 .004 .082 .423 
BMI  -.033 -.006 -.128 .898 -.540 .474 -.180 -.029 -.620 .536 -.750 .391 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 




 Age 11 
12.9.1 Dependent variable: central retinal artery equivalent 
Table 12-17: Multiple linear regression analysis for age 11 variables. Dependent Variable: CRAE. 















SBP -.225 -.170*** -3.666 <.001 -.346 -.104 -.162 -.110** -2.657 .008 -.282 -.042 
DBP K-5 -.165 -.128** -2.704 .007 -.286 -.045 -.067 -.055 -1.350 .178 -.165 .031 
DBP K-4 -.238 -.171*** -3.690 <.001 -.365 -.111 -.134 -.097* -2.439 .015 -.243 -.026 
MABP K-5 -.273 -.173*** -3.697 <.001 -.419 -.128 -.132 -.085* -2.077 .039 -.257 -.007 
MABP K-4 -.315 -.198*** -4.313 <.001 -.458 -.171 -.191 -.117** -2.911 .004 -.320 -.062 
BMI  .067 .013 .279 .781 -.408 .542 .440 .090* 2.193 .029 .045 .835 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 




12.9.2 Dependent variable: central retinal vein equivalent 
Table 12-18: Multiple linear regression analysis for age 11 variables. Dependent Variable: CRVE. 















SBP .238 .133** 2.865 .005 .075 .402 .109 .053 1.253 .211 -.062 .280 
DBP K-5 .241 .138** 2.983 .003 .082 .400 .082 .048 1.174 .241 -.055 .218 
DBP K-4 .324 .173*** 3.804 <.001 .157 .492 .099 .052 1.268 .206 -.055 .253 
MABP K-5 .354 .166*** 3.607 <.001 .161 .548 .129 .060 1.442 .150 -.047 .305 
MABP K-4 .398 .185*** 4.078 <.001 .206 .590 .137 .061 1.467 .143 -.047 .322 
BMI  .312 .044 .906 .366 -.366 .990 -.430 -.064 -1.454 .147 -1.012 .152 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 




 Age 9 
12.10.1 Dependent variable: central retinal artery equivalent 
Table 12-19: Multiple linear regression analysis for age 9 variables. Dependent Variable: CRAE. 















SBP -.165 -.114* -2.481 .014 -.296 -.034 -.224 -.161*** -4.042 <.001 -.333 -.115 
DBP K-5 -.040 -.034 -.736 .462 -.147 .067 -.076 -.070 -1.777 .077 -.160 .008 
DBP K-4 -.108 -.072 -1.549 .123 -.246 .029 -.224 -.145*** -3.738 <.001 -.342 -.106 
MABP K-5 -.104 -.069 -1.468 .143 -.243 .035 -.175 -.119** -3.020 .003 -.288 -.061 
MABP K-4 -.174 -.102* -2.179 .030 -.332 -.017 -.298 -.174*** -4.460 <.001 -.430 -.167 
BMI  .274 .042 .973 .332 -.280 .828 .516 .079* 2.041 .042 .018 1.013 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 




12.10.2 Dependent variable: central retinal vein equivalent 
Table 12-20: Multiple linear regression analysis for age 9 variables. Dependent Variable: CRVE. 















SBP .165 .084 1.829 .069 -.013 .342 .236 .122** 2.955 .003 .079 .394 
DBP K-5 .082 .052 1.118 .265 -.062 .225 .126 .084* 2.119 .035 .009 .243 
DBP K-4 .113 .056 1.197 .232 -.073 .298 .292 .136** 3.444 .001 .125 .459 
MABP K-5 .150 .074 1.583 .115 -.037 .337 .239 .117** 2.950 .003 .080 .399 
MABP K-4 .177 .077 1.640 .102 -.036 .391 .363 .151*** 3.790 <.001 .174 .551 
BMI  .050 .006 .121 .904 -.761 .861 -.535 -.059 -1.447 .149 -1.264 .193 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 




 Age 7 
12.11.1 Dependent variable: central retinal artery equivalent 
Table 12-21: Multiple linear regression analysis for age 7 variables. Dependent Variable: CRAE. 















SBP -.142 -.099* -2.273 .024 -.265 -.019 -.138 -.095* -2.418 .016 -.251 -.026 
DBP K-5 -.099 -.072 -1.622 .106 -.219 .021 -.164 -.123** -3.192 .002 -.265 -.063 
DBP K-4 -.117 -.073 -1.642 .102 -.257 .023 -.196 -.131** -3.402 .001 -.310 -.083 
MABP K-5 -.164 -.098* -2.215 .028 -.309 -.018 -.223 -.137*** -3.539 <.001 -.348 -.099 
MABP K-4 -.174 -.097* -2.189 .029 -.330 -.018 -.234 -.137*** -3.549 <.001 -.364 -.104 
BMI  .041 .005 .130 .897 -.575 .656 .851 .108** 2.743 .006 .241 1.461 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 




12.11.2 Dependent variable: central retinal vein equivalent 
Table 12-22: Multiple linear regression analysis for age 7 variables. Dependent Variable: CRVE. 















SBP .181 .094* 2.127 .034 .014 .349 .166 .082** 2.079 .038 .009 .322 
DBP K-5 .197 .107* 2.404 .017 .036 .358 .208 .113** 2.911 .004 .068 .349 
DBP K-4 .210 .097* 2.186 .030 .021 .399 .264 .126** 3.291 .001 .106 .421 
MABP K-5 .278 .124** 2.795 .006 .082 .474 .280 .123** 3.180 .002 .107 .454 
MABP K-4 .272 .113* 2.535 .012 .061 .483 .306 .129** 3.331 .001 .125 .486 
BMI  .277 .027 .606 .545 -.623 1.178 -.479 -.044 -1.064 .288 -1.366 .407 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. SBP and DBP 
not adjusted for age 38 MABP. Variable not adjusted for same variable at age 38. * significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 
 Age 5 
12.12.1 Dependent variable: central retinal artery equivalent 
Table 12-23: Multiple linear regression analysis for age 5 variables. Dependent Variable: CRAE. 















BMI  .106 .012 .295 .768 -.599 .811 .914 .106** 2.904 .004 .295 1.533 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. Variable not 




12.12.2 Dependent variable: central retinal vein equivalent 
Table 12-24: Multiple linear regression analysis for age 5 variables. Dependent Variable: CRVE. 















BMI  .269 .023 .532 .595 -.727 1.265 -1.080 -.090* -2.331 .020 -1.991 -.169 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. Variable not 
adjusted for same variable at age 38. * significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 
 Age 3 
12.13.1 Dependent variable: central retinal artery equivalent 
Table 12-25: Multiple linear regression analysis for age 3 variables. Dependent Variable: CRAE. 















BMI  .422 .053 1.385 .167 -.177 1.020 .576 .068 1.819 .070 -.047 1.198 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. Variable not 
adjusted for same variable at age 38. * significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 
12.13.2 Dependent variable: central retinal vein equivalent 
Table 12-26: Multiple linear regression analysis for age 3 variables. Dependent Variable: CRVE. 















BMI  -.111 -.010 -.240 .811 -1.021 .799 -.612 -.054 -1.358 .175 -1.498 .274 
Adjusted for age 38 variables: MABP, BMI, Waist-Hip, HbA1c, Tot. Chol., HDL, WBC, hsCRP, Fibrinogen, IL-6, Tot. Smk. VO2 Max., F-RHI, SES; childhood SES and fellow RVC. Variable not 
adjusted for same variable at age 38. * significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
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 Summary of significant results from multiple linear regression analysis 
This is a summary of the statistically significant findings from the multiple linear regression analysis categorised by age. (The significant association 
between CRAE and CRVE is not included in these tables) 
12.14.1 Central retinal artery equivalent 
 Females 
Table 12-27: Significant associations between variables and CRAE for females, p < 0.05. 




38 SBP -.265 -.277*** -6.894 <.001 -.340 -.189 
DBP  -.378 -.318*** -8.064 <.001 -.470 -.286 
MABP -.380 -.326*** -8.232 <.001 -.470 -.289 
HbA1c 2.176 .089* 2.358 .019 .361 3.990 
32 SBP -.152 -.154*** -3.649 <.001 -.234 -.070 
DBP -.220 -.173*** -4.138 <.001 -.325 -.116 
MABP -.234 -.184*** -4.380 <.001 -.340 -.129 
26 SBP -.104 -.092* -2.153 .032 -.198 -.009 
DBP -.126 -.102* -2.421 .016 -.228 -.024 
MABP -.148 -.110** -2.616 .009 -.260 -.037 
18 SBP -.119 -.107* -2.405 .017 -.216 -.022 
DBP -.105 -.091* -2.051 .041 -.206 -.004 
MABP -.161 -.114* -2.571 .011 -.285 -.038 
15 SBP -.096 -.094* -2.089 .038 -.186 -.006 
SBP -.225 -.170*** -3.666 <.001 -.346 -.104 
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11 DBP K-5 -.165 -.128** -2.704 .007 -.286 -.045 
DBP K-4 -.238 -.171*** -3.690 <.001 -.365 -.111 
MABP K-5 -.273 -.173*** -3.697 <.001 -.419 -.128 
MABP K-4 -.315 -.198*** -4.313 <.001 -.458 -.171 
9 SBP -.165 -.114* -2.481 .014 -.296 -.034 
MABP K-4 -.174 -.102* -2.179 .030 -.332 -.017 
7 SBP -.142 -.099* -2.273 .024 -.265 -.019 
MABP K-5 -.164 -.098* -2.215 .028 -.309 -.018 
MABP K-4 -.174 -.097* -2.189 .029 -.330 -.018 





Table 12-28: Significant associations between variables and CRAE for males, p < 0.05. 




38 SBP -.181 -.194*** -5.006 <.001 -.252 -.110 
DBP 
-.265 -.241*** -6.424 <.001 -.346 -.184 
MABP 
-.274 -.246*** -6.454 <.001 -.358 -.191 
HbA1c 
-2.137 -.077* -2.091 .037 -4.145 -.128 
32 SBP -.104 -.110** -2.997 .003 -.173 -.036 
DBP -.104 -.098** -2.677 .008 -.181 -.028 
MABP -.132 -.115** -3.142 .002 -.214 -.049 
HbA1c 
-2.250 -.076* -2.128 .034 -4.330 -.171 
Non-HDL 
-.734 -.075* -2.017 .045 -1.449 -.018 
26 SBP -.095 -.094* -2.548 .011 -.168 -.022 
DBP -.139 -.135*** -3.757 <.001 -.212 -.066 
MABP -.157 -.136*** -3.770 <.001 -.238 -.075 
BMI .235 .084* 1.980 .048 .002 .467 
WBC 
-.587 -.089* -2.383 .018 -1.072 -.103 
18 SBP -.121 -.110** -2.790 .006 -.207 -.036 
DBP -.091 -.093* -2.288 .023 -.170 -.013 
MABP -.148 -.119** -2.932 .004 -.247 -.049 
15 DBP -.086 -.086* -2.133 .034 -.165 -.007 
MABP -.109 -.093* -2.304 .022 -.202 -.016 
13 SBP -.189 -.154*** -3.602 <.001 -.293 -.086 
DBP K-5 -.077 -.088* -2.052 .041 -.151 -.003 
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DBP K-4 -.128 -.114** -2.658 .008 -.223 -.033 
MABP K-5 -.164 -.133** -3.137 .002 -.268 -.061 
MABP K-4 -.237 -.162*** -3.796 <.001 -.360 -.114 
11 SBP -.162 -.110** -2.657 .008 -.282 -.042 
DBP K-4 
-.134 -.097* -2.439 .015 -.243 -.026 
MABP K-5 -.132 -.085* -2.077 .039 -.257 -.007 
MABP K-4 -.191 -.117** -2.911 .004 -.320 -.062 
BMI  .440 .090* 2.193 .029 .045 .835 
9 SBP -.224 -.161*** -4.042 <.001 -.333 -.115 
DBP K-4 -.224 -.145*** -3.738 <.001 -.342 -.106 
MABP K-5 -.175 -.119** -3.020 .003 -.288 -.061 
MABP K-4 -.298 -.174*** -4.460 <.001 -.430 -.167 
BMI  .516 .079* 2.041 .042 .018 1.013 
7 SBP -.138 -.095* -2.418 .016 -.251 -.026 
DBP K-5 -.164 -.123** -3.192 .002 -.265 -.063 
DBP K-4 -.196 -.131** -3.402 .001 -.310 -.083 
MABP K-5 -.223 -.137*** -3.539 <.001 -.348 -.099 
MABP K-4 -.234 -.137*** -3.549 <.001 -.364 -.104 
BMI  .851 .108** 2.743 .006 .241 1.461 
5 BMI .914 .106** 2.904 .004 .295 1.533 




12.14.2 Central retinal vein equivalent 
 Females 
Table 12-29: Significant associations between variables and CRVE for females, p < 0.05. 




38 SBP .158 .122** 2.714 .007 .043 .272 
DBP  .288 .179*** 3.979 <.001 .145 .430 
MABP .271 .172*** 3.772 <.001 .130 .413 
Tot. Smk. .168 .091* 1.994 .047 .002 .334 
32 SBP .131 .097* 2.248 .025 .016 .247 
MABP .159 .091* 2.074 .039 .008 .310 
18 DBP .233 .146** 3.366 .001 .097 .370 
MABP .278 .142** 3.243 .001 .109 .446 
11 SBP .238 .133** 2.865 .005 .075 .402 
DBP K-5 .241 .138** 2.983 .003 .082 .400 
DBP K-4 .324 .173*** 3.804 <.001 .157 .492 
MABP K-5 .354 .166*** 3.607 <.001 .161 .548 
MABP K-4 .398 .185*** 4.078 <.001 .206 .590 
7 SBP .181 .094* 2.127 .034 .014 .349 
DBP K-5 .197 .107* 2.404 .017 .036 .358 
DBP K-4 .210 .097* 2.186 .030 .021 .399 
MABP K-5 .278 .124** 2.795 .006 .082 .474 
MABP K-4 .272 .113* 2.535 .012 .061 .483 





Table 12-30: Significant associations between variables and CRVE for males, p < 0.05. 




38 DBP  .219 .145*** 3.584 <.001 .099 .339 
MABP .194 .127** 3.064 .002 .070 .319 
Waist-Hip 23.058 .104* 2.307 .022 3.403 42.713 
F-RHI 
4.403 .105** 2.752 .006 1.257 7.550 
32 MABP .120 .076* 2.049 .041 .005 .235 
HbA1c 
3.353 .082* 2.226 .027 .390 6.316 
WBC 
.668 .082* 2.084 .038 .038 1.298 
26 DBP  .155 .109** 2.982 .003 .053 .257 
MABP .164 .103** 2.804 .005 .049 .278 
18 DBP  .110 .083* 2.066 .040 .005 .215 
MABP .162 .096* 2.385 .018 .028 .295 
15 DBP  .132 .097* 2.380 .018 .023 .241 
MABP .151 .095* 2.326 .021 .023 .279 
13 SBP .161 .098* 2.185 .030 .016 .305 
DBP K-4 
.151 .101* 2.299 .022 .022 .280 
MABP K-5 
.174 .106* 2.409 .017 .032 .316 
MABP K-4 
.252 .129** 2.913 .004 .082 .423 
9 SBP .236 .122** 2.955 .003 .079 .394 
DBP K-5 .126 .084* 2.119 .035 .009 .243 
DBP K-4 .292 .136** 3.444 .001 .125 .459 
MABP K-5 .239 .117** 2.950 .003 .080 .399 
226 
 
MABP K-4 .363 .151*** 3.790 <.001 .174 .551 
7 SBP .166 .082* 2.079 .038 .009 .322 
DBP K-5 .208 .113** 2.911 .004 .068 .349 
DBP K-4 .264 .126** 3.291 .001 .106 .421 
MABP K-5 .280 .123** 3.180 .002 .107 .454 
MABP K-4 .306 .129** 3.331 .001 .125 .486 
5 BMI -1.080 -.090* -2.331 .020 -1.991 -.169 
* significant at p < 0.05, ** significant at p < 0.01, *** significant at p < 0.001. 
 
 
 
